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ABSTRACT OF THE DISSERTATION 
Functional and Skeletal Muscle Impairments In Progressive Diabetic CKD 
by 
Daniel Christopher Bittel 
Doctor of Philosophy in Movement Science 
Program in Physical Therapy 
Washington University in St. Louis, 2018 
Professor David R. Sinacore, PT, PhD, FAPTA, Chair 
1-in-3 persons with type 2 diabetes (T2DM) develop chronic kidney disease (CKD), which is 
characterized by progressive renal dysfunction leading to end-stage renal disease. In response to 
elevated blood glucose and systemic inflammation of diabetes, a process of active thickening of the 
renal glomerular basement membrane ensues with concomitant damage to the structural supports 
(podocytes) of the kidney’s filtration barrier. This results in impaired renal filtration. The metabolic 
sequelea of T2DM and CKD also, synergistically, alter skeletal muscle’s degradative pathways, 
satellite cell function (muscle reparative cells), and mitochondrial health (muscle energetic 
machinery) -- resulting in muscle breakdown, poor muscle quality, and exercise intolerance, and 
immobility that exacerbates CKD. The temporal nature and extent of these changes in CKD, 
however, remains unknown. With mandates from the Center for Disease Control (CDC) urging 
avenues of treatment that impede the progression of CKD, it is critical now, more than ever, to gain 
a better understanding of the factors that contribute to disease progression. This will inform more 
effective targeted interventions. We therefore aim to determine how renal dysfunction dictates the 
activity of muscle degredative pathways, the status of muscle reparative cells, and the energetic 
production of muscle, to ultimately influence muscle quality, performance and physical mobility. 




In chapter 1, we examine how CKD progression in T2DM, impacts muscle performance and 
physical function. Our results suggest that muscle performance of the lower extremity, particularly 
the quadriceps, and physical function decline in-parallel with progression of CKD in T2DM, with 
these declines becoming clinically evident in stage 3. Moreover, we find that CKD-stage, and renal 
filtration/function (eGFR) are both significant predictors of overall physical function, with 
increasing CKD stage/worsening kidney filtration predicting worse functional mobility. In chapter 2, 
we examine the CKD-stage specific functional status of skeletal muscle mitochondrial ATP 
production, and electron transport chain kinetics, as these are critical cellular processes to fuel 
muscle cross-bridge cycling, contraction and movement. We find that intrinsic skeletal muscle 
mitochondrial electron transport chain function is reduced with progression of CKD, with significant 
reductions in ATP-production capacity emerging as early as stage 3 CKD. Moreover, these changes 
may derive from transcriptome-level alterations in gene networks governing muscle mitochondrial 
health and function. In Chapter 3, we examine muscle regenerative and maintenance capacity in 
relationship to CKD progression. We find the muscle-resident satellite cell pool to decline 
significantly with CKD progression, and exhibit impaired myogenic capacity with altered gene 
activation patterns, that relate strongly to findings of poor muscle quality with progressive CKD 
stage. Using transcriptomics, we report signi ficant dowregulation in gene networks that influence 
muscle SC behavior and myogenesis.  
Overall, our data suggests that the progression of diabetes-induced chronic kidney disease, is 
paralleled by impairments in skeletal muscle ATP-producing capacity, and these energetic deficits 
are accompanied by CKD-associated reductions in muscle SC abundance, and reparative function. 




altered uremic environment. These impairments may promote the development of poor muscle 
































Over 30 million persons in the United States (~10%) have diabetes, with type 2 diabetes (T2DM) 
constituting 95% of all cases (1). T2DM is increasingly prevalent health condition, with 1.5 million 
new diagnosed cases each year (1). Diabetes is a syndrome characterized primarily by dysfunction in 
glucose regulation leading to hyperglycemia (2). The two principles of blood glucose regulation are 
insulin secretion by the pancreatic B-cell, and insulin sensitivity by peripheral tissues. Glucose 
absorbed from the meal is sensed, stimulating pancreatic insulin production and secretion (ie. by 
GLP1 and GLP2 peptides) (3). Insulin stimulates the uptake of glucose by peripheral insulin-
sensitive tissues like skeletal muscle and adipose tissue by binding to, and activating the insulin 
receptor, which leads to phosphorylation of several different substrates, namely the insulin-receptor 
substrates (IRSs) (4). This phospho-activation leads to subsequent pathway signaling cascades 
resulting in glucose, fatty acid and amino acid uptake by both skeletal muscle and adipose tissue. 
Insulin resistance is defined by a failure of insulin, at even normal concentrations, to exert its effects, 
predictably leading to elevated blood glucose concentrations (4). A common index of glycemic 
control is the hemoglobin A1C test (HbA1c). HbA1c provides an indication of chronic 
hyperglycemia over a 120 day period, as it fundamentally asesses glycation of hemoglobin (red-
blood cells) that provides evidence of an individuals average blood glucose levels during the 
previous ~3 months (5). Thus, diabetes results from impairment at either end of the insulin 
sensitivity/insulin secretion axis.  
The more prevalent phenotype of diabetes (T2DM), results from an interaction between 
genetic predisposition and behavioral (excess nutrient intake, obesity, sedentary behavior, obesity) 
and environmental risk factors (3). T2DM often demonstrates as impaired glucose tolerance, 
reflected by a decrease in glucose-responsive insulin secretion resulting in postprandial 




resistance of peripheral tissues like skeletal muscle, as impaired insulin action at these tissues results 
in inadequate glucose uptake, thus prompting the pancreas to produce and secrete more insulin, and 
tissues like skeletal muscle to instead rely upon fats and protein for oxidation and energy production 
(6, 7, 8). With this postprandial deficit in mind, peripheral insulin sensitivity and insulin secretion 
assessment with glucose ingestion is the hallmark of T2DM diagnosis (8). While numerous clinical 
tests are utilized, among the most common are the oral glucose tolerance test (OGTT) and 
homeostatic model assessment (HOMA). The OGTT is administered as a single glucose bolus 
ingestion following an overnight fast and subsequent tracking of blood glucose and insulin 
concentrations over a 2-hour “post-prandial” period. Higher glucose excursions despite elevated 
insulin secretion provides a reasonable index of insulin resistance, and/or impaired insulin secretion. 
Conversely, the HOMA relies on the product of fasting plasma glucose and fasting plasma insulin 
concentrations, which shows a reasonable estimate of tissue sensitivity to insulin (8).  
 While the root cause of T2DM from a pathophysiological perspective remains debated, it is 
hypothesized that caloric excess and adiposity contributes largely to peripheral insulin resistance and 
ultimately pancreatic B-cell exhaustion (9). Adipose tissue accrual, a hallmark of obesity and 
development of T2DM, is linked with a litany of hormonal systemic effects. Of chief importance is 
the inflammatory response (10). With diabetes and obesity, hypertrophic adipocytes become 
hypoperfused, leading to local upregulation of hypoxia-inducible factor-1, along with activation of 
signaling cascades, mainly JNK1 and NFkB pathways, and genes involved in inflammation and 
endoplasmic reticulum stress. This leads to chemokine release from adipose tissue, and generalized 
low-grade systemic inflammation in T2DM (11). This adipose-tissue-mediated inflammation 
contributes to peripheral insulin resistance. Due to the insensitivity of skeletal muscle to insulin, and 




other metabolic substrates, namely fatty acids. Not surprisingly, obese individuals express a higher 
rate of fatty acid breakdown, uptake and fatty acid flux (9). The increased fatty acid flux of T2DM 
results in elevated circulating free-fatty acids (FFA) and increased FFA uptake into muscle. Within 
skeletal muscle, FFA are converted to fatty acyl CoAs and transported into the energetic powerhouse 
of skeletal muscle – mitochondria, via carnitine palmitoyl transferase (CPT), for beta oxidation and 
energy production. In the event of mitochondrial inadequacy (due to oversupply of FFA, or 
reduction in oxidation capacity, or mitochondrial abundance, or all 3), fatty acyl CoAs are instead 
converted to diacylglycerol (DAG) and used to re-synthesize triglyceride. This leads to 1. ectopic 
lipid accumulation known as intermuscular adipose tissue (IMAT) beneath fascia and between 
muscle fascicles, and 2. intramuscular adipose tissue accumulation within muscle cells themselves 
(9,12,13).  
In support of this theory, it has been shown that in T2DM, the oversupply of fatty acids 
exhausts skeletal muscle mitochondria, leading to accrual of fatty acid intermediates (DAG, 
ceramide, fatty acyl-CoA, etc.) in muscle that impairs insulin receptor signaling and contributes to 
insulin resistance (11, 14, 15, 16). More specifically, lipid intermediates have been shown to activate 
protein kinase C – a potent inhibitor of tyrosine phosphorylation of the insulin receptor and its 
substrates, while other intermediates (ie. ceramide) dephosphorylate Akt/protein kinase B, resulting 
in inhibition of GLUT4 translocation and subsequent glucose uptake (17,11). As skeletal muscle is 
responsible for 90% of peripheral glucose uptake, disruption in its ability to take up glucose and 
oxidize it (via glucose-fatty acid cycle or randle cycle competition) is a well-established key 
pathophysiological feature of T2DM and its progression (18). However, while T2DM is 
characterized by impairments in insulin signaling, sensitivity, and secretion, the potential causative 




Accrual of the aforementioned IMAT depot may impair extrinsic muscle contractile 
performance by interfering with muscle fascicle arrangement, pennation angle, excursion during 
contraction and perimysial function (19, 20, 21). Indeed, numerous studies have demonstrated 
reduced muscle strength, power, and twitch speed with increased IMAT deposition (19,22). 
Moreover, intermuscular fat storage is associated with enhanced lipid peroxidation, which, along 
with accumulation of fatty acid metabolic intermediates like DAG and ceramides, not only impair 
contractile mechanics, but act through inflammatory cytokines (TNF-alpha, IL-6) and signaling 
pathways (NF-KB, JNK) to upregulate protein-degrading machinery – ubiquitin proteasome system, 
and E3 ubiquitin-ligase MuRF1 (23,11,24). This upregulation promotes muscle atrophy – a negative 
balance between muscle protein synthesis and breakdown rates. In support of the presence of this 
signaling cascade, those with T2DM indeed exhibit muscle atrophy that is initially mild, and 
becomes more substantial with older age and severity of disease. In addition to systemic 
inflammation and lipid intermediates promoting muscle atrophy in T2DM, the reduced insulin 
sensitivity and signaling in T2DM skeletal muscle results in muscle atrophy as well (21).  
Under normal conditions, insulin and insulin-like growth factor 1 (IGF-1) interact with their 
cell membrane receptors, which in-turn phosphorylate insulin receptor substrate 1 (IRS-1) (26). 
Phosphorylated IRS-1 then acts as a docking site to recruit and activate phosphatidylinositol-3-
kinase (PI3K), which subsequently phosphorylates muscle inner membrane phospholipids, and 
generates phosphoinositide-3,4,5-triphosphate (PIP3). PIP3 acts as a docking site for the kinase Akt, 
which, upon binding, is phosphorylated and activated. This activated Akt inhibits protein 
degredation by phosphorylating and thus repressing the FoxO family – which transcriptionally 
upregulate production and activity of the E3 ubiquitin ligases of the ubiquitin proteasome, Atrogin-




dephosphorylated IRS-1, dephosphorylated (inactive) Akt, in-turn upregulating FoxO transcription 
factors, leading to a more active ubiquitin proteasome pathway while simultaneously inhibiting 
mTOR pathway signaling, the primary protein synthesis pathway (19). Thus, muscle contractile 
function may be hampered in T2DM due to mechanical disruption secondary to IMAT accrual, and 
loss of muscle mass through overactive protein degradation. However, it is theorized that these 
interconnected impairments of T2DM skeletal muscle may stem from upstream mitochondrial 
dysfunction.  
 As mentioned previously, mitochondrial inadequacy may be a prime causative factor in 
skeletal muscle metabolic derangments and insulin resistance in T2DM. Mitochondria have 4 
functions in their host cell – 1. provision of ATP for cell function, 2. mediation of cell death via 
apoptosis, 3. heat production, and 4. calcium homeostasis. Abundant in skeletal muscle, 
mitochondria are suspended in cytoplasm at locations where energy is needed -- between myofibrils 
to fuel muscle contraction, under the sarcolemma to assist in ion exchange and substrate transport 
and cell signaling, and near the nucleus (27). Mitochondria couple substrate oxidation (ie. glucose, 
fatty acids, and amino acids) with phosphorylation of ADP to ATP through generation and 
utilization of a proton gradient over the inner mitochondrial membrane - termed oxidative 
phosphorylation (28). Impaired functional capacity of mitochondria is a factor that may contribute to 
perturbations in glucose and fatty acid substrates in T2DM. Indeed, a reduction in the activity of 
enzymes of oxidative pathways observed in T2DM skeletal muscle correlates with severity of insulin 
resistance (29,13). This suggests impairment in mitochondrial function as a key aspect of the 
pathogenesis of insulin resistance, presumably due to decreased lipid oxidation and production of 
lipid intermediates (13,14). Moreover, studies have found smaller and damaged mitochondria in 




genes involved in mitochondrial oxidative phosphorylation and those encoding proteins of 
respiratory chain complexes, specifically the B-subunit of ATP synthase (30). T2DM also seems to 
negatively impact skeletal muscle mitochondrial function, namely through inhibition of a coactivator 
of nuclear gene transcription factors, PGC-1a. PGC-1a, which is reduced in T2DM, regulates the 
expression of key genes governing mitochondrial replication, oxidative phosphorylation, and energy 
homeostasis (31). Thus, impaired mitochondrial function may serve as a key initial factor in the 
pathogenesis of skeletal muscle metabolic derangements in T2DM. However, while skeletal muscle 
metabolic deficiencies may serve as a linchpin of T2DM and development of hyperglycemia, poor 
glycemic control also contributes to a host of sequelae in other tissues of the body. 
 T2DM, and its associated hyperglycemia, can lead to macrovascular disease involving large 
vessels, and microvascular complications involving capillaries and arterioles. Specific 
macrovascular complications include atherosclerosis affecting arteries in the limbs, those supplying 
the brain, and coronary arteries (7). This can cause reduced blood supply to the limbs, promoting 
reduced wound healing, and can also impair bloodflow in the cerebro-vascular network resulting in 
stroke, dementia and other neurological deficits. Coronary artery alterations, both in structure and 
function with T2DM promotes cardiovascular disease, a common comorbidity of diabetes (7). 
Microvascular complication are thought to mostly stem from glycation-induced thickening of the 
capillary basement membrane rendering it impermeable, stiffer, and less compliant (7,33). As 
capillary permeability and compliance is critical for nutrient and oxygen delivery to target tissues, 
these microvascular complications predictably lead to elevated blood pressure (HTN), eye problems 
(retinopathy), nerve impairments (neuropathy), and kidney issues (nephropathy) (7,33). Proper 
glycemic control and oxygenation is important for the maintenance of neuronal structural integrity 




thickening of endoneurial microvessels, decline in nerve conduction velocity, axonal atrophy and 
degeneration and loss, glial insult and lipid peroxidation (33,34). Diabetes-induced neuropathic 
changes can affect large-fiber sensory, small fiber sensory, autonomic, and motor nerves. These 
metabolic, structural and functional alterations synthesize to produce classic neuropathic symptoms 
most commonly in sensorimotor nerves and termed diabetic sensorimotor polyneuropathy (33,34). 
This peripheral neuropathy is characterized first by a painful “pins and needles” sensation, and 
followed by a lack of cutaneous sensation in a stocking and glove distribution, that when paired with 
macrovascular-induced deficits in bloodflow, lead to impaired circulation, wound healing, and 
sensation, resulting in things like cutaneous ulceration (35). Such occurrences are usually found 
primarily in distal regions like the foot, that may lead, in some cases, to amputation. However, motor 
nerve involvement is not atypical, and can affect large and small fibers resulting neuromuscular 
deficits. While T2DM and hyperglycemia clearly result in a wide array of whole-body alterations in 
metabolism, sensation, and endocrine and cardiovascular function, of growing epidemiological 
significance is the pervasiveness of T2DM-induced kidney problems, or diabetic nephropathy. 
 One out of every 3 individuals with diabetes, have what is known as chronic kidney disease 
(CKD) (36). Diabetes, and in particular, T2DM, is the most common cause of CKD, and constitutes 
70% of all cases of end-stage renal disease, the end-point of CKD (36). CKD and its progression, is 
characterized by declining renal function and can be classified into 5 different  stages according to 
the presence of albuminuria (protein in the urine) and degree of renal impairment (renal filtration 
rate decrements) (37,38, 39) (see below charts). The genesis of CKD development and progression is 
thought to stem from the metabolic and hemodynamic abnormalities of T2DM. Blood travels via the 
renal artery to afferent arterioles and subsequently into capillaries of the glomerulus (the basic 




into the glomerular capsule through several layers – 1. Slats and fenestrated holes of capillary 
endothelium, 2. Slits in the squamous endothelium (basement membrane), and 3. Slits between 
interdigitating feet of podocytes (glomerular capillary structural support proteins), to filter 
unnecessary toxins and metabolic bi-products in circulation (40). However, the microvascular 
alterations induced by T2DM mentioned previously, result in glomerular hyperfiltration, 
hypertrophy and hyperperfusion within the kidney. A “silent phase” follows this hyperfiltration and 
is associated with morphological changes of the glomerulus and its capillaries that include 
glomerular basement membrane thickening, glomerular hypertrophy, and mesangial cell expansion 
that leads to protein leaking in the filtrate and overt proteinuria with declining renal filtration 
capacity and function (41).  
While there are numerous interactive factors that predispose individuals with T2DM to 
developing CKD, a primary causative 
factor is accumulation of the 
extracellular matrix of the renal 
glomerulus. The chronic 
hyperglycemia, glycated albumin 
(AGEs), low-grade systemic 
inflammation, and excess glomerular 
capillary pressure and hypertrophy of 
T2DM, stimulate production of the 
pro-fibrotic protein TGF-B in the glomerulus, where it localizes to 
glomerular podocytes (42). Once localized, TGFB induces connective tissue growth factor (CTGF) 




of the glomerular basement membrane to promote renal fibrosis (42, 43). This process becomes 
routine in nature in T2DM, leading to a progressive cycle of basement membrane thickening, 
glomerular hypertrophy and declining renal filtration (42). Accordingly, CKD is divided into 5 
stages, the defining criteria of which are degree of proteinuria and renal filtration rate. Staging is 
shown above, and below ( NICE Clinical Guidelines, No.182, National Clinical Guideline Centre 
(UK), 2014.) 
Spot Urinary Albumin:Creatinine Ratio (index of renal filtration barrier integrity) 
Microalbuminuria >30 mg albumin/g creatinine 
Macroalbuminuria >300 mg albumin/g creatinine 
 
Physical mobility is independently associated with renal functional decline in T2DM-CKD. 
However, CKD-associated muscle wasting and metabolic impairments complicate the clinical 
pathways and progression of CKD (44). The collective term for the state of muscle wasting and 
multifactorial metabolic impairment in CKD, is uremic myopathy. This uremic myopathy is 
superimposed on the T2DM-induced skeletal muscle metabolic derangements to exacerbate skeletal 
muscle decline in this population. Uremic myopathy was first described by Serratric et al. (1967), in 
a group of patients with chronic renal failure (ESRD) and progressive proximal muscle weakness 
caused by an intrinsic disorder of muscle function (45). Presently, though often debated, uremic 
myopathy – a collection of functional and structural muscle abnormalities in patients with CKD – is 
considered to be a consequence of the uremic state itself (46, 47). The uremic state is a term used to 
describe the excess metabolic bi-products (ie. urea, creatinine, etc.) in the blood that, due to the 




most often associated with ESRD (stage 5 CKD) (48). Indeed, subsequent studies have shown that 
the progression of uremic myopathy runs parallel to the decline in renal function, with clinical signs 
becoming obvious upon ESRD (47). Muscle morphological features of uremic myopathy include – 
1. fiber atrophy and loss of myofilaments, 2. reduced mitochondrial content, with 
mitochondrial damage and increased lipid droplet content, and 3. internalized nuclei 
(indicative of attempted regeneration of muscle fibers) with z-band damage and cellular 
degeneration (47). This constellation of muscle cellular alterations implicates dysfunction of 
systems governing muscle protein degradation, mitochondrial dysfunction, and systems governing 
new muscle fiber formation and injury repair in uremic myopathy. These dysfunctional systems are 
best examined in the context of the structural effects they produce in uremic muscle. 
1. Fiber atrophy and loss of myofilaments in CKD: The decrease in muscle fiber size and 
number observed in CKD is due, in part, to protein degradation (49). As mentioned previously, 
protein degradation indicates an outpacing of protein synthesis, by protein breakdown, with small 
persistent imbalances causing substantial protein loss (44). The loss of these cellular proteins 
increases the risk of morbidity and mortality in CKD and hampers muscle performance and mobility. 
The main cause of this loss of contractile protein in uremic myopathy is the upregulation of the 
ubiquitin proteasome pathway.  
The ATP-dependent ubiquitin proteasome pathway (UBP) confers a specificity to muscle 
breakdown through its unique ubiquitin tagging process in which the muscle protein to be degraded 
is marked with a heat-shock family protein (ubiquitin). Ubiquitin is equipped with lysine residues 
(adherence ions that allow it to tag proteins) by an E1 ubiquitin-activating enzyme (50). Ubiquitin is 
subsequently transferred to an E2 carrier protein, which shuttles it to the muscle protein to be 




protein. Specificity is realized through the 20 different E2 carrier proteins, and >500 forms of E3 
enzyme, with each specific E2 carrier and E3 enzyme recognizing a specific set of muscle proteins 
(44). This process is repeated, ultimately producing a 5-ubiquitin “tag” attached to the protein, 
allowing its recognition by the degradative complex – the 26S proteasome. The proteasome contains 
19S complexes at each of its ends, which serve to cleave the protein of its ubiquitin tag, unfold it, 
and feed the protein into an assembly line of proteases and peptides within the proteasome (51,50). 
In the uremic myopathy of CKD, there is drastic (4-15 fold) upregulation of the genes encoding 
components of the UBP – FOXO32 and FOXO1 (encoding Atrogin-1/MAFbx, and MuRF-1, both 
E3 ubiquitin ligases specific for contractile proteins of muscle), proteasome 19S subunit non-
ATPase 11 (PSMD11, a “gatekeeper” 19S complex that recognizes, and unfolds muscle proteins 
before entry into the proteasome), and ubiquitin B and C (UBB and UBC, ubiquitin tags) (51,52,53). 
The physiological impetus for this upregulation of the UBP is multifaceted. One primary cause is a 
state of insulin resistance of T2DM, A second causative factor in ubiquitin proteasome upregulation 
in uremic myopathy is systemic inflammation that is characteristic of CKD (44).  
Inflammatory cytokines, such as IL-6, TNF-alpha, and C-reactive protein are increasingly 
generated in CKD in response to uremic toxins (methylguanidine, ouabain, creatinine, urea) and 
reduced renal clearance (54). These inflammatory cytokines phosphorylate signal transducer and 
activator of transcription 3 (Stat3), which in-turn increases expression of suppressor of cytokine 
signaling 3 (SOCS-3). SOCS-3 dephosphorylates and inhibits IRS-1 production, thereby further 
interfering with the insulin/PI3K/Akt signaling pathway, and allowing FoXO transcription of the E3 
ligases to go unchecked (44,54). However, the inflammatory cytokines also activate a TGF-beta 
family protein – myostatin. Stat3 independently increases the expression of CCAAT/enhancer 




of Akt via the Smad2/3 pathway, leading to activation of the ubiquitin proteasome pathway (44). 
Additionally, in rodent models of CKD, the uremic toxins that accumulate with impaired renal 
filtration/function contribute to metabolic acidosis – a condition that increases expression of 
ubiquitin mRNA and key 19S subunits of the proteasome (44,47). Yet, other metabolic contributors 
to the activation of the degredative ubiquitin proteasome system are present in uremic myopathy, a 
primary protein being angiotensin 2.  
Angiotensin 2 is the main effector of the renin-angiotensin-aldosterone system that controls 
fluid and electrolyte balance through coordinated effects on the heart, vasculature, and kidneys. 
Renin is secreted from the glomeruli of the kidney, and through a conversion cascade, generates 
angiotensin 2 (55). Angiotensin 2 acts on the kidney by binding to specific g-protein-coupled 
receptors, causing subsequent vasoconstriction and hypertrophy of afferent glomerular arterioles, 
leading to excess intraglomerular pressure and progressive damage and death of renal nephrons that 
is characteristic of CKD progression (55). Angiotensin 2 is upregulated in T2DM and even early 
CKD (56). However, angiotensin 2 also promotes endogenous production of various inflammatory 
cytokines (TNF-apha, IL-6, monocyte chemotactic protein-1, and nuclear factor-KB), which 
interfere with insulin signaling and thus promote E3 ligase production of the UBP as mentioned 
above (57,55,44).  
Beyond these multifactorial contributions to UBP-mediated muscle breakdown in uremic 
myopathy, there is a primary muscle protein-cleaving enzyme that actively feeds the UBP in CKD – 
caspase 3. Caspases are a family of proteases that cleave proteins. In the uremic state, caspase-3 is 
activated, and subsequently cleaves actomyosin to be tagged for degredation in the UBP, allowing 
for more rapid protein degradation (58). Indeed, studies have shown that in those with ESRD of 




of the FoxO-generated Atrogin-1/MAFbx and MuRF-1 E3 ubiquitin ligases, and in-vitro studies 
have even shown a direct stimulation of the proteasome by caspase-3 (58). Given the numerous 
contributing metabolic pathways of CKD that stimulate it, the UBP is responsible for the bulk of 
muscle breakdown observed in uremic myopathy. However, the second major route of muscle 
proteolysis – the autophagy lysosome system – may also play a role in the muscle atrophy of uremic 
myopathy.    
The autophagy pathway is a homeostatic mechanism that degrades cytoplasmic constituents 
– organelles (mitochondria), protein aggregates (including protein toxins), and intracellular 
metabolites and pathogens (59). Autophagy is initiated by the formation of a semicircular double-
membrane phagaphore that expands and engulfs selected intracellular components (including muscle 
proteins), and fuses to create a closed vesicle – the autophagasome (59). This autophagasome 
subsequently fuses with lysosomes which degrade the contained proteins and organelles, and expels 
the vacuolar debris via exocytosis (60). A crucial step in this degredative process is the conjugation 
of cytosolic microtubule-associated protein light chain 3 version 1 (LC3-1) to LC3-2. This protein 
must be conjugated to LC3-2 during the growth of the autophagasome, to act as both a structural 
support of the membrane, and as a sequesterer/docking site with proteins and organelles to be 
degraded (59,61). The overall formation of the autophagasome, however, is instigated by the Bnip3 
gene. The Bnip3-produced protein localizes to the outer mitochondrial membrane and endoplasmic 
reticulum, and may induce cell death by perturbing mitochondrial function and calcium handling of 
the ER. Moreover, Bnip3 protein serves as the interactive docking site with LC3-2 of the 
autophagasome, resulting in autophagic degradation of mitochondria and cristae of the endoplasmic 
reticulum (62,59). Predictably, an overactive autophagic system would remove excess proteins, 




deficient autophagy, toxic protein aggregates and defective organelles (ie damaged mitochondria) 
may accumulate, promoting muscle degredation and atrophy as well (59,63). However, autophagy is 
inhibited by phosphorylated Akt, as pAkt stops the conjugation of LC3-1 to LC3-2, prevents the 
transcription of LC3 proteins, and inhibits the transcription of the Bnip3 gene (64). Yet, in uremic 
myopathy of CKD, Akt is dephosphorylated, leading to an upregulation of the FoxO family 
transcription factors that interact with key autophagy genes. FoxO3 for instance, may access 3 
binding sites in the promoter region of the LC3 and Bnip3 genes, thus upregulating autophagy 
(61,64). Indeed, in CKD, FoxO3 is upregulated, leading to enhanced transcription of LC3 protein 
and Bnip3, which synergistically activate autophagy, and provide enough requisite protein to keep it 
active, resulting in muscle breakdown (44). However, the contribution of autophagy to CKD and 
uremic myopathy has only recently garnered investigative attention. The findings of reduced 
mitochondrial number and damaged mitochondria in uremic myopathy, certainly lend theoretical 
support for involvement of the aforementioned autophagic genes and protein (ie Bnip3). However, 
such findings also strongly implicate dysfunctional mitochondrial regulation. 
2. Reduced mitochondrial content/mitochondrial damage/ increased lipid droplet content 
in CKD: Mitochondrial production, or biogenesis, is critical in maintaining the functional and 
structural integrity of muscle, as it serves as muscle’s main energy-generating system (65). Studies 
have shown low concentrations of aerobic enzymes, with impairment of ATP synthesis and 
increased rate of intracellular acidification in uremic myopathy. This indicates that uremic muscle 
depends more upon anaerobic metabolism (47). However, this begs the question, is this due to 
deficient mitochondrial function, or deficient number of mitochondria? While the answer remains 
unclear, evidence suggests both may be true. Several studies have demonstrated in the deltoid, 




reduced oxidative enzyme activity, increased type 2 fiber percentage, low capillary density, 
mitochondrial inclusions (damaged mitochondria) and low myoglobin content (66,67,68,69). These 
are suggestive of an oxygen-independent energy metabolism preference in uremic myopathy (66). 
One study examined the in-vitro function of mitochondrial electron transport chain complex 2, SDH, 
in uremic muscle of an ESRD rodent-model, and found impaired ability of the complex to transfer 
electrons from administered succinate, down the transport chain (70). This predictably leads to 
impaired generation of ATP. Similar results are echoed in other works showing decreased 
activity/capacity of mitochondrial oxidative enzymes – cytochrome C (responsible for electron 
transport between ETC complexes), and citrate synthase (pace-maker for the 1st step of the citric acid 
cycle - catalyzes the reaction between acetyl CoA and oxaloacetate to form citrate and CoA-SH) 
(71). In-vivo, these results have been corroborated with 31P-MRS studies examining 
phosphocreatine depletion with contraction of uremic muscle. In these studies, with dynamic 
repetitive contraction, uremic muscle produces a greater and more rapid reduction in PCr 
concentration, suggesting reduced oxidative generation of ATP (66). A hypothesized reason for this 
deficient ATP production and storage, is an exhaustion of mitochondrial machinery due to 1. 
Reduced mitochondrial number,  2. Greater fractional energy expenditure for non-contractile ATP-
dependent processes (ie ion pumping), and 3. Lower pH. This leads to increased demand for 
oxidative ATP production from the fewer remaining mitochondria, exhausting these energetic 
systems, and leading to mitochondrial morphological changes. Indeed, Tamaki et al (2014) showed 
in a CKD mouse model, that these mice exhibited classic morphological features of uremic 
myopathy, and had reduced levels of PGC-1-alpha and phosphorylated AMPK (indicative of 
reduced mitochondrial content) in all fiber types (72). These results are also confirmed through 




(73). Interestingly, however, other studies examining in-vivo mitochondrial function, have observed 
no difference in mitochondrial oxidative capacity between those receiving dialysis with diagnosed 
uremic myopathy and a control group (67,47). After administration of glutamate, succinate, and 
ascorbate, ADP phosphorylation to ATP was not deficient in uremic myopathy, and function of all 5 
complexes of the ETC had similar specific activity. However, these studies did not account for the 
well-established acidic cellular environment of uremic myopathy which could interfere with ATP 
production, and were limited to those undergoing maintenance hemodialysis for ESRD (47). These 
studies suggest that deficient ATP production in-vivo likely stems from reduced mitochondrial 
number, and lower intracellular pH, that together may place undue burden on remaining 
mitochondria, leading to mitochondrial DNA mutations, structural damage observed in histological 
studies, and respiration deficits. Indeed, Lim et al. (2002) has shown that in those with uremic 
myopathy, there are large-scale deletions (mtDNA4977, 8,041-bp deletion), and higher content of 
lipid peroxides and protein carbonyls in mitochondrial membranes (74). The 70-fold increase in 
mtDNA-4977 deletion in uremic myopathy, causes removal of major structural genes of cytochrome 
c oxidase, and ATPases that are crucial to proper mitochondrial function, structure, and integrity 
(75). With the increased burden on existing mitochondria, and large-scale mtDNA deletions that 
exacerbate deficient mitochondrial energy production and structure, it is not surprising that oxidation 
of metabolites such as fatty acids, may be impaired, leading to lipid droplet accumulation observed 
in histological samples of uremic muscle. In support of this theory, numerous studies have shown 
carnitine deficiency in uremic myopathy, which would predictably lead to deficient fatty acid 
transport within the intermembranous space of the mitochondria, and ultimately lead to impaired 
beta-oxidation, and lipid accumulation above that experienced in T2DM alone (74,75,47). Moreover, 




(thereby promoting FA oxidation), is downregulated in uremic myopathy (71). The status of 
mitochondria in uremic muscle remains understudied, and may be a large contributor to muscle 
dysfunction in this disease. However, known histological and morphological changes in skeletal 
muscle also raise other questions regarding muscle health in this population. 
3. Internalized nuclei with z-band damage and cellular degeneration:  These findings in 
uremic muscle of CKD implicate muscle-repair mechanisms may be deficient, resulting in 
structurally weak and perpetually remodeling muscle fibers. Skeletal muscle is a highly plastic tissue 
that responds to a variety of physiological and pathological stimuli due, in part, to constant turnover 
or remodeling of muscle proteins, organelles and cell populations. Muscle repair is the duty of 
satellite cells, a normally quiescent cell population located beneath the basal lamina of myofibers 
(76). Muscle homeostasis requires that these cells proliferate, differentiate and fuse to repair injured 
muscle fibers, form new muscle fibers, or return to a quiescent state to re-populate the cell pool (76). 
With muscle injury, among other signaling mechanisms, Notch ligand-delta is upregulated, and 
binds to notch-1 receptors on satellite cells, and activates the myogenic transcription of satellite cell 
functional genes Myf5, MyoD, and myogenin leading to satellite cell proliferation, and 
differentiation to repair damaged or necrosed fibers (76,77). However, obligatory to this repair 
process, is the simultaneous mobilization of fibroblasts, a cell population charged with producing 
temporary extracellular matrix components (collagen type 1 and 3, fibronectin, elastin, laminin, etc.) 
to stabilize the tissue and act as scaffolds for generation of new fibers (78). In rodent models of CKD 
with signs of uremic myopathy however, transcription of satellite cell function genes (MyoD, Myf5 
– proliferation, Myogenin – differentiation) and contractile proteins (eMyHC) are decreased (79). 
Additionally, these satellite cells, when grown in-vitro and in-vivo to examine their proliferative and 




myosin content in resultant muscle fibers (79). This is paired with persistently elevated low-grade 
systemic inflammation observed in CKD – a state that provides positive feedback to muscle-resident 
fibroblasts in ECM deposition. Thus, with deficient satellite cell function, daily weight-bearing and 
activity induces muscle damage that is poorly rectified. Muscle repair becomes slowed, with 
deficient synthesis of key structural and functional proteins in new muscle cells, with simultaneous 
replacement with non-contractile fibrotic or adipose tissue (78). This may explain the appearance of 
centrally located nuclei in uremic myopathy, as this is indicative of newly formed muscle fibers in a 
perpetually damaged environment, though the degree of non-contractile tissue accrual in uremic 
muscle remains unknown. In uremic myopathy, theoretically, newly formed muscle fibers are not 
strong enough to withstand the continual demands of daily activity, and incur damage. Satellite cell 
response to this continual damage is both inadequate and delayed, and muscle atrophy ensues with 
potential concomitant fibrous or fatty replacement. The underlying reason for the proposed deficient 
satellite cell repair mechanism in uremic myopathy is still largely unknown, and remains to be 
determined in human muscle. However, some evidence suggests that insulin and IGF-1 signaling 
deficits, inflammation, and angiotensin 2, synergistically inhibit satellite cell function (79).  
Satellite cells possess an angiotensin type 1 receptor, which upon activation by angiotensin 2, 
suppresses notch signaling and subsequent satellite cell functional gene transcription (80). IGF-1 is 
necessary for activation of satellite cells, and is also deficient in a state of insulin resistance as in 
CKD and T2DM (79). Additionally, IGF-1 binds to its receptor IGF-1BP-5, which in-turn modulates 
the extracellular matrix surrounding satellite cells and facilitating their proliferation (52).  
The z-disc streaming seen in uremic muscle is theorized to stem from 2 causes in uremic 
myopathy – altered extracellular matrix protein production, and immature muscle fiber generation. 




incapable of withstanding the high strain rates placed upon them, resulting in z-disc rupture and 
damage (66). Concurrently, evidence shows reduced mRNA levels for extracellular matrix proteins 
(filamin C, vinculin, talin) linking costameres (a tether linking and reinforcing the z-disc to the 
extracellular matrix lattice) to z-discs in skeletal muscle in uremic myopathy (81,66). Lacking these 
proteins, uremic muscle may possesses a less-stable z-disc that is predictably prone to damage 
during contraction. Moreover, muscle satellite cells and their purported dysfunction in uremic 
myopathy may also impact inherent metabolic health of mature skeletal muscle fibers through 
improper maintenance of myonuclear domain sizes of the muscle fibers. 
Each myonucleus of a mature, elongated, multinucleated muscle cell, governs an area of 
surrounding cytoplasm, and produces enough protein and regulates signaling to support the limited 
area of cytoplasmic and structural components and organelles within it. This is called the nuclei’s 
domain (82). With changes in the metabolic health of skeletal muscle, and in conditions of muscle 
wasting or atrophy (ie. uremic myopathy), myonuclear domain sizes continually shift, and the 
required incorporation (via satellite cell fusion) or removal (via autophagy or apoptosis) of nuclei 
becomes critical to the maintained functional and metabolic viability of the muscle cell (82). For 
instance, protein synthesis requires steady supply of nuclear derived genetic information to code the 
building of new proteins. Accumulation of DNA damage and deregulation of gene expression results 
in decreased tissue remodeling, and required nuclear removal and replacement through satellite cell 
mobilization (83). Thus, it is not unreasonable to suggest that satellite cell dysfunction or loss, may 
also contribute to conditions of muscle wasting and metabolic impairment through inadequate 
myonuclear contribution or regulation (84), though this remains to be investigated. 
 In community-dwelling elderly, research has examined the connection between anemia, 




mobility deficits. Indeed, functional mobility/physical activity decrements in advanced stage CKD, 
is strongly associated with mortality and poor clinical outcomes (86). However, while mobility and 
physical activity are independently associated with renal function and overall health in this 
population, the aforementioned uremic myopathy (CKD-induced loss of muscle proteins, organelles, 
energetic deficiencies, and regenerative deficits) presumably imparts a state of muscle dysfunction 
that hinders continued mobility (44,85). Indeed, those with T2DM and late CKD exhibit fast-onset 
muscle fatigue and reduced exercise capacity and physical performance, stemming from dysfunction 
of muscle regulatory mechanisms and impaired muscle mitochondrial energy production (37). 
Together, muscle breakdown and impaired energy production may produce poor muscle quality that 
exacerbates mobility deficits and renal decline. These underlying factors that drive uremic myopathy 
in CKD has largely been examined in the context of advanced CKD, and ESRD in particular. When 
in the progression of CKD in T2DM, the effects of this process become apparent, and to what extent, 
is unknown. Determining when along the progression of CKD, these muscle regulatory pathways 
implicated in uremic myopathy become dysfunctional, may reveal key windows of opportunity to 
prescribe conservative exercise intervention to preserve muscle performance, mobility, and quality 
of life in T2DM-induced CKD. 
Primary Purpose: To determine the unique contributions and temporal nature of CKD progression 
on skeletal muscle health, regulation, performance, and overall physical mobility in those with 
T2DM. In determining when along the progression of T2DM-induced CKD, skeletal muscle 
regulatory pathways become dysfunctional, and how this dysfunction manifests poor muscle health 
and performance, clinicians may then better understand the specific muscular sub-systems to target 





Specific Aims and Hypotheses: 
Specific Aim 1 (Chapter 1)- Determine how renal function (filtration capacity) and associated 
systemic factors (hyperglycemia, uremic status) relate to physical function and skeletal muscle 
performance across stages of T2DM-CKD.  
Approach – Renal filtration capacity and stage of CKD determined via serum creatinine and CKD-
EPI equation, and denoted as estimated glomerular filtration rate (eGFR). Glycemic control/insulin 
sensitivity using HbA1c. Uremic status determined via blood-urea-nitrogen concentration (BUN). 
Physical function is to be determined using the 9-item physical performance test (PPT) score, while 
muscle performance of major lower extremity muscle groups is determined via isokinetic 
dynamometry (to measure knee extensor peak torque at different contraction velocities and at 
optimal sarcomere length).  
Aim 1 – Hypotheses: Elevated BUN (uremia), and poor glycemic control (HbA1c) will both 
positively correlate with renal filtration rate (eGFR). Physical mobility (PPT score) will directly 
correlated with eGFR, even when controlling for comorbidities. Declining eGFR will correlate with 
declines in proximal muscle strength of the lower extremities (knee extensor torque production).  
Specific Aim 2 (Chapter 2) - Determine the functional status of muscle mitochondria, and activity 
of gene pathways governing muscle health, protein and organelle turnover and regulation, across 
stages of CKD. These measures will be additionally assessed for their relationships to muscle 
performance and physical function.  
Approach – 1. Stage of CKD and filtration rate determined as in aim 1, with additional assessment of 
renal filtration barrier stability determined via proteinuria quantification (urinary spot 




(oxidative phosphorylation capacity, electron transport system capacity, ETC-complex 1 function, 
ROS production) assessed via high-resolution respirometry of permeabilized muscle fibers, 3. 
Mitochondrial enzyme activity determined by enzymatic spectrophotometric assay, 4. Mitochondrial 
abundance determined via mitochondrial DNA copy number and qPCR, and citrate synthase enzyme 
activity. 5. RNA-sequencing to analyze the transcriptome of gene pathways governing mitochondrial 
oxidative phosphorylation, turnover, and protein import 6. Muscle performance and physical 
function will be determined for major lower extremity muscle groups via isokinetic dynamometry 
(to measure hip and knee extensor peak torque, work, average power -watts, and fatigue resistance).  
Aim 2 – Hypotheses: Reductions in renal filtration rate in CKD will positively correlate with:1. 
Lower extremity muscle performance, 2. Physical function (PPT score, gait speed, chair rise 
capacity), 3 mitochondrial function. With CKD progression, there will be stage-wise reductions in 
mitochondrial abundance, and enzyme activity. Mitochondrial function will significantly positively 
correlate with muscle performance and physical function. The skeletal muscle transcriptome will 
reveal altered gene expression in pathways governing mitochondrial regulation and function in later 
stages of CKD compared to early-stage.  
Specific Aim 3 (Chapter 3) - Determine the status of muscle quality and regenerative capacity, and 
explore the abundance and myogenic function of skeletal muscle satellite cells and muscle-resident 
inflammatory cells with CKD progression. Secondarily, explore how these measures relate to muscle 
quality and performance, and determine the relationship to relevant myogenic gene networks. These 
measures will also be assessed for their relationships to systemic inflammatory indices and uremic 
status across stages of CKD.  
Approach – 1. Genome-wide expression analysis of protein-coding gene families governing satellite 




sequencing. 2. Stage of CKD and filtration rate determined as in aims one and two. 3. Skeletal 
muscle satellite cell abundance determined via fluorescence-activated cell sorting (FACS) of muscle 
biopsies, and functional status (proliferative capacity, myogenic function and gene expression) 
determined via cell culture and qPCR. 4. Muscle quality determined via histology and image 
quantification of non-contractile- tissue accumulation. 5. Muscle performance determined as 
described in aim two. 6. Systemic inflammatory indices determined via plasma cytokine 
concentrations (IL-6, TNF-a), and uremic status via serum BUN levels as in aim one.  
Aim 3 – Hypotheses: Reductions in renal filtration rate in CKD will correlate with: 1. Reduced 
satellite cell abundance, 2. Impaired satellite cell myogenic capacity, and 3. Increased non-
contractile tissue accumulation in skeletal muscle. Muscle-resident inflammatory cell population 
will increase with progression of CKD. Poor muscle quality will correlate with poor muscle 
performance and increased systemic inflammation and uremia in CKD. 4. The skeletal muscle 
transcriptome will reveal altered gene expression in gene networks that influence SC regenerative 
function (cell morphology pathways, growth factor signaling, extracellular matrix regulation, and 
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Progressive CKD in Type 2 Diabetes Impairs Skeletal Muscle 

















Over 29 million persons in the United States (~9%) have diabetes mellitus, with 90% exhibiting the 
obese type 2 phenotype (T2DM). Nearly two thirds of those with diabetes have or will develop 
chronic kidney disease (CKD) – an early complication of T2DM (1). CKD, or diabetic nephropathy, 
is characterized by a progressive and persistent decline in kidney function classified into 5 
categorical stages according to the degree of renal filtration impairment, or renal filtration rate (2). 
Renal filtration rate, or glomerular filtration rate (GFR), is the volume of fluid filtered from the 
glomerular capillaries in the bowmans capsule of the kidney per unit time (minute) (3). The genesis 
of CKD and its progression in T2DM is thought to stem from the metabolic and hemodynamic 
abnormalities of T2DM. Specifically, a key causative factor identified is the accumulation of 
extracellular matrix of the renal glomerulus. Chronic hyperglycemia, among other factors including 
glycated albumin -AGEs, low-grade systemic inflammation, and excess glomerular capillary 
pressure and hypertrophy observed in T2DM, stimulates production of pro-fibrotic protein TGF-B in 
the glomerulus, where it localizes to podocytes – a key filtration-barrier support protein (4). Once 
localized, TGFB induces connective tissue growth factor (CTGF) and vascular endothelial growth 
factor (VEGF), and type 4 collagen production- the main components of the glomerular basement 
membrane, to ultimately result in renal fibrosis (4,5). This process promotes progressive basement 
membrane thickening, glomerular hypertrophy and ultimately declining renal filtration and 
degradation of the filtration barrier leading to proteinuria (4). Accordingly, CKD is divided into 5 
stages characterized by decline in the rate of glomerular filtration, estimated from serum creatinine 
concentrations, as creatinine derives from creatine degradation, and is freely filtered by the kidney 




 Given the pathophysiology of CKD in T2DM, its not surprising that those with T2DM 
exhibit a more rapid decline in kidney function above their age-matched counterparts. Indeed, in a 
10-year prospective longitudinal study of 1682 participants with T2DM, and baseline eGFR >60 
mL/min, the authors found between a 1 (“non-decliner”) and 6 (“rapid decliner”) mL/min annual 
decline in kidney function in those with T2DM (2). The authors also found that HbA1c (glycemic 
control), and diabetes duration and severity (ie. presence of peripheral neuropathy), were significant 
modifiers of the annual rate of decline (2). Other studies have supported a faster rate of renal decline 
in those with T2DM, ranging from 1 mL/min per year for those without proteinuria, to nearly 3 
mL/min per year decline when proteinuria is present (6,2). These data all support the observations of 
a faster rate of kidney decline in those with T2DM, as non-diabetic individuals of similar age 
experience <1 mL/min annual decline (7,8,9). However, a key modifiable factor in the rate of renal 
decline in progressive CKD is physical activity and function. Evidence shows that among those in 
stage 4 CKD (eGFR 15-29 mL/min), those who reported no leisure time physical activity over a 
typical 4-week period, had an annual decline in kidney function of ~10%. This was contrasted by an 
annual decline in renal filtration of only 6% in those who reported meeting consensus guidelines for 
physical activity in the general population (150 minutes/wk) (10). However, despite the seeming 
renal-protective effect of physical activity, it is well established that in those in ESRD (stage 5 CKD 
– eGFR <15 mL/min), there is marked impairment in aerobic capacity and physical performance, 
and subsequent lower activity compared to healthy populations (11). Thus, the disease state may 
hinder physical mobility. This hindrance may stem from secondary impairments in muscle function, 
something often observed in advanced CKD. 
 CKD configures well to a geriatric syndrome model, specifically in its propensity to promote 




combination of objective and subjective findings such as slowed gait, physical inactivity, exhaustion 
or fatigue, muscle weakness and loss of muscle mass (12). Bao et al. found that 74% of those 
undergoing maintenance hemodialysis (end-stage renal disease - ESRD) were frail, and at 57% 
increased risk of death (13). Similarly, in the Canadian Frailty Observation and Interventions Trial 
(CanFIT), examining 600 advanced stage CKD participants (stage 4-5, pre-dialysis) over a 2 year 
period, 56% of individuals exhibited reduced physical function (assessed with short physical 
performance battery), and 8-times higher risk of physical frailty (14). This frailty state and impaired 
physical function may stem from uremia-induced muscle dysfunctions, collectively referred to as 
uremic myopathy.  
Uremic myopathy was first described by Serratric et al. (1967), in a group of patients with 
chronic renal failure (ESRD) and progressive proximal muscle weakness caused by an intrinsic 
disorder of muscle function (15). Presently, though often debated, uremic myopathy – a collection of 
functional and structural muscle abnormalities in patients with CKD – is considered to be a 
consequence of the uremic state itself (16,17). The uremic state is a term used to describe the excess 
metabolic bi-products (ie. urea, creatinine, etc.) in the blood that, due to the declining filtration 
capacity of CKD, are no longer filtered by the kidneys and excreted in the urine, most often 
associated with ESRD (stage 5 CKD) (18). Urea, a nitrogenous end-product of protein and amino 
acid catabolism, is produced by the liver and distributed throughout intra- and extracellular fluid, and 
filtered out of circulation by glomeruli. This rise in blood urea concentration in CKD is due to a 
disequilibrium between the rate of amino acid incorporation into skeletal muscle, rate of amino acid 
release from tissue and muscle breakdown, and the capacity of the liver to form urea from these 
amino acids (19). Urea is of critical importance in the implicated pathophysiology of uremic 




biochemical preparations to denature them (20). In fact, increasing urea concentrations have been 
shown to alter tertiary structure of skeletal muscle myosin by selectively targeting its globular 
catalytic domain, specifically interfering with protein structure to alter ATP-binding and cross-
bridge cycling that drives muscle contraction (20). However, this has been demonstrated in a 
laboratory setting in-vitro, and the precise mechanisms that drive uremic myopathy and muscle 
impairment in CKD remain unknown.  
  While the physiological basis for uremic myopathy remains poorly understood, the clinical 
manifestation has been readily documented. Liu et al. (21) examined lower extremity function in 
community-dwelling elderly, with eGFR <60 mL/min with or without CKD, and found that those 
with CKD-induced kidney deficits had greater decline in walking speed over a 6.5 year observation 
period compared to non-CKD. Similarly, those with CKD were 55% more likely to have self-
reported dependence in walking or climbing stairs compared to their non-CKD counterparts (21). 
Additionally, Roshanravan et al. studied 385 participants with mean eGFR of 41 mL/min (stage 3 
CKD) with or without CKD, and assessed lower extremity physical performance via timed-up-and-
go (TUG), 4-minute walk distance, 6-min walk distance, and grip strength (22). While upper 
extremity function was preserved, performance on lower extremity functional tasks – such as gait 
speed, TUG, and 6-minute walk distance, were at least 30% impaired in those with CKD compared 
to non-CKD (22). To compound the findings of impaired functional mobility in CKD, this functional 
deficit translates into a significantly elevated risk of death in those with CKD. Indeed, lower 
extremity performance measures have been shown to be stronger predictors of mortality than kidney 
function in those with CKD (both those in ESRD and those pre-dialysis) (22). A small, .1 m/second 
drop in gait speed increases the risk of death by 26%, while a 1-second increase in timed-up-and-go 




affect functional performance, that subsequently increases risk for mortality and disease progression, 
and this may be due to the CKD-related metabolic and systems affects on skeletal muscle health and 
function, though this remains unknown. Similarly, while the vast majority of research has been 
devoted to advanced or progressed CKD on physical function and mortality risk, some studies, as 
mentioned previously, have demonstrated impairments in function in earlier CKD. However, these 
findings are largely in respect to matched controls without CKD. Given that progression of uremic 
myopathy runs parallel to the decline in renal function (17), and other studies reporting a mere 14% 
prevalence of frailty in those with earlier stages of CKD (contrasted with reports of 74% of frailty in 
those undergoing hemodialysis in ESRD)(12), there is a need to investigate the relationship between 
CKD progression and muscle performance decrements and physical mobility impairments across 
stages of CKD in those with T2DM. Thus, the purpose of this study is to determine the relationship 
between CKD progression (ie. stage of CKD, and eGFR decline) and muscle performance and 
physical function, and to investigate the contribution and predictive value of uremia, and CKD-
predisposing factors (glycemic control, severity and duration of diabetes) to these measures in those 
with T2DM.  
Methods and Procedures 
Participants 
Ninety five subjects participated in this study – 80 with diagnosed T2DM and peripheral neuropathy 
(PN), and 15 without evidence of PN. Participants of each categorical stage of CKD progression 
were – n = 21 in stage 1 CKD (16 male, 5 female), n=25 in stage 2 CKD (16 male, 9 female), n=24 
in stage 3 CKD (15 male, 9 female), and n=20 in pre-dialysis stages 4&5 combined (15 male, 5 




duration of T2DM (TABLE 1). Participants were recruited from the Washington University School 
of Medicine Diabetes Clinic, Washington University’s Volunteers for Health, the Center for 
Community Based Research, the Washington University Medical School Renal Clinic, and from the 
surrounding St. Louis community. Study inclusion criteria included individuals with BMI >27 
kg/m2, with diagnosis of diabetes mellitus and diabetes-induced CKD (diabetic nephropathy), with 
or without evidence of peripheral neuropathy. DM status was based on clinical report of a diagnosis 
of DM from a physician, confirmation of medication usage for DM (insulin, oral hypoglycemic 
agents or both) and verification of HbA1c levels either currently or at the time of diagnosis >6.5%. 
Participants were excluded from the study if they weighed more than 300 pounds (equipment weight 
limit), presented with any illness or hospitalization within the last 6 months, had any infection or 
ulceration of either foot, had prior botulinum toxin injections, severe foot deformity or amputation, 
or any co-morbidity (ie. rheumatic disease, peripheral arterial disease, dialysis, current cancer 
treatment, acute coronary syndrome, heart failure requiring medication, anemia, uncontrolled 
proliferative retinopathy) or medication that would limit participant on physical activity testing. 
Each participant read and signed an IRB-approved protocol and informed consent that was approved 
by the Human Research Protection Office at Washington University in St. Louis, MO. 
CKD Staging (eGFR) 
CKD staging was performed using serum creatinine concentrations. Serum creatinine was measured 
with a standardized assay, and used to estimate glomerular filtration rate (eGFR) - computed based 
on the Chronic Kidney Disease Epidemiology Collaboration equation and was classified into 5 
categories: eGFR > 90 mL/min per 1.73 m2 (stage 1 CKD), 60-90 mL/min (stage 2 CKD), 30-60 
mL/min (stage 3 CKD), 15-30 mL/min (stage 4 CKD), <15 mL/min (stage 5 CKD) with no kidney 





Laboratory measures including serum creatinine (mg/dl) as above, blood-urea nitrogen - BUN 
(mg/dl), HbA1c (%)  
Participant Demographics- 
Participants age, duration of T2DM, weight, height, and BMI (calculated as weight in kg divided by 
the square of height in meteres, used to define obesity) were collected through participant interview, 
weight balance, and stadiometer, respectively at the initial visit, prior to any dynamometry or 
physical performance testing. 
Neuropathy Assessment- 
Determined by the presence of either diminished or absent plantar sensation to light touch or 
pressure or vibration perception threshold. Lower extremity sensation was assessed via 
biothesiometry and semmes Weinstein monofilament testing. Neuropathy was defined clinically as 
the inability to feel the 5.07 (10 gram) monofilament on at least one non-callused site on the plantar 
aspect of either foot or the inability to perceive vibration <25 volts on the biothesiometer 
(Biomedical Instrument, Newbury, OH, USA) applied to the hallux (23). 
Physical Function – 
Functional physical performance was assessed using the 9-item modified physical performance test 
(PPT). The PPT is a timed observational assessment of performance on nine daily physical activities 
including: 5 consecutive sit-to-stand transfers without arm assistance, climbing a flight of stairs with 
10 steps, a 50-ft. walk test, turning 360 degrees, picking up a coin from the floor, donning/doffing a 




open, and ability to ascend 4 flights of stairs (23). Each item is scored from 0-4 based on the time 
taken to complete each task, with a maximum score of 36 (higher scores indicate better physical 
function/performance). Each task is performed twice with the average time used to score the task. 
Interrater reliability, validity with other functional assessments, and predictive validity of lack of 
independence and mortality have all been well established for the mPPT (24,25,26,27). The mPPT 
possesses a test-retest reliability of .964, while individual sub-items have reliability ranging from 
.51-.99, and Cronbach alpha of .785 (25,26). 
Stair Vertical Power- 
Stair vertical power was calculated from the stair-climbing component of the PPT, using the 
equation as previously described (23) 
Stair Power = [(weight in Kg)(9.8)(1.95)] / (avg. stair climb time in seconds) 
1.95 à cumulative height of the 10 steps (each step is 19.5 cm) 
Muscle Performance Assessment- 
Maximal isokinetic torque was measured at 60 deg/sec and 180 deg/sec for knee extension, using a 
Biodex System 3 Isokinetic Dynamometer (Shirley, NY, USA). Each isokinetic movement was 
repeated three times, with the average of the three trials used in the final analysis. Additionally, 
isometric peak knee extensor torque was measured at optimal quadriceps sarcomere length (knee 
flexion angle of 600) and averaged from 3 repetitions, each held maximally for 5 seconds.  
Physical Frailty Classification – 
Physical frailty was classified as described previously (26). Briefly, from the PPT scoring, a score 




percentile of community dwelling older adults, and scores less than or equal to 21 indicates function 
below the 25th percentile (25). Thus, frailty was subsequently classified based on PPT score as – 
mild/no frailty (PPT=30-36), moderate frailty (PPT=22-29), and severe frailty (PPT=21 or less).  
Statistical Analysis - 
Pearson Chi-square test for equality of proportions was used to determine the homogeneity of sex 
distribution, and neuropathy status between CKD-staged groups (stage 1, stage 2, stage 3, and 
stage4&5). CKD-group differences in PPT score, PPT sub-item measures, muscle performance 
measures, and stair power, were analyzed using 1-way ANOVAs and analysis of covariance 
(ANCOVA) to control for potential covariate confounders. Post-hoc testing for CKD-staged group 
differences was determined using Tukey’s HSD or Games-Howell in the event of a violation of 
homogeneity of variance. Bivariate pearson correlation coefficients were used to assess relationships 
between eGFR and the aforementioned measures, including lab measures. All analyses were 
evaluated at an alpha level set at .05.  
Forced entry multiple regressions were used to predict 1. 9-item PPT score using predictors – group 
status (using stage 1 CKD as reference), HbA1c, age, BMI, and duration of diabetes (years). 2. 9-
item PPT score using eGFR and the same predictors as model 1. 3. 9-item PPT score using 
predictors – BUN, HbA1c, age, duration of diabetes, and BMI. 4. Stair power using predictors – 
group status (using stage 1 CKD as reference), eGFR, BUN, HbA1c, age, duration of diabetes, BMI. 
Overall model fit was assessed using the Hosmer-Lemeshow goodness of fit test, and the potency of 
the model was determined using Nagelkerke’s Pseudo R2. All statistical analyses were performed in 







As shown in Table 1, there were no group differences in gender composition, PN status, BMI, or 
duration of diabetes. Groups did differ with respect to HbA1c, and age. For this reason, subsequent 
analyses for CKD-stage-based differences were performed with ANCOVA, adjusting for the 
covariates of age and HbA1c. Additionally, these variable were included in multiple regression 
analyses to ensure statistical control when analyzing for CKD progression contributions to functional 
declines. 
Muscle Performance- 
eGFR was significantly positively correlated with knee extensor torque production (600/sec – r=.523, 
p<.001/ and 1800/sec – r=.5, p<.001), and knee extensor isometric strength (r=.49, p<.001) (Table 2). 
As shown in Figure 1, there was a significant step-wise decline in muscle performance of the lower 
extremity with progression of CKD. Specifically, those in stage 3 exhibit a 33% decline in knee 
extensor torque at 600/sec, and 40% decline at 1800/sec (p=.001), while those in stages 4/5 exhibit a 
43% and 50% decline respectively (p<.001). Similar relationships were demonstrated in isometric 
force production of the knee extensors (23% decline from stage 1 to 3, p=.05, 41% decline in stage 
4/5, p<.001) (Figure 1). These declines in muscle performance across CKD stages persist, even after 
controlling for age, and HbA1c (knee extensor isometric torque – p=.004, knee extensor torque 
1800/sec – p=.003, knee extensor torque 600/sec – p=.006). There was no significant different in 
muscle performance between stages 1 and 2 CKD. Interestingly, muscle performance was negatively 





As shown in Table 2, eGFR was significantly negatively correlated with 50-ft walk time (lower time 
= faster gait speed) (r=-.434, p<.001), and time to climb 1 flight of stairs (r=-.3, p=.005). eGFR was, 
however, positively correlated with stair power (r=.482, p<.001), and PPT score (r=.43, p<.001). As 
shown in Figure 2, there is a significant decline in PPT score across stages of CKD, however, this is 
not significant until reaching stage 3 CKD, even after adjusting for age, and HbA1c (p=.05). 
Similarly, there is significant reduction in gait speed from stage 1 to stages 3 and 4 and 5, even after 
controlling for age and HbA1c (Figure 2). However, there is significant step-wise decline in 
functional stair power (watts), from stage 1 to stage 2 (p=.03), stage 1 to stage 3 (p=.009), and from 
stage 1 to stages 4 and 5 (p<.001) (Figure 2). Additionally, similar to its relationship to muscle 
performance, serum BUN concentrations were significantly positively correlated to 50-ft walk time 
(r=.471, p<.001), time to climb 1 flight of stairs (r=.39, p<.001). However, BUN was negatively 
correlated with stair power (r=-.342, p=.001), PPT score (r=-.48, p<.001). Additionally, those in 
stages 3 and 4 exhibited significantly higher frequency (Fishers exact, p=.018) of frailty (both 
moderate frailty and severe frailty) than those in stages 1 and 2, and those in stage 4 exhibited 
significantly fewer than expected individuals without frailty. 
However, the predictive value of kidney decline in muscle performance and functional impairment 
requires predictive regression modeling. 
 Multiple Linear Regression- 
Model 1 (predicting PPT score from CKD stage, HbA1c, age, BMI, and duration of 
diabetes). Using these predictors, the model accounted for nearly 50% of the variance in PPT score 




duration of T2DM, CKD stage was a significant  negative predictor of PPT score, with those in later 
stages (4 or 5) exhibiting a striking ~6 point decline in physical function scores (p<.001). (Table 3) 
Model 2 (9-item PPT score from eGFR, HbA1c, age, BMI, and duration of diabetes). Using 
these predictors, the resultant model accounts for 43% of the variance in physical function score 
(p<.001). eGFR, even after controlling for HbA1c, age, duration of diabetes, and BMI, is a 
significant positive predictor of PPT score (p=.005). (Table 3)  
Model 3 (9-item PPT score from BUN, HbA1c, age, duration of diabetes, and BMI). Using 
this combination of predictors, which accounted for 48% of the variance in PPT score, BUN is a 
significant negative predictor of physical function, even after controlling for potential confounding 
factors (p<.001). Specifically, for every 10 mg/dL increase in BUN, PPT score declines nearly 2 
points (Table 3). 
Model 4 (Stair power from CKD stage - using stage 1 CKD as reference, eGFR, BUN, 
HbA1c, age, duration of diabetes, BMI). This model accounted for 33% of the variance in stair 
power (p<.001), and when accounting for glycemic control, age, duration of diabetes, and BMI, 
CKD stage was a significant negative predictor of stair power, where stage 3 and stages 4 and 5, 
significantly negatively predict functional stair performance (p=.04, and p=.001 respectively). (Table 
3) 
Discussion 
Lower extremity muscle performance plays an essential role in mobility, as sufficient strength of the 
knee extensors is a requisite for optimal performance of weight-bearing tasks (27). Indeed, in other 
chronic conditions, progressive weakness of the quadriceps muscles constitute an early clinical 




Moreover, disability in CKD may be associated more with muscle strength than muscle mass, as 
recent studies in patients undergoing hemodialysis report poorer muscle function than matched 
controls for a given muscle mass (28). While we did not assess muscle mass, our findings support 
this notion, and demonstrate across the spectrum of CKD severity. Specifically, eGFR was 
significantly positively correlated with muscle performance of the quadriceps (r=.49 knee extensor 
isometric torque, r=.52 knee extensor torque 60 deg/sec, r=.5 knee extensor torque 180 deg/sec), a 
key mobility-dictating lower extremity muscle group. Predictably, muscle performance of the knee 
extensors exhibits moderate to strong correlations with functional performance, from gait speed, to 
stair climbing, and functional battery test scores (PPT). Moreover, when analyzed by CKD stage, 
muscle performance decrements become significant when considering differences between early 
CKD (stages 1 and 2), middle (stage 3), and late (stages 4 and 5) stages. Specifically, stage 3 CKD 
marks the earliest stage where muscle performance declines to a significant extent compared to early 
CKD (30-40% decline in torque production, p=.001). This is exacerbated by CKD progression to 
later stages. These findings are supported by other studies demonstrating performance deficits at 
stage 3 CKD and beyond (21, 22 ). Although conducted in a different population, the Heart and Soul 
Study (average age 67, n=1,024) found that those with eGFR <60 mL/min (stage 3+) had 6x higher 
odds of possessing exercise capacity below 5 metabolic equivalents (METS), a level constituting 
only moderate-level daily activity similar to, for instance, raking leaves or easy swimming (29). 
Moreover, exercise capacity was graded - with lower eGFR associated with worsening activity 
capacity. The investigators theorized this was secondary to poor muscle performance and strength 
that increased the physiological and metabolic cost of such activity (29,30). Similarly, the Health 
Aging and Body Composition study observed significant reductions in grip strength in those with 




seems to surpass a threshold whereby muscle performance decrements become significantly 
negatively impacted. This is of critical importance, as it is well established that declining physical 
performance may signal a high-risk state, even before overt disease-specific thresholds have been 
crossed (32). Much work has been conducted to dissect the mechanisms that drive these muscle 
performance decrements in CKD, mostly in the ESRD and late-stage CKD population. A large 
portion of this work has been dedicated to the network of atrophy signals that lead to protein-energy 
wasting in skeletal muscle (33,34,35).  
 Loss of lean mass secondary to CKD is termed CKD-cachexia and appears clinically as an 
accelerated form of sarcopenia (36). It has been theorized, among other potential causes, that uremic 
toxins, like urea, creatinine, etc. that accumulate in the circulation with impaired renal filtration, 
contributes to metabolic acidosis – a condition that increases expression of ubiquitin mRNA and key 
19S subunits of the proteasome that degrade contractile muscle proteins (34,17). This may 
predictably lead to loss of muscle mass, quality, and performance. This is supported, in part, by our 
findings that BUN is not only significantly negatively correlated with muscle performance (r=-.32-(-
.37)), but also with physical function (gait speed, stair climbing capacity, whole-body functional 
battery scores). BUN was a significant negative predictor of PPT scores (B=-.169, p<.001) and 
accounts for 24% of its variance (when controlling for potential confounding factors, model 3).  
However, despite the potentially harmful signaling cascades exerted upon skeletal muscle in CKD, 
the Singapore Longitudinal Aging Study of 1,315 community-dwelling older adults, found that 
eGFR was not predictive of muscle or functional performance limitations (37). Given that muscle 
homeostasis is complex and depends on hormonal, immunologic factors, and muscle stem cell 
function, this balance may be adversely or differentially affected by different pathomechanisms 




metabolic complications such as insulin-like growth factor 1 resistance, not observed to the same 
extent with aging-induced CKD, excess inflammation, dietary and nutrient metabolism deficits, and 
excess angiotensin 2 production above that observed in aging-induced CKD. Angiotensin 2, though 
not measured in this study, also promotes inflammation (upregulating TNF-a, IL-6, NFK-B) and 
interferes with insulin signaling that promotes muscle degradation (38,39,34,36). Hence, diabetic 
nephropathy progression, as shown in this study, significantly predicts muscle performance where 
other aging-induced models may not. This may, perhaps, be due to the metabolic environment and 
unique factors that challenge muscle homeostasis differently than simple aging-induced kidney 
changes. However, aside from significant impairments in muscle performance, perhaps of greater 
clinical significance, are the apparent deficits in functional mobility with CKD progression. 
 Those in stage 3 CKD exhibit, on average, a 4.5 point deficit in PPT functional scores, while 
those in later stages of disease experience a ~10 point drop, and these are both significant (p=.05, 
p=.001 respectively). However, while there appears to be a trend, there are not significant 
differences between stage 3 and stages 4 and 5 CKD with respect to any functional or muscle 
performance measures. This may indicate that underlying skeletal muscle pathology is present as 
early as stage 3 and already significantly affects muscle performance and subsequent function, and 
further progression of CKD beyond this point imparts more subtle progressive deficits. Additionally, 
even when accounting for glycemic control (HbA1c), age, duration of diabetes, and BMI, eGFR is a 
significant predictor of PPT score (B=.062, p=.005), and accounts for 10% of its variance. Given 
previous research that establishes the clinically significant decline threshold for PPT score at 2.4, 
this indicates that a ~39 mL/min drop in eGFR results in clinically meaningful declines in functional 
capacity (27). Given our results, when applied to the standard delineations for CKD stage, 




experiences a 39 point decline in eGFR, this would put them in stage 3 CKD (eGFR=52 mL/min) 
and would be predicted to exhibit a significant decline in functional capacity (PPT score). Such 
functional performance decrements may result in profound impairments in exercise capacity, 
engagement in physical activity, and ability to complete key activities of daily living (ADL). Indeed, 
in agreement with our results, in a study of aging-associated CKD in the United Kingdom (13,179 
participants), the authors report a parallel in functional impairment deficits with CKD progression, 
as those with eGFR <30 mL/min had a 2.2x higher odds of impairment in ADLs, while those with 
eGFR 30-44 mL/min exhibit a 1.6x higher odds of impairment, compared to those with eGFR >60 
mL/min (40). However, aside from decrements in a battery of functional measures, specific sub-
items of the PPT also emerged with significant differences between CKD stages.  
Slow gait is a robust biomarker of health, and a predictor of functional decline and death in 
older adults. In this study, there were step-wise significant increases in 50-ft walk time (slower gait 
speeds) across all stages of CKD, when compared to stage 1 (stage 2-p=.04, stage 3-p=.004, stages 
4&5-p=.001). This is also in agreement with the findings of the Health Aging and Body 
Composition study that measured 400 meter walk times, and lower extremity performance in a large 
cohort of 3,075 people, and found that those with eGFR <60 mL/min, took 20 seconds longer to 
complete the 400 meter walk (31). While the mechanistic underpinnings of slowed gait in CKD 
progression may stem from aforementioned muscle impairments, the Baltimore Longitudinal Study 
of Aging assessed energetic cost of walking over a 7-year period with portable indirect calorimetry 
and tracked its longitudinal association with 6-meter gait speed (41). Not surprisingly, increased 
energetic cost of walking significantly predicted rate of gait speed decline, as increased energetic 
cost of walking had an associated 57% greater risk of developing slowed gait (41). While not 




for CKD progression and skeletal muscle energetics. Mitochondria serve as the muscle’s main 
energy-generating system (42), and studies have shown low concentrations of aerobic enzymes, 
mitochondrial inclusions (damaged mitochondria), and impaired electron transport in muscle 
mitochondria of an ESRD rodent model (42,43,17,44). However, in light of our results, the 
implications that mitochondrial dysfunction may increase the metabolic cost of simple activities such 
as walking, and may even present earlier than ESRD to reduce gait speeds and impair skeletal 
muscle, are intriguing and warrant further study.  
The ability to climb stairs strongly correlates with other measures of functional disability and 
decline in medical status (45). Our previous work has demonstrated that along the continuum of 
metabolic and morphological impairments in those with type 2 diabetes alone, individuals who 
produce less than 441 watts of power while ascending stairs are very likely to be in a sarcopenic 
state (46). In this study, while those in stage 1 CKD exhibit only slight reduction in stair power from 
this cutoff (~411 watts), those in stages 3, 4 and 5, exhibit drastic deficits in stair power capacity 
(278 and 193 watts respectively). Although not conducted in a CKD population, Shimada and 
colleagues (47) found that among older community dwelling adults (avg. age of 80), leg extensor 
power of 484 watts differentiated those who reported difficulty with ascending stairs from those who 
did not (<484 watts equated with self-reported difficulty). In this respect, our results lend support to 
the notion that CKD represents an accelerated geriatric syndrome model, and may promote a 
sarcopenic process. Interestingly, our results also suggest that this geriatric, and potentially 
sarcopenic, state is imparted as early as stage 3 CKD. This is further supported by the BUN results 
from model 3. BUN, as mentioned prior, may serve as a potent atrophy-inducing agent (48,49). 
Given the results of model 3, possessing an elevated BUN (>20 mg/dL) translates into a significant 




muscle-specific performance is impaired upon reaching stage 3 CKD. This may be due, in part, to 
BUN elevations exceeding a threshold at stage 3, that negatively affects function and skeletal 
muscle. For instance, the average BUN in stage 2 CKD was within normal limits (~19 mg/dL), 
however, BUN was substantially elevated in stage 3 CKD (32 mg/dL). However, the specific 
underlying mechanisms behind this relationship require further study. 
Conclusion 
The findings of this study demonstrate that muscle performance of the lower extremity and 
physical function decline in-parallel with progression of CKD in T2DM, with these declines 
becoming clinically evident in stage 3. CKD-associated metabolic bi-products, like BUN was a 
significant negative predictor of functional mobility, and those in stage 3+ CKD demonstrate 
functional deficits that reflect a pre-mature geriatric state. The mechanistic causes that drive skeletal 
muscle impairments in CKD progression remains to be determined, but given the functional deficits 
observed relatively early in disease progression, such mechanistic studies should be devoted to 










Tables for Chapter 1: 
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20,1 19,6 20,4 16,4 p=.35 
Table 1: Demographics. * denotes significant F-test indicating difference between groups. The 
following symbols represent post-hoc pairwise comparisons: ^ (between CKD stage 1 and 4&5), + 
(between CKD stage 1 and 3), #(between stage 1 and 2), ∍ (between CKD stage  3 and 4&5), δ 
























































































































































































































TABLE 2- Bivariate pearson correlation coefficients were calculated between measures of physical 
function (PPT score, Stair power, stair climb time, 50-ft walk time), muscle performance (Knee 
extensor torque – 1800/sec, 1200/sec, isometric), and serum chemistries (eGFR, BUN). Inset within 
each block is the r-value correlation coefficient between the two correlated variables (row vs. 
column), with the corresponding p-value. Color coding is as follows  



























Table 3 (models) 
 
TABLE 3 
Linear regression model to determine 9-item PPT score (models 1-3) from various 
combinations of predictor variables, and a linear regression model to predict stair 
power from different predictors. Beta coefficients for each predictor represent change 
in PPT score or stair power, due to disease status or 1 unit change in the respective 
predictor. Model significance, amount of variance in 9-item PPT score or stair power, 
explained by the model (R2), and amount of variance in PPT or stair power, explained 
by each predictor are shown in the bottom panel. UPPER LEFT – Model 1. Predicting 
PPT score from HbA1c (glycemic control), BMI, duration of diabetes, age, and CKD 
stage (stage 1 is reference). 45% of the variance in PPT is explained by this model, 
with age, BMI, and CKD stage being significant negative predictors of PPT score (all 
p<.05). UPPER RIGHT – Model 2. Predicting PPT score from HbA1c (glycemic 
control), age, renal filtration rate (eGFR), duration of diabetes, and BMI. 43% of the 
variance in PPT is explained by this model, with age and BMI being significant 
negative predictors and eGFR being a significant positive predictor of PPT score (all 
p<.05). Note- shown below, eGFR accounts for 10% of the variance in PPT score. 
LOWER LEFT – Model 3. Predicting PPT score from HbA1c (glycemic control), age, 
duration of diabetes, BMI, and serum BUN. 48% of the variance in PPT is explained 




score (all p<.05). Note- shown below, BUN accounts for a surprising 24% of the 
variance in PPT score. LOWER RIGHT – Model 4. Predicting stair power (watts), 
from HbA1c, age, duration of diabetes, BMI, and CKD-stage (CKD stage 1 is 
reference). This model accounts for 33% of the variance in stair power, with CKD-

























Figures for Chapter 1: 
Figure 1 (muscle performance) 
 
 
Figure 1. Lower extremity muscle strength (knee extensor peak torque, and isometric torque) was 
assessed across CKD-stage groups with 1-way ANOVAs. Bar heights indicate group means, with 
error bars indicating + SD. The black lines connect two groups for post-hoc comparisons, with the 
corresponding p-value noted above it. LEFT- Group differences in knee extensor torque (assessed at 
isokinetic speed of 600/sec, knee extensor torque measured in ft-lbs) (p<.05). Significant differences 
were found between stage 1 and 3 (p=.001), stage 1 and 4&5 (p<.001), and stage 2 and 4&5 (p=.05). 
MIDDLE - Knee extensor torque (1800/sec, ft-lbs) (p<.05). Significant differences were found 
between stage 1 and 3 (p=.001), stage 1 and 4&5 (p<.001), and stage 2 and 4&5 (p=.03). RIGHT - 
Knee extensor isometric peak torque (measured in ft-lbs) (p<.05). Significant differences were found 













Figure 2 (physical function) 
 
Figure 2. Physical function capacity (PPT score, stair power, 50-ft walk time) was assessed across 
CKD-stage groups with 1-way ANOVAs. Bar heights indicate group means, with error bars 
indicating + SD. The black lines connect two groups for post-hoc comparisons, with the 
corresponding p-value noted above it. LEFT- Group differences in PPT score (scored 0-36, higher 
scores = better performance) (p<.05). Significant differences were found between stage 1 and 3 
(p=.05), stage 1 and 4&5 (p=.001), and stage 2 and 4&5 (p=.05). MIDDLE -50-ft walk time 
(seconds) (p<.05). Significant differences were found between stage 1 and 3 (p=.004), stage 1 and 
4&5 (p=.001), and stage 1 and 2 (p=.04). RIGHT – Stair power (watts) (p<.05). Significant 
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Skeletal muscle energetic impairments in progressive CKD: 















Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD) in the United 
States, as nearly two thirds of those with diabetes have or will develop CKD (1). CKD, or diabetic 
nephropathy, is characterized by a progressive and persistent decline in kidney function, classified 
into 5 categorical stages according to the degree of renal filtration impairment, or renal filtration rate 
(eGFR), with stage 5 constituting end-stage renal disease (ESRD) (2). Predictably, subsequent to the 
high prevalence of CKD in this population, T2DM is attributed as the cause of over 44% of all 
annual new cases of ESRD (3). This high burden of CKD in T2DM is associated with a litany of 
adverse outcomes, comorbidities, reduced quality of life, and significant health-care costs (3). 
 Those with T2DM exhibit more rapid declines in kidney function above their age-matched 
counterparts. Indeed, in a 10-year prospective longitudinal study of 1682 participants with T2DM, 
and baseline eGFR <60 mL/min, the authors found between a 1 (“non-decliner”) and 6 (“rapid 
decliner”) mL/min annual decline in kidney function (filtration rate) in those with T2DM (4). The 
authors also found that HbA1c (a measure of glycemic control), and diabetes duration and severity 
(ie. presence of peripheral neuropathy), were significant modifiers of the annual rate of decline (4). 
Other studies have supported a faster rate of renal decline in those with T2DM, ranging from 1 
mL/min per year for those without proteinuria, to nearly 3 mL/min per year in those with proteinuria 
(5,2). These data all support a faster rate of kidney decline in those with T2DM, as non-diabetic 
individuals of similar age experience <1 mL/min annual decline (6,7,8). However, a key modifiable 
factor in the rate of renal decline in CKD is physical activity and function. 
 It is now well established that those with CKD possess lower physical function, impaired 




disability, and increased risk of mortality and poor patient outcomes (9,10). Roshanravan and 
colleagues specifically demonstrate that in 385 participants with average eGFR of 41 mL/min (stage 
3 CKD), performance on lower extremity functional tasks – such as gait speed, timed-up-and-go 
(TUG), and 6-minute walk distance, was at least 30% impaired compared to those without CKD 
(11). Moreover, these functional deficits drastically elevate the risk of death in those with CKD, as 
for instance, a small .1 m/second decline in gait speed increases mortality risk by 26%, while a 1-
second increase in timed-up-and go (TUG) time elevated this risk by 8% (11). Yet, aside from 
increased risk of mortality, these functional deficits independently contribute to kidney functional 
decline and CKD progression. The Cardiovascular Health Study of 4011 older adults (age >65 years) 
shows that both energy expenditure and physical activity-mobility were inversely associated with 
rapid kidney functional decline (rapid defined as a loss of >3 mL/min per year in GFR) in patients 
with CKD (12). Similarly, the Seattle Kidney Study, examining those in stages 3-4 CKD, found that 
higher physical activity attenuated annual loss in kidney function by roughly 4% compared to 
sedentary behavior, and that just 60 minutes of weekly activity slows annual decline in eGFR by .5% 
(13). Though seemingly small effects, results from the Seattle study suggest that physical 
activity/mobility may independently delay ESRD initiation by almost 4 years compared to non-
activity (13). These findings are echoed in the large dataset (5888 participants) of the Cardiovascular 
Health Study that showed that physical activity nearly cuts the risk of rapid kidney decline (>3 
mL/min per year) in half compared to very low activity (16% risk vs. 30% risk) (14). Meanwhile, 
others have shown nearly 8 mL/min improvement in kidney function after 12 weeks of low-intensity 
aerobic activity and home-based walking (15). Additionally, other authors find that exercise intensity 




In light of such findings, physical activity may be a potent intervention prescription for such 
patients. However, CKD progression, and especially ESRD, imparts a state of intolerance to such 
activity and exercise. Indeed, the Heart and Soul Study found that those with eGFR <60 mL/min 
(stage 3+ CKD) had 6x higher odds of possessing an exercise capacity below 5 METS, or moderate-
level daily activity, and this was exacerbated with progression of disease (16). This exercise 
intolerance has also been demonstrated in those in ESRD receieving hemodialysis treatment (17). 
Given that skeletal muscle tissue is critical for performance of many daily functions in the body and 
is responsible for movement, impairments in skeletal muscle may be the focal point of CKD-induced 
functional and exercise capacity deficits. Indeed, reduced kidney function leads to the retention of 
uremic solutes, culminating in inflammation, hypercatabolism, oxidative stress, and insulin 
resistance which combine to promote skeletal muscle dysfunction (9). A direct assessment of this 
hypothesis was performed by Diesel and colleagues (1990), who aimed to determined if CKD-
induced exercise intolerance was derived more from central cardiorespiratory origins or skeletal 
muscle origin (17). Using measures of peak oxygen consumption during maximal exercise testing, 
serum chemistries (blood lactate, total hemoglobin, hematocrit), along with isokinetic dynamometry 
and ergometry, and peak heart rates, rates of ventilation and respiratory exchange ratio measures 
(RER), the investigators found significant correlations between isokinetic muscle strength and 
exercise duration, peak ventilation and peak blood lactate concentrations (17). However, no such 
relationships were found for the other cardiorespiratory measures and exercise duration. This study 
elegantly demonstrated that skeletal muscle strength predicts exercise capacity as opposed to blood-
oxygen carrying capacity, and that altered skeletal muscle function explains the observed exercise 
and mobility intolerance in those with CKD (17). Others have attempted to investigate further, the 




Low renal filtration rate is associated with marked muscle impairment and heightened risk 
for functional limitations. In fact, a recent study demonstrates significant reductions in knee extensor 
strength with progression of CKD (18). Moreover, a more mechanistic recent study demonstrated 
reduced calf muscle density in older adults with lower kidney function, theoretically due to increased 
adipose tissue accrual that subsequently interferes with metabolism and contractile mechanics 
(19,20). By the same token, the authors also found more rapid declines in quadriceps muscle strength 
over time in those with lower eGFR (19). These results are intriguing, as lower extremity strength, 
specifically quadriceps strength, has been demonstrated to more strongly dictate functional mobility 
capacity, and risk of mortality in those with CKD (10,9). Indeed, many have theorized that 
functional mobility and exercise capacity deficits in this population are secondary to poor muscle 
performance and strength that increases the physiological and metabolic cost of such activities 
(16,21). Given that muscle size, among other factors, is critical for muscle strength and performance, 
loss of muscle mass may explain some of these mobility deficits and intolerance to exercise (10). 
Indeed, even minor losses of muscle contractile proteins (ie. Myosin, actin) can be association with 
large decrements in force due to resultant reduction in cross-bridge formation with contraction (10).  
In concordance with this theory, the CKD hormonal and systemic milleiu promotes a state of 
protein-energy wasting and cachexia that targets contractile proteins (22,23,24,25). As evidence, 
individuals on hemodialysis with ESRD experience rampant muscle and whole-body degradation 
through the contractile-protein targeting ubiquitin proteasome pathway (26).  
Interestingly, however, it has been shown that in those undergoing hemodialysis in ESRD, muscle 
dysfunction and poor strength was only marginally correlated with muscle atrophy, and that these 
patients displayed poorer muscle function than matched controls for a given muscle mass, even after 




this point, remains unresolved, and the underlying mechanism driving inherent muscle performance 
impairment remains unknown in CKD. However, a key skeletal muscle component that influences 
exercise tolerance, muscle performance, and muscle breakdown and therefore a potential key player 
in muscle and mobility dysfunction in CKD is mitochondria and its capacity for oxidative 
phosphorylation. 
 Mitochondria are the powerhouses of biological tissues. In muscles, they link oxidation of 
substrates to phosphorylation that generates ATP. The contractile fibers then use ATP to generate 
force and motion (27). Of the two populations of mitochondria in skeletal muscle (subsarcolemmal, 
intermyofibrillar), intermyofibrillar mitochondria not only constitutes the vast majority (~80%), but 
also produce more ATP, via oxidative phosphorylation, to fuel cross-bridge cycling and muscle 
contraction (28). Thus, mitochondria provide the bridge between oxygen delivery and synthesis of 
ATP that fuels muscle contraction and exercise performance (27). This is supported by the findings 
of the Baltimore Longitudinal Study of Aging, in which the examiners investigated the relationship 
between in-vivo mitochondrial ATP-producing capacity (via 31-PMRS) and knee extensor muscle 
performance, and found that even after accounting for age, sex, height, and weight, mitochondrial 
function is significantly positively associated with muscle strength (and muscle strength per volume 
of muscle) (29). When combined with the findings by Diesel et al. (1990), that muscle strength 
deficits rather than oxygen delivery in CKD causes the observed limitations in exercise performance 
- skeletal muscle mitochondrial deficits emerge as a potential underlying mechanism, as these 
organelles translate oxygen into fuel for muscle performance. Indeed, others have demonstrated that 
mitochondrial ATP-producing capacity is closely linked to the capacity of muscles to generate 
contractile power as well (27). This has been clearly demonstrated in aging studies that show 50% 




power output per muscle volume (27), and these age-related reduction in mitochondrial function are 
strong predictors of walking speed, and more challenging gait tasks such as climbing stairs (30).  
This is intriguing, especially considering that CKD imparts a similar state of functional impairment 
and muscle weakness for a given muscle mass as well (27). Subsequent to these findings, 
improvements in mitochondrial oxidative metabolism and ATP-supplying capacity have been shown 
to directly relate to improved generation and maintenance of leg muscle power and endurance 
(27,31).  Such reductions in ATP-production capacity of skeletal muscle mitochondria have been 
theorized to stem from either 1. More H+ leak in the mitochondria that does not lead to 
phosphorylation, 2. Reduced oxidative capacity due to electron transport chain deficiencies, or 3. 
altered mitochondrial density and organization (27). Increase H+ proton leak, otherwise known as 
uncoupling, in skeletal muscle has been linked to higher metabolic coast of locomotion, reduced 
exercise capacity, greater fatigability, and reduced mobility (27). This uncoupling promotes reduced 
muscle contractile capacity that limits speed and sustainability of functional tasks (27). This 
uncoupling of oxidative phosphorylation also promotes redox stress (32,33) that can result in DNA 
damage, protein oxidation, and apoptosis in skeletal muscle. Interestingly, those undergoing 
hemodialysis in ESRD demonstrate increased plasma isofuran levels indicative of mitochondrial 
oxidative stress, yet underlying mitochondrial function has not been thoroughly examined (34). 
Thus, mitochondrial function, and coupling efficiency constitutes a ripe area of investigation in the 
pathogenesis of CKD-induced muscle impairments and functional decrements, though this remains 
unstudied.  
 Thus, the purpose of this study is to determine how lower extremity skeletal muscle 
mitochondrial function (coupling efficiency, H+ leak, electron transport chain function) and 




mitochondrial health relates to lower extremity muscle performance, and overall physical function. 
In understanding the underlying energetic contributions to muscle and mobility impairments in CKD 
progression, we may gain a better understanding of not only which biological mechanisms hinder 
mobility to secondarily promote renal decline, but also the temporal nature of this process in the 
course of disease. This may inform key targets and windows of opportunity for conservative 
treatments to remedy functional deficits and improve activity engagement/tolerance and attenuate 
CKD progression in those most vulnerable – those with T2DM.  
Methods  
Participants 
Twenty seven subjects participated in this study – all with diagnosed T2DM, 12 with diagnosed and 
clinically confirmed peripheral neuropathy (PN), and all with clinically diagnosed diabetic 
nephropathy (diabetes-induced CKD) by a nephrologist. Participants were stratified into early CKD 
stages (eGFR >60 mL/min, stages 1 and 2), middle-stage CKD (eGFR 30-59 mL/min, stage 3), and 
late CKD (eGFR<29 mL/min, stages 4 and5). Participants of each categorical stage/group of CKD 
progression were – n = 9 in early CKD (stage 1 and 2 - 7 male, 2 female), n=9 in middle-stage  CKD 
(stage 3 - 6 male, 3 female), and n=9 in late-CKD (stages 4 and 5 - 5 male, 4 female). The groups 
were matched for age, diabetes severity (i.e. presence of PN), BMI, duration of T2DM, glycemic 
control, and gender composition (TABLE 1). Participants were recruited from the Washington 
University Volunteers for Health, the Center for Community Based Research, the Washington 
University Medical School Renal Clinic, and from the surrounding St. Louis community.  
Study inclusion criteria included a diagnosis of T2DM based on clinical report of a diagnosis 




agents or both) and verification of HbA1c levels either currently or at the time of diagnosis >6.5%, 
and/or OGTT >200 mg/dL. A diagnosis, particularly for those with eGFR <60 mL/min, of diabetic 
nephropathy based on nephrologist clinical assessment of patient medical history, degree of 
proteinuria (must be present at least at the microalbuminuria level – urinary ACR >30 mg/g), 
glycemic control, diabetic medication use, hypertension status, and rate of kidney decline (eGFR 
utilizing creatinine), all according to KDIGO guidelines.  
Participants were excluded from the study if they weighed more than 350 pounds (due to 
equipment weight limit), had any infection or ulceration of either foot, severe foot deformity or 
amputation, or any serious medical co-morbidity. Serious medical comorbidities included - dialysis 
treatment, heart failure requiring medications, or New York Heart Association class 3 or class 4 
heart failure, coagulation disorders (platelets <100,000, PT > 2 seconds above control, or INR >1.5), 
anemia (Hbg < 10g/dL), uncontrolled proliferative diabetic retinopathy, joint replacement or 
musculoskeletal injury that precludes intense muscular contraction, within 1 year of enrollment, 
symptoms that meet the requirement for class C or class D of the AHA risk stratification criteria, 
individuals who are participating in regular structured exercise programs, or may be pregnant or 
breast feeding, current cancer treatment, and organ transplant requiring immunosuppressant therapy. 
Each participant read and signed an IRB-approved protocol and informed consent that was approved 
by the Human Research Protection Office at Washington University in St. Louis, MO. 
CKD Staging (eGFR) 
CKD staging was performed using serum creatinine concentrations. Serum creatinine was measured 
with a standardized assay, and used to estimate GFR (eGFR) - computed based on the Chronic 




90 mL/min per 1.73 m2 (stage 1 CKD), 60-90 mL/min (stage 2 CKD), 30-60 mL/min (stage 3 CKD), 
15-30 mL/min (stage 4 CKD), <15 mL/min (stage 5 CKD) with no kidney transplant or dialysis. 
Laboratory Measures 
Laboratory measures including serum creatinine (mg/dl) as above, BUN (mg/dl), HbA1c (%), and 
urine albumin:creatinine ratio (ACR – mg/g) to quantify degree of proteinuria.  
Participant Demographics- 
Participants age, duration of T2DM, weight, height, and BMI (calculated as weight in kg divided by 
the square of height in meteres, used to define obesity) were collected through participant interview, 
weight balance, and stadiometer, respectively at the initial visit, prior to any dynamometry or 
physical performance testing. 
Neuropathy Assessment- 
Determined by diminished or absent plantar sensation to light touch or pressure or vibration 
perception. Lower extremity sensation was assessed via biothesiometry and semmes Weinstein 
monofilament testing. Neuropathy was defined clinically as the inability to feel the 5.07 (10 gram) 
monofilament on at least one non-callused site on the plantar aspect of either foot or the inability to 
perceive vibration <25 volts on the biothesiometer (Biomedical Instrument, Newbury, OH, USA) 
applied to the hallux (20). 
Physical Function – 
Functional physical performance was assessed using the 9-item modified physical performance test 
(PPT). The PPT is a timed observational assessment of performance on nine daily physical activities 




with 10 steps, a 50-ft. walk test, turning 360 degrees, picking up a penny from the floor, 
donning/doffing a jacket, lifting a book onto an overhead shelf, a Romberg standing balance 
assessment with eyes open, and ability to ascend 4 flights of stairs (20). Each item is scored from 0-4 
based on the time taken to complete each task, with a maximum score of 36 (higher scores indicate 
better physical function/performance). Each task is performed twice with the average time used to 
score the task. Interrater reliability, validity with other functional assessments, and predictive 
validity of lack of independence and mortality have all been well established for the mPPT 
(35,36,37). The mPPT possesses a test-retest reliability of .964, while individual sub-items have 
reliability ranging from .51-.99, and Cronbach alpha of .785 (36,37). 
Muscle Performance Assessment- 
Muscle performance of lower extremity major muscle groups was assessed via Biodex System 3 
isokinetic dynamometer as described previously (38,39,40,41). Major muscle groups assessed were 
hip extensors, knee extensors, and ankle plantarflexors as these muscle groups are critical to 
ambulation and functional mobility (42). For each movement, the anatomical axis of rotation (ie. hip 
joint center/greater trochanter, knee joint femoral condyles, and ankle joint malleolus) was aligned to 
the dynamometer axis using visual inspection and manual palpation.  
Participants upper extremities, trunk, and contralateral limb were secured with padded straps 
to ensure minimal accessory movement contributed to force production. Prior to each test, 
participants became familiar with procedures by performing 3-5 submaximal contractions, and the 
tested leg was weighted to correct for the effects of gravity on the torque measured, according to the 
specifications of the Biodex Manual. Range of motion was set for each movement to obtain ~110 




extension), and maximal ankle plantarflexion and dorsiflexion. The isokinetic tests for each muscle 
group included 5 maximal concentric contractions each separated by 5 seconds. Isometric tests 
consisted of 4 maximal contractions held for 5 seconds each, separated by 10 seconds rest between 
repetitions. Isometric force production was assessed at 60 degrees of hip flexion, 60 degrees of knee 
flexion, and slight ankle dorsiflexion to achieve optimal muscle-specific sarcomere length (43,44). 3 
minutes rest separated each test. Isokinetic strength was assessed for each joint extensor movement 
at 30°/sec and 120°/sec. To assess peak torque production (ft-lbs) as a measure of maximal muscle 
strength, the highest 3 repetitions were selected and averaged for each joint at each repetition speed. 
At each selected repetition, rate of torque production, seconds to peak torque, total work, and power 
was also assessed and averaged. Power was determined by the time-averaged integrated area under 
the curve at the constant velocity of movement in the available range of motion (38,39) To avoid 
sub-maximal performance or outliers, tests were re-done or data discarded if the coefficient of 
variation exceeded 10% for the knee and ankle, and 15% for the hip (45).  
Finally, we also assessed muscle fatigueability/fatigue resistance of the aforementioned 
muscle groups using a fatigue protocol detailed as follows – participants performed 50 maximal 
repetitions at 90 degrees per second, with 2 second rest period between repetitions. Torque 
production was assessed for each repetition, and work was calculated across the first, second, and 
third portion of the fatigue set, and totaled for an index of fatigue resistance as detailed previously 
(46,47). Recovery from this fatigue task was tracked over 2 recovery phases. In phase 1, participants 
performed 5 maximal repetitions separated by 10 seconds of rest immediately following the fatigue 
set. In phase 2, participants performed 5 maximal repetitions separated by 25 seconds of rest. Torque 





As renal decline can contribute to skeletal muscle insulin resistance, an oral glucose tolerance test 
and fasting glucose and insulin values were obtained to assess and control for any differences in 
insulin sensitivity, as this may confound the relationship between mitochondrial function and muscle 
performance. All diabetes medications (except insulin) were stopped 2 days before admission to the 
CRU to decrease residual drug effects on the metabolic measurements (long-acting GLP-1 agonist 
and thiazolidinediones were stopped 7 days before admission). Subcutaneous insulin was stopped 
after the final dose on the day prior to admission to the clinical research unit. Blood glucose 
concentration was checked by fingerstick twice daily at home (once before breakfast, and once 
posprandially after dinner before bedtime) for 2 days before admission (7 days before admission in 
subjects taking long-acting GLP-1 agonist or thiazolidinediones) to ensure adequate glycemic 
control was maintained prior to metabolic testing. Participants refrained from eating for 10 hours 
prior to administration of the 3-hour oral glucose tolerance test as previously described (48).  
Participants fasting plasma glucose was assessed 10 minutes prior to administration of a 75g 
glucose drink. Plasma samples were subsequently obtained at the time of drink ingestion, and at 10, 
20, 30 minutes, and then every half hour until 3 hours post-ingestion. Plasma glucose was assayed 
by automated glucose analyzer (Yellow Spring Instruments), and plasma insulin by enzyme-linked 
immunosorbent assay (49). Insulin sensitivity as a measure of basal insulin sensitivity during an 
OGTT was estimated using homeostasis model assessment of insulin resistance (HOMA-IR), 
calculated as [(fasting glucose (mg/dL)] x [fasting insulin (µU/mL)]/405 (50).  
Body Composition: 
Each participant was assessed for body composition with a whole-body, dual energy x-ray 




assess composite and regional lean and fat mass as described previously (57). Bilateral upper and 
lower extremity fat-free masses, region-specific lean mass (ie. thigh region), whole-body lean mass 
and fat masses were assessed.  
Muscle Biopsy: 
Participants were positioned supine in a hospital bed with the thigh of their dominant leg exposed. 
Participants were then asked to contract the thigh so as to visualize the vastus lateralis (anterior to 
fascia lata, approximately 1/3rd of the distance from patella to great trochanter). The area was 
prepped and cleaned with iodine, and draped. The skin was anesthetized with 2% lidocaine solution 
injected into the dermis and allowed to take effect over a 3 minute period. A 1-2 cm incision was 
made through the skin and subcutaneous tissue, and a 5 mm Bergstrom needle was introduced with 
vacuum suction into the vastus lateralis. 2 passes of the biopsy needle were performed for each 
participant obtaining ~250-350 mg of skeletal muscle tissue as previously described (58). ~50-75 mg 
of the sample were immediately snap-frozen in liquid nitrogen and stored at -80°C until further 
analysis (mtDNA copy number, qPCR, enzyme testing, RNA-sequencing).  
Mitochondrial Functional Analysis: 
10 mg of the biopsy sample was immediately placed into ice-cold relaxing buffer, 50 mM K+-MES, 
20 mM taurine, 0.5 mM dithiothreitol, 6.56 mM MgCl2, 5.77 mM ATP, 15 mM phosphocreatine, 20 
mM imidazole, pH 7.1, adjusted with 5 N KOH at 0 °C, 10 mM Ca–EGTA buffer (2.77 mM 
CaK2EGTA + 7.23 mM K2EGTA; 0.1 µM free calcium) (60,61) and trimmed of surrounding 
epithelial and fat tissue. The sample was then transferred to an ice-cold glass plate, where fiber 
bundles were separated mechanically with sharp angular forceps over a standardized period of 5-10 




remained connected in a meshlike framework, and immediately transferred into 2 mL freshly 
prepared saponin permeabilization solution (.003% saponin – weight/volume in relaxing buffer) and 
put on a rocker at 4°C for 20 minutes. The tissue was then equilibrated in respirometry media (110 
mM sucrose, 60 mM K+-lactobionate, 0.5 mM EGTA, 3 mM MgCl2, 20 mM taurine, 10 mM 
KH2PO4, 20 mM HEPES adjusted to pH 7.1 with KOH at 37 °C; and 1 g/l BSA essentially fatty 
acid free) for 15 minutes. Samples were then blot dried, weighed, and split into two 3-mg samples, 
and placed into the respirometry chamber (1 sample per chamber). Chamber parameters were set to 
37°C internal temperature, with a stirrer speed of 750 rpm (12.5 Hz), with oxygen flux data 
collection interval of 2 seconds, and filled with respirometry media (per chamber - 2.1 mL of 
respirometry media supplemented with 2.1 uL of 10µM blebbistatin and 6.3 mg creatine). O2 flux 
was calculated as a time derivative of oxygen concentration using the DatLab4.3 Analysis software 
(OROBOROS), and was initially measured by adding malate (.5 mM), followed by glutamate (10 
mM), and pyruvate (5 mM), in the absence of ADP (State 2-C1, ie. LEAK state respiration). State 3 
respiration using complex 1 (C1) substrates (state 3-C1) was then achieved by the addition of ADP 
(5 mM). This was followed by the addition of succinate (10 mM) to reach state 3 respiration through 
both C1 and complex 2 (C2) (State 3-C1+C2). As a quality control measure, cytochrome c (10 µM) 
was then added to the chamber. As cytochrome c does not pass the intact outer mitochondrial 
membrane, any increase is oxygen flux with cytochrome c administration would indicate damage to 
the mitochondrial membrane during preparation. Oxygen flux changes that did not exceed 15% upon 
cytochrome c administration, were deemed evidence of non-damaging permeabilization as described 
previously (62). Next, carbonylcyanide-4-(trifluoromethoxy)-phenyl-hydrazone (FCCP) was titrated 
(3x, .5uM each injection) to evaluate maximum flux through the electron transfer system (ETS 




across the inner mitochondrial membrane, thereby removing the electrochemical backpressure on the 
proton pumps and represents maximal respiration in the uncoupled state (60). Finally, Rotenone (.5 
uM) was added to inhibit C1-mediated flux.  
 Additional flux-control ratios were calculated from the aforementioned analyses to further 
probe mitochondrial coupling efficiency. The oxidative phosphorylation system control ratio (P/E) 
was assessed to analyze for phosphorylation system deficits as lower ratios indicate phosphorylation 
deficit within mitochondria. The respiratory-control ratio (RCR – P/L) provides insight into the 
coupling efficiency of mitochondria, with higher values indicating improved coupling.  
O2 flux values are expressed relative to tissue wet weight per second. When possible, all 
respiration values were further normalized to citrate synthase activity (CS) as a measure of 
mitochondrial number. Inversely, the calculated phosphorylation control ratio (L/P) is indicative of 
increased dyscoupling. Similarly, the oxidative phosphorylation coupling efficiency ratio was also 
calculated (L-P)/P. Lastly, the ETS coupling efficiency was measured (E-L)/E, to assess coupling 
efficiency, as ratios closer to 1 indicate more efficient mitochondrial coupling. 
mtDNA Copy Number- 
To determine if mitochondrial density/abundance contributed to any differences found with 
respiratory function of these muscle samples, mtDNA copy number was performed. From the flash 
frozen sample, a ~15-20 mg portion was used for DNA extraction using a QIAgen DNeasy Blood 
and Tissue Kit (QIAGEN, Valencia, CA) according to the manufacturers instructions. Briefly, 
samples were lysed with 100 uL of the supplied buffer (Buffer ATL) for 50-90 minutes in the 
presence of proteinase K (2.5 mg/mL) in a 70°C water bath. The lysis was completed by adding 200 




spin column, centrifuged at 8000 rpm for 1 min., and washed twice with 500 uL supplied wash 
buffer (Buffer AW), and DNA is eluted three times with elution buffer (buffer AE). Following DNA 
isolation, precise quantitation of DNA was obtained via nanodrop. DNA concentrations ranged from 
20-45 ng/uL per sample. To measure mtDNA copy number, oligonucleotide primers for mtDNA-
encoded 12s ribosomal RNA and nucleus-encoded β2 microglobulin were used[Nuclear genome B2-
microglobulin gene (forward 5’- TGCTGTCTCCATGTTTGATGTATCT-3’, reverse 5’-
TCTCTGCTCCCCACCTCTAAGT-3’), Mitochondrial genome 12s Ribosomal RNA (mt806F 5’-
CCACGGGAAACAGCAGTGATT-3’, mt929R 5’-CTATTGACTTGGGTTAATCGTGTGA-3’)]. 
DNA was diluted to 2 ng/uL in DEPC water with both forward and reverse primers, and added to 10 
uL of 2x PCR SYBR Green mastermix and 9.2 uL of DEPC water (total volume per reaction – 20 
uL) per well in a 96-well plate and covered with optical adhesive. Sample PCRs were run in 
triplicate per gene probe. mtDNA and nDNA Ct values were averaged from the triplicate. To 
determine mtDNA content relative to nuclear DNA, the ΔCt method was used -- ΔCt = (nDNA Ct – 
mtDNA Ct), where relative mitochondrial DNA content = 2x2ΔCt (63).  
Mitochondrial Enzymatic Testing: 
To more precisely determine mitochondrial quantity in these samples, enzymatic Citrate Synthase 
(CS) activity was determined spectrophotometrically as described previously (64). Briefly, CS was 
determined spectrophotometrically at 30 deg C by measuring decreased absorbance of the Acetyl 
CoA at 232 nM, due to the hydrolysis of the thioester in the formation of CoA-SH with CS activity. 
Due to the testing requirements of 50 mg of frozen muscle tissue, this and all enzymatic analysis was 
performed on a subset of 13 participants (n=5 in CKD stages 1&2, n=5 in stage 3, and n=3 in stages 




were homogenated in .5mL of medium consisting of 50 mM Tis HCL (pH 7.4) and .15M KCL and 
aliquotted and stored at -80 deg C for subsequent enzymatic analysis.  
Citrate Synthase Activity (CS) - for the citrate synthase testing, each sample was run in 
duplicated with 5 uL aliquots per reaction as described previously (64). In a water bath, maintained 
at 30 deg celsius to increase reaction kinetics, samples were prepared by adding 1 mL of 100 mM 
Tris (pH 8.1), used as a buffer, 3.4 uL of .17 mM Oxaloacetic Acid, and 10 uL of .2M Acetyl CoA. 
The samples were poured into a quartz cuvette and inserted into a UNICO spectrophotometer 
maintained at 30 deg c. Readings were taken at 232 nM, the ideal wavelength for Acetyl CoA 
thioester absorption at 1 minute intervals for 10 minutes. The absorbance values were then plotted 
against time and the rate of absorbance decay determined and expressed per minute per milligram 
tissue as described previously (65). CS activity (expressed as umol/min/g) was used as a control 
factor in respiration measures as a secondary analysis of those 13 participants. 
 SDH enzymatic activity (Complex 2)- 10 uL of the 1:10 muscle homogenate is added to 100 
uL of freshly made assay reagent as described previously (64). Briefly, fresh assay reagent consists 
of .5mL of 1M Imidazole HCL (pH 7.4) for a reaction concentration of 50mM, 1 mL of 1M 
succinate for a final concentration of 100 mM, .2 mLs of 500mM K3FeCN6 for an assay 
concentration of 10 mM, and finally, .2 mLs of 1% BSA (64). Once added, homogenate/assay 
mixture is incubated at room temperature for 60 minutes. Subsequently, 10 uL of 1N NaOH is added 
and heated at 600C for 20-minutes, followed by addition of 1mL fumarate indicator reagent (50mM 
2-amino2 methyl propaneidol+200uM NAD+10mMglutamate+50ug/mL pig heart 
fumarase+2ug/mL GOT), and read at 340 nM in a UNICO spectrophotometer, using disposable 





 Cytochrome Oxidase, COX (Complex 4) - Enzymatic analysis of complex 4 of the ETC is 
based on the principle that absorption of cytochrome C at 550 nm changes with its oxidation state. 
Its oxidation by cytochrome oxidase (complex 4) is a measure of COX activity. The COX enzyme 
testing was thus conducted as described previously (64). Briefly, 5 uL of muscle homogenate is 
added to a cuvette containing .95 mL of .01M phosphate buffer (pH 7), and 50 uL of 1% reduced 
cytochrome C, and measured with a UNICO spectrophotometer at wavelength of 550 nm at 15, 30, 
45, and 60 minutes. COX activity is expressed as described in citrate synthase above (64). 
Transcriptome Analysis (RNA-Sequencing): 
~20 mg of snap frozen tissue per participant, was ground into a fine powder in a liquid-nitrogen 
cooled mortar and pestal system. Ground samples were subsequently emptied into a vial containing 
1mL of Trizol reagent (Invitrogen # 15596026) supplemented with 20 mg/mL glycogen and 
incubated for 10 minutes, and precipitated with chloroform, centrifuged at 13200 rpm (16000g) for 
15 minutes, and the aqueous layer was transferred, precipitated with isopropanol and centrifuged at 
13200 rpm (1600g) for 10 minutes. Finally the pellet was re-suspended in 75% ethanol and 
centrifuged at 11000 rpm for 5 minutes and allowed to air dry for 15 minutes and re-suspended in 
DEPC water. Concentration and quality of mRNA were measured using a nanodrop 
spectrophotometer. 1 ug of total RNA was subsequently utilized for RNA-sequencing and library 
preparation. Library preparation was performed using a Clontech SMARTER kit according to the 
manufacturer’s protocol. The resulting cDNA ends were rendered blunt, an A base was added to the 
3’ ends, and Illumina sequencing adapters were ligated to the ends. The ligated fragments were then 
amplified for 12 cycles using primers that incorporated unique index tags, and the resulting 
fragments were sequenced on an Illumina HiSeq 2500 sequencing system using single reads that 




seq reads were aligned to the Ensembl top-level assembly with STAR version 2.0.4b.  Gene counts 
were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount 
version 1.4.5.  Transcript counts were produced by Sailfish version 0.6.3.  Sequencing performance 
was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and 
transcripts detected, ribosomal fraction known junction saturation and read distribution over known 
gene models with RSeQC version 2.3. 
All gene-level and transcript counts were then imported into the R/Bioconductor package 
EdgeR and TMM normalization size factors were calculated to adjust for samples for differences in 
library size.  Ribosomal features as well as any feature not expressed in at least the smallest 
condition size minus one sample were excluded from further analysis and TMM size factors were 
recalculated to created effective TMM size factors.  The TMM size factors and the matrix of counts 
were then imported into R/Bioconductor package Limma and weighted likelihoods based on the 
observed mean-variance relationship of every gene/transcript and sample were then calculated for all 
samples with the voomWithQualityWeights function.  Performance of the samples was assessed 
with a spearman correlation matrix and multi-dimensional scaling plots.  Gene/transcript 
performance was assessed with plots of residual standard deviation of every gene to their average 
log-count with a robustly fitted trend line of the residuals. Generalized linear models were then 
created to test for gene/transcript level differential expression. Differentially expressed genes and 
transcripts were then filtered for FDR adjusted p-values less than or equal to 0.05. 
The biological interpretation of the large set of features found in the Limma results were then 
elucidated for global transcriptomic changes in known Gene Ontology (GO) and KEGG terms with 
the R/Bioconductor packages GAGE and Pathview. Briefly, GAGE measures for perturbations in 




versus the background log 2 fold-changes observed across features not contained in the respective 
term as reported by Limma. For GO terms with an adjusted statistical significance of FDR <= 0.05, 
heatmaps were automatically generated for each respective term to show how genes co-vary or co-
express across the term in relation to a given biological process or molecular function.  In the case of 
KEGG curated signaling and metabolism pathways, Pathview was used to generate annotated 
pathway maps of any perturbed pathway with an unadjusted statistical significance of p-value <= 
0.05. 
Statistics- 
Pearson Chi-square test for equality of proportions was used to determine the homogeneity of sex 
distribution, and neuropathy status between CKD-staged groups (stages 1 and 2, stage 3, and stages 
4 and 5). CKD group baseline demographic variables (age, BMI, duration of diabetes, glycemic 
control – HbA1c, total body lean mass, and eGFR) were analyzed and compared via 1-way analysis 
of variance (ANOVA). CKD-group differences were also assessed via 1-way ANOVA for OGTT 
area under the curve and HOMA-IR (measures of insulin resistance), PPT score, lower extremity 
torque production and power, fatigue-related work production, all mitochondrial functional 
measures, and mitochondrial DNA copy number and enzymatic testing. Post-hoc testing for CKD-
staged group differences was determined using Tukey’s HSD or Games-Howell in the event of a 
violation of homogeneity of variance. Bivariate pearson correlation coefficients were used to assess 
relationships between eGFR and the aforementioned measures, including lab measures, and between 
mitochondrial function/abundance/enzyme measures (mtDNA copy number, complex 2, complex 1, 
and complex 4 enzymes) and muscle performance and PPT scores. All analyses were evaluated at an 






As shown in Table 1, there were no group differences in gender composition, age, BMI, duration of 
diabetes, BMI, age, duration of diabetes, glycemic control (HbA1c), PN status, whole-body lean 
mass, insulin sensitivity (OGTT AUC) or albuminuria. The groups inherently differed in eGFR, as 
this was the defining criteria of the groups (early, middle, and late-stage CKD) (p<.001), and also 
differed in BUN, a measure of uremia (p<.001). 
Physical Function- 
As shown in Figure 1A and Table 2, eGFR was significantly positively correlated with PPT score 
(r=.8, p<.001), and other functional measures like the ability to rise from a chair (r=.761, p<.005), 
but was negatively correlated with 50-ft walk time (r=-.68, p<.001, Fig.1B), or in other words, worse 
kidney function was associated with slowed gait (from 4 ft./sec in stages 1&2, to 3 ft./sec in stage 3, 
and 2 ft./sec in stages 4&5). Similarly, PPT score and 50-ft walk time significantly declined with 
progression of CKD (Figure.1 C,B). 
Muscle Performance- 
eGFR was positively correlated with hip extensor torque production (r=.82, p<.001), knee extensor 
torque production (r=.79, p<.001), and knee extensor total work during fatigue task (a measure of 
fatigue resistance – r=.83, p<.001) (Table 2, Figure 2,C). With progression from early to middle to 
late CKD, there is a significant stepwise decline in knee extensor torque, power production, and hip 
extensor torque (Figure 2, A,D,C). Not surprisingly, knee extensor torque production and hip 
extensor torque both significantly positively correlated with PPT scores (r=.78, p<.001, r=.88, 
p<.001 respectively), and functional sub-tasks, uncluding the efficiency/speed in rising from a chair 




also assessed for hip and knee extensors, with no differences found between stages in regards to 
seconds-to-peak torque (a measure of muscle activation capacity) (knee extensors p=.4, hip 
extensors p=.18). As shown in Figure 3 (middle row, far right), knee extensor torque production 
significantly correlated with PPT score (r=.721, p<.001). 
Mitochondrial Function/Coupling efficiency- 
As shown in Figure 4A, there were no differences between groups in mitochondrial density as 
assessed via mtDNA copy number (Stage 1&2 – 2498.7 + 798.7, Stage 3 – 2317.4 + 570.6, and 
Stage 4&5 – 1637.4 + 998.1, p>.05). Similarly, there were no significant differences between CKD 
stages on the 13-participant citrate synthase activity analysis (Figure 4B), supporting the copy 
number findings that mitochondrial number and density did not differ in our sample of CKD 
participants. However, there were progressive increases in mitochondrial LEAK-state respiration 
with progression of CKD (State L) (Figure 5A). This remained significant when normalizing LEAK 
respiration to mitochondrial number (citrate synthase) (Table 3) . Conversely, significant declines in 
mitochondrial complex-1-mediated respiration (state3-C1) were observed with progressive stage of 
CKD (Stage 1&2 CKD: 52.85 +11.4 pmol/sec, Stage 3 CKD: 39.9 +5.2 pmol/sec, Stage 4&5 CKD: 
26.5 +7.5 pmol/sec, p<.001) (Figure 5B). After controlling for CS-activity, this relationship 
remained significant between early and late-sage CKD (p=.018, Table 3), with subsequent power 
analysis revealing 10 participants would be needed per stage for this measure to reflect our 
unadjusted respirometry measure differences. Similarly, CKD stage progression related to significant 
declines in mitochondrial maximal oxidative capacity (State3-C1+C2, P), with no difference 
observed between stage 3 and 4&5 (Figure 5C), and this relationship remained after normalizing to 
CS (Table 3). This same relationship was true of maximal mitochondrial electron transport capacity 




differences between early and late-stage CKD is shown in Figure 5E. Moreover, LEAK-state 
respiration, maximal oxidative phosphorylation capacity, and complex-1-mediated respiration, all 
normalized to CS, significantly correlated with renal filtration (r=-.75, r=.81, r=.82, p<.001 
respectively, Table 3), while CS-normalized complex 4 enzyme activity significantly positively 
correlated with renal filtration (r=.53, p=.02, Table 3), and exhibited significant functional declines 
in stage 3 CKD that persisted into later stages (stage 1&2: 4.29(1.96), vs. stage 3: 1.95(.61), vs. stage 
4&5: 1.84(.35), p<.001, Figure.4D). No samples exhibited an increase in respiration exceeding 15% 
with cytochrome-c administration, indicating no damage was inflicted to the outer mitochondrial 
membrane in preparation.  
To further probe mitochondrial function and coupling, mitochondrial respiratory flux control 
ratios were calculated from the aforementioned states and listed in Table 3. There were significant 
reductions in oxidative phosphorylation control ratio with CKD progression, where lower values 
indicate intrinsic mitochondrial deficits within the phosphorylation system (p=.017), though these 
differences were not observed between early stages of disease (stages 1&2 vs. stage 3). However, the 
respiratory control ratio, an index of mitochondrial coupling, whereby larger values reflect better 
coupling between phosphorylation system and ATP-production, was significantly different between 
stages, with progressive disease reflecting poorer coupling (p<.001). This was also true of the ETS 
coupling efficiency, where values closer to 1 are indicative of better coupling (p<.001). Conversely, 
while the PCR and OPC ratios both demonstrate impairment with CKD stage-wise progression 
(p=.001), PCR did not differ between middle and late stage CKD, while OPC did not differ between 
early and middle stage disease. 
After demonstrating apparent intrinsic mitochondrial functional deficits across CKD stages, 




mobility. As shown in Figure 3. predictably, mitochondrial maximal oxidative phosphorylation 
capacity (P) significantly positively correlated with total knee extensor work performed over the 
fatigue task, with better phosphorylation capacity related to increased work production and fatigue 
resistance (r=.72) (Figure.3A). Interestingly, complex-1-mediated respiration (state3-C1), and max 
oxphos (P) both were strongly related to knee extensor torque (r=.75, r=.77 respectively, Figure 3 
B,C) and power production (r=.67, r=.68 respectively) (Figure 3 G,H). Moreover, mitochondrial 
electron transport capacity (E), significantly correlated with knee extensor power production, 
although this was among the moderate correlations observed (r=.58, Figure. 3I). Given the strong 
relationship between mitochondrial functional measures and muscle performance, it was not 
surprising to see the strong positive relationship between these same measures and PPT scores 
(state3-C1 vs. PPT: r=.73, P vs. PPT: r=.74) (Figure 3, D,E). 
Transcriptome Analysis (RNA-seq)- 
The RNA-seq analysis resulted in approximately 19–28 million raw sequence reads for each of the 
25 cDNA libraries generated from the human skeletal muscle samples. On average, 99% of the 
trimmed reads mapped to the human reference genome (Figure 6C). The muscle samples contained 
44,000–66,000 transcripts, with ~5,000-8,000 genes detected. The ribosomal fraction was <5% 
across all samples. To determine the similarity between expression profiles, we used Pearson 
correlation plots. The correlation values indicate closely similar expression values for transcripts 
between biological samples. Differentially expressed genes in the stage 1&2 CKD group, stage 3 
CKD group, and stage 4&5 CKD were filtered based on the highest fold change and significant p-
values and the genes were annotated using Ensembl, leading to the identification of genes that were 
significantly altered between stages of disease (Figure 6A). As shown in Figure 6B, there were 448 




between early and middle-stage CKD, and 1775 differentially expressed genes between middle and 
late-stage CKD, all with p-value <.05.  
GO and KEGG gene pathways that differed between CKD stage groups are shown in Figure 
7. As demonstrated in Figure 7, oxidative phosphorylation, electron transport chain, couple ATP 
synthesis, and ETC complex-1 activity were the most significantly down-regulated gene pathways 
(GO and KEGG terms) (all FDR <.05) in late-stage CKD (stages 4&5) compared to early disease. 
Conversely, gene networks involved in regulatory region DNA binding, histone modification, 
chromatin modification, and complement cascade were all among the most significantly upregulated 
pathways in late-stage disease. Figure 7A (bottom), lists selected genes from the aforementioned GO 
and KEGG terms that were significantly altered in expression. In Figure 7B, the significant down-
regulated gene networks/pathways in stage 3 CKD compared to early disease, include PI3K-Akt 
signaling, lipid localization, mitochondrial organization, oxidative phosphorylation, complex 1 
assembly, and electron transport chain. Conversely, upregulated gene families were observed for the 
PPAR signaling pathway, mRNA spicing, and non-coding RNA metabolic processes. Tables 5 and 6 
describe general functions of selected significantly differentially expressed genes from the selected 
GO and KEGG pathways. Figure 8 depicts a subunit visualization of the electron transport chain 
effected in late-stage CKD. 
Discussion- 
While mitochondria play a key role in energy metabolism of all organs, especially skeletal muscle, 
the available data on the effect of CKD on mitochondrial function, structure and abundance in 
skeletal muscle remains limited. This study demonstrates for the first time, to the authors knowledge, 




performance impairments and functional mobility loss in the progression of CKD across its stages in 
those with T2DM. Our cohort of participants did not differ in any potential confounding variables 
(ie. age, gender, peripheral neuropathy, BMI, duration of diabetes, glycemic control, insulin 
sensitivity, or lean mass), lending strong support to the analyzed connections between renal 
dysfunction and skeletal muscle health, energetics, and performance.  
Our findings that CKD progression from early, to middle, to late stages was accompanied by 
impairments in a battery of physical function measures (ability to rise from a chair, gait speed, and 
PPT scores), even in early CKD (stage 3), relates strongly to studies of larger cohorts of those with 
CKD. For instance, Roshnaravan and colleagues, in a study of 385 participants with mean eGFR of 
41 mL/min (eGFR <60 mL/min) found reduced performance in 6-minute walk distances, decreased 
grip strength, impaired ability to rise from a chair and walk, and gait speed reductions that increased 
the risk of death (11). Moreover, as weak quadriceps are accepted measures of muscle impairment 
most strongly associated with functional limitation and mobility disability among those with CKD, 
our findings that quadriceps and hip extensor torque production, power, and endurance/fatigue 
resistance, were all related to physical function was to be expected. However, this study 
demonstrates significant declines in quadriceps and hip extensor strength, knee extensor power, and 
reduced knee extensor endurance with CKD progression, with many of these decrements reaching 
significance at even early stages of disease (stage 3). Given that muscle size and neurological aspects 
are important in muscle strength, our results are intriguing, in that no difference in muscle size was 
noted with DXA analysis, while neurological activation of these muscle groups was similar between 
groups (time-to-peak-torque). However, previous research has shown reduced muscle density in the 
lower extremity of older adults with reduced kidney function theoretically due to adipose tissue and 




with DXA scanning, and warrant further investigation in T2DM-indued CKD (10). Additionally, 
even minor losses of muscle contractile proteins can be associated with even larger decrements in 
force – conditions that may promote functional changes that precede noticeable loss in muscle mass, 
as may be the case in our study (10). Indeed, in other works, muscle dysfunction is only marginally 
correlated with muscle atrophy in those in ESRD (stage 5 CKD), with these patients demonstrating 
poorer muscle function for a given muscle mass (27).  
 Recent studies have shown that impaired exercise capacity is induced prior to development 
of muscle atrophy, and theorize that this is mainly caused by mitochondrial dysfunction in muscle 
(67). Indeed, this is substantiated in a recent rodent model of CKD showing that in intermediate-
stage CKD nephrectomy mouse, there were elevated uremic toxin intermediates (specifically indoxyl 
sulfate – IS) that stimulate myostatin, atrogin-1, and decreased Akt phosphorylation and exercise 
capacity, that all contribute to atrophy (67). However, upon administration of AST-120, a drug that 
impairs IS action by inhibiting its pro-reactive oxygen species stimulation on skeletal muscle 
mitochondria, exercise capacity was restored, along with mitochondrial function and muscle mass 
(67). These results suggest that mitochondrial redox stress is a key mechanistic link between poor 
kidney function and impaired muscle performance, findings that are reflected in our results.  
We show significant increases in mitochondrial LEAK state respiration with progression of 
CKD, that remains even after normalizing to mitochondrial number (CS). The electron transport 
chain (ETC) is tasked with continual re-synthesis of ATP through generation of a proton gradient 
and proton-motive force between the mitochondrial matrix and intermembrane space (68). Loss of 
membrane potential, however, results when protons move back toward the matrix via non-specific 
leaks, often at specific ETC complexes or through channels such as the mitochondrial permeability 




is determined in part by efficiency of electron transfer. Reduced mitochondrial ETC activity causes 
cellular ROS production, as electrons accumulate in the early stages of the transport chain (primarily 
at complex 1), where they can be donated directly to molecular oxygen to give rise to superoxide 
anion (70,71). Given our findings that complex-1 specific respiratory function (even after 
normalizing to CS) is impaired as early as stage 3 CKD, and to a greater extent in later stages, the 
presumable complex 1 deficit may cause electron leak at this protein, and increase ROS production 
and accumulation observed in this study. Indeed, other research has clearly demonstrated that 
superoxide radicals are largely produced from ETC complex 1 deficiencies as complex 1 marks the 
entry point for electron transport and proton gradient generation (72,73). Thus, in our study, while 
complex-1 mediated respiration is significantly diminished in stage 3 CKD, LEAK/ROS production 
appears elevated, though not to a significant extent until stages 4 and 5 CKD. In this respect, perhaps 
complex-1 deficiencies develop early in disease and contribute to steadily increasing ROS, which 
may further exacerbate ETC-complex dysfunction.  
 Indeed, it is now well established that mitochondrial ROS promotes mtDNA and nuclear 
DNA mutations in genes encoding ETC subunit proteins, and ROS itself directly damages specific 
ETC subunits to alter their respiratory function (73,74). Recent elegant studies have shown, using 
mass spectrometry and BN-Page, the effects of age-related mitochondrial ROS production on 
specific protein subunits of quadriceps mitochondrial ETC enzymes. They found that ROS 
specifically carbonylates FE-S subunit 1 and 2 of Complex 1, SDHA subunit of complex-2, and 
COX1 subunit of complex 4, that all related to decreased mitochondrial oxidative function (73). 
Indeed, others have demonstrated that impairment in complex-1 function by as little as 20%, 
corresponds to ~10% decline in whole-mitochondrial respiration and oxidative function (74). Similar 




skeletal muscle ROS relates strongly to impaired mitochondrial respiration, and poor ATP 
production (75). Moreover, prolongued ROS exposure, as may be the case in our study, has been 
shown to contribute to widening of the MPTP (69). This creates a positive feedback loop whereby 
ROS production promotes increased mitochondrial inner membrane permeability, exacerbating 
proton leak and subsequent ROS production. However, the clinical implications of our findings of 
increased LEAK and potential redox stress with progression of CKD, are striking. We found very 
strong relationships between mitochondrial respiratory function, and muscle performance measures 
(torque production/strength, power, and endurance). 
 Increased ROS in studies of CKD animals, results in declines in muscle specific-force, alters 
myofilament function, and promotes muscle fatigue (76,77,78). Others have observed similar 
findings, in which skeletal muscle exposure to ROS (ie. H2O2) reduces myofibrillar calcium 
sensitivity, calcium uptake, action potential amplitude, impairs sarcoplasmic reticulum calcium 
release, and carbonylates myosin heavy chain protein, thereby drastically reducing cross-bridge 
force production at the single fiber and whole-muscle levels (79, 27, 80, 81). Similarly, muscle fiber 
exposure to ROS prolongues time-to-peak tension and half-relaxation time - mechanisms that 
severely hamper muscle fiber power production (81). Thus, while we did not probe single-fiber 
contractile capacity or calcium-related contraction mechanics, these studies may provide potential 
mechanistic explanations for our findings between mitochondrial dysfunction and muscle force-
generation impairments with CKD progression. Muscle endurance, similarly, is negatively affected 
by chronic-disease-associated ROS signaling. However, LEAK-state respiration, as studied in our 
participant samples may also be indicative of impaired coupling of electron transport to ATP-





We demonstrate significant step-wise declines in the respiratory control ratio(RCR) with 
CKD progression, an index in which larger values indicate better coupling between the 
phosphorylation system and ATP-production. Interestingly, Roshanravan and colleagues (2016) 
determined, using 31-p MRS of the first dorsal interosseous muscle of non-diabetic CKD patients 
with mean eGFR of 39 mL/min (stage 3) compared to controls, that the mean mitochondrial 
coupling ratio was 34% lower in those with CKD (82). We report here, a strikingly similar 39% 
reduction from early to middle stage CKD (stage 3) in the RCR coupling index, albeit using different 
methodology, and this remained after normalizing for mitochondrial number (CS). Moreover, we 
find that this coupling deficit grows to a 63% reduction in late-stage CKD (39% lower than those in 
stage 3). Thus, skeletal muscle mitochondrial coupling efficiency appears significantly impaired 
early in CKD in those with T2DM. Once again however, this poor coupling may explain, in part, the 
poor resistance to fatigue exhibited with progression of CKD in our study – as mitochondrial 
uncoupling is associated with greater fatigability, reduced muscle endurance, and requires higher 
energy expenditure to accomplish the same physical tasks (83,27). This, in conjunction with the 
aforementioned connections between increased LEAK and muscle deficits, may also lend 
mechanistic explanation for the reductions in gait speed seen with disease progression in our sample, 
along with impairments in repeatedly rising from a chair -- as those in middle and later stages of 
disease may bear a higher metabolic cost to complete these functional tasks.  
 As mentioned previously, the mitochondrial ROS production/exposure cycle may promote 
deficiencies in specific ETC complexes that further deteriorate ATP production capacity and 
energetic supply for skeletal muscle. However, we find significant reduction in complex-4 enzyme 
activity in middle and late-stage CKD (compared to stages 1 and 2), and a strong negative trend in 




respiration. Moreover, we show strong positive correlations between the function of these complexes 
and renal function across the spectrum of filtration rates. While the underlying mechanism for our 
findings of complex-specific deficits with CKD progression, remains unclear, these results are 
supported by mitochondrial modeling data and rodent studies. In rats with 5/6th nephrectomy, after 
12 weeks, the investigators discovered complex-4 enzyme activity to be reduced 13% in the 
gastrocnemius, with subunit 4 of the complex being significantly reduced in abundance (84). Other 
studies, albeit in younger populations with ESRD, have also found depressed complex-4 activity in 
skeletal muscle mitochondria (85). Though a seemingly small effect, computer modeling has shown 
that for every 5% decline in complex 4 function, maximal oxidative phosphorylation declines 1%, 
independent of other complexes (74). While the negative trend in complex 2 enzymatic function 
remains to be confirmed with a larger sample size, our strong downward trend suggests that complex 
2 deficits may also be present in the skeletal muscle mitochondria of those with the condition, even 
early on. Complex 2 is the only ETC component that is entirely encoded by mtDNA- hence, DNA 
mutations potentially caused by ROS exposure, may have a disproportionately larger impact on the 
function of this enzyme, and this warrants further study. However, CKD-associated uremic 
biproducts (indoxyl sulfate-IS, indole-3-acetic acid, etc.) have also been shown to inhibit 
mitochondrial complex-2 by as much as 20%, while indole-3-acetic acid specifically decreases 
electron transport capacity (ETS) by 18% (86). Similarly, we show deficits in ETS capacity 
beginning in stage 3 CKD, whicht remains deficient in later stages. It is theoretically plausible that 
these CKD-induced environmental exposures, over a prolonged period of time, may promote 
epigenetic re-programming of both mitochondrial and nuclear genes that govern mitochondrial 
function and organization to ultimately negatively impact mitochondrial ATP-production. The 




suggest that epigenetic modification in skeletal muscle may be a ripe area for future investigation in 
this disease.  
Thus, perhaps the uremic environment contributes directly to complex-specific deficits that 
together with increased LEAK and potential ROS production and uncoupling, results ultimately in 
impaired mitochondrial oxidative phosphorylation capacity. Our results demonstrate significant 
declines in mitochondrial oxidative phosphorylation capacity across stages of CKD, which may 
simply reflect a culmination of the aforementioned specific mitochondrial deficits. Once again 
however, our results reflect the animal literature that demonstrate state-3 mitochondrial respiration 
(maximal oxidative phosphorylation) to be impaired 39% in nephrectomy rats – as we found 27% 
reduction in stage 3, and 43% reduction in late-stage compared to stages 1 and 2 (84).  
The skeletal muscle transcriptome analysis lends further support for mitochondrial 
respiratory and coupling deficits observed with CKD progression. Interestingly, the most 
significantly altered KEGG pathway or GO term in late-stage CKD was that of oxidative 
phosphorylation and electron transport chain function (Figure 7,A). As demonstrated, the oxidative 
phosphorylation gene network was downregulated with a striking mean log 2 fold change of -8. 
More specifically, this downregulation of genes governing oxidative phosphorylation spanned a 
wide range of critical mitochondrial regulatory functions. However, in middle stage CKD (stage 3), 
transcriptional differences are most evident in metabolism pathways, with contributions from altered 
gene expression in networks governing mitochondrial genome maintenance and protein synthesis 
(Figure 7,B).  
 Those in late-stage CKD (stages 4&5) demonstrate a global downregulation in genes 




transcription or deficiencies in these mitochondrial subunits can have profound consequences for 
mitochondrial electron transport and respiration (87). As shown in Figures 7A,8, and table 5, those 
in late-stage CKD demonstrate significantly reduced expression of two complex 1 subunit genes 
(MTND3, MTND6), one subunit of complex 3 (MT-CYB), five subunits of complex 4 (COX5A, 
MT-CO3, COX6A2, COX7A2, MT-CO2), and four subunit proteins of complex 5 (MT-ATP6, MT-
ATP8, ATP5MC3, ATP-MC1). Moreover, these muscles demonstrate significant reduction in 
expression of key complex assembly proteins (SURF1 – complex 4 assembly, and NDUFAF2 – 
complex 1 assembly) (Table 5). These results lend potential mechanistic insights into enzymatic 
results demonstrating significantly reduced complex 4 enzyme activity in later-stage CKD (FIG.4D), 
as RNA-seq data clearly indicates that complex 4 may be significantly impacted through inadequate 
subunit transcription and/or deficient complex assembly, a finding that echoes previous results in a 
rodent CKD-model (84). However, although not as diffuse across the ETC as later-stage 
transcriptional changes, we find reduced expression of NDUFAB1 in stage 3 CKD - a key complex 
1 subunit charged with electron transfer from complex 1 to the ubiquinone carrier (88) (Figure 7B, 
Table 6). Others have demonstrated similar reductions in expression with aging, suggesting that this 
may be implicated in age-related increase in ROS production, and as shown here, potentially a 
player in CKD-associated respiration deficiencies and LEAK (88). Moreover, similar to late-stage 
CKD, we find reduced expression of complex assembly gene TMEM70 in stage 3 CKD - a key 
player in ATP-synthase biogenesis (89) (Figure 7B, Table 6). Indeed, it is well understood that 
mitochondrial functional deficiencies may disrupt nuclear and mitochondrial transcription, which 
may then negatively influence mitochondrial function to manifest a negative feedback cycle (90). 
Thus, while it is unclear whether these gene expression changes precede or follow mitochondrial 




may be a key mechanistic explanation for the mitochondrial deficits observed in late-stage CKD. 
However, beyond reductions in expression of these key subunits, their import to the mitochondria is 
also critical for mitochondrial function. As mitochondria are not formed de novo, nuclear-derived 
transcripts must translocate into the mitochondria via the TIM23 and TOM20 mitochondrial 
transporters (91). 
Our results demonstrate, however, reductions in TIMM17A – an essential component of 
TIM23 – responsible for protein import into the mitochondria, in stages 4&5 CKD muscle (91) 
(Figure 7A, Table 5). It has been previously shown that TIMM17A expression is reduced under 
cellular stress conditions, resulting in impaired mitochondrial protein construction and stress 
signaling related to the mitochondrial unfolded protein response (91). Conversely, muscle in stage 3 
demonstrates reduced expression of CSNK2A2 – a phosphorylator (activator) of the TOM20 
mitochondrial ETC subunit protein importer (92) (Figure 7B, Table 6). When considered along with 
our finding of reduced expression of GRPEL2 and MRPL12 – a vital activator of mitochondrial 
RNA polymerase, this suggests potentially deficient protein transport and protein transcription in 
mitochondria in stage 3 CKD skeletal muscle (93,94).  
As mentioned above, stress conditions that impair mitochondrial protein transport may be 
promoted by the increase in LEAK respiration observed in CKD progression, and potential 
accompanying ROS production. Interestingly, in stage 4&5 CKD muscle, the GPD2 gene was 
significantly upregulated - an electron transfer protein the shuttles electrons to the COQ carrier for 
complexes 1 and 2 (95). Given our findings of significantly reduced complex 1 function, and 
increased electron LEAK, and now transcriptomic evidence for upregulation of GPD2 – a protein 
known to contribute to electron backflow to complexes 1 and 2 and subsequent electron leak and 




mitochondrial stress in late-stage CKD muscle (95). Moreover, we also find elevated expression of 
TP63 – a p53 family protein that stimulates ROS production through REDD1 gene pathways, and a 
reduction in the ROS-inhibiting TIGAR (96,97).  
However, while not as prominent a finding in the transcriptome analysis, muscle in stage 3 
CKD exhibits reduced expression of SOD2, the superoxide dismutase ROS scavenger (Figure 7B, 
Table 6). Also downregulated in stage 3, was TSPO – a gene expression pattern indicative of 
oxidative stress, as this is a cellular attempt at limiting mitochondrial permeability transition pore 
enlargement – a major site of electron leak, in the presence of oxidative stress (98) (Figure 7B, Table 
6). Thus, in stage 3 CKD, while not significantly elevated above stages 1&2 CKD, LEAK and 
accompanying ROS may be poorly buffered secondary to SOD deficiency, thus causing 
compensatory limiting of mtPTP size via TSPO downregulation. This mechanism, though plausible 
given our transcript expression data, warrants further investigation. However, it is well understood 
that cellular stress signaling that may disrupt mitochondrial protein import and synthesis may derive 
from more than mitochondrial ROS production, and may also relate to skeletal muscle damage and 
metabolic signaling pathways. 
 Indeed, we report significant reductions in SH3BGRL3 expression in late-stage CKD muscle, 
a key gene governing sarcomere assembly at the z-disc (Figure 7A, Table 5.) (99). Additionally, we 
observe reduced expression of the myostatin and TGF-beta inhibitor DCN, which also promotes 
mitochondrial biogenesis (100). Lastly, we also observe significant upregulation of MDM2 – an E3 
ubiquitin ligase that activates the FoXO3 atrophy pathway. Intriguingly however, elegant work by 
Arena and colleagues (2018), recently demonstrated that MDM2 is imported into skeletal muscle 
mitochondria, and impairs mitochondrial respiration and dynamics via repression of MT-ND6 




and downstream impairment in skeletal muscle fatigue resistance (101). Specifically, the authors 
demonstrate that MDM2 impairs complex-1 mediated state 3 respiration (using glutamate, malate, 
pyruvate) by ~36%, a deficiency bearing striking similarity to our own ~48% reduction in complex-1 
state 3 respiration in late-stage CKD with accompanying downregulation of MT-ND6. These results 
represent an intriguing potential mechanism observed in our study – later-stage (4&5) CKD 
upregulates the E3-ubiquitin ligase MDM2, an atrophy-pathway activator, which simultaneously 
impairs mitochondrial complex 1 function via attenuation of the production of its subunit-6 protein, 
to ultimately impair muscle performance. This potential mechanism is an exciting area of future 
study. Thus, given our genomic results, skeletal muscle integrity may be impaired in later-stages of 
CKD, potentially more so at the z-disc - a theory supported by other findings of z-disc streaming in 
uremic muscle (102,103), with disinhibition of atrophy signaling (via myostatin and TG-beta) that is 
detrimental to muscle health and mitochondrial function. However, the stage 3 skeletal muscle 
transcriptome suggests poor lipid handling and metabolism may play a more influential role in 
muscle integrity and quality than the implicated structural deficiencies of late-stage muscle. 
 Stage 3 CKD muscle exhibited striking reduction in adiponectin gene expression (Figure 7B, 
Table 6). Adiponectin plays a key role in mitochondrial fat metabolism via AMPK phosphorylation, 
while also negatively regulating TNF-alpha expression and inhibiting NF-KB signaling through 
cAMP-dependent pathway (104). It has been demonstrated previously, that reduced ADIPOQ 
expression results in increased oxidative stress, and inflammation (104). This finding is intruiging, 
especially when paired with the striking reductions in PPARG and leptin gene expression, as skeletal 
muscle secreted leptin, induced by PPARG, stimulates mitochondrial fatty acid oxidation via AMPK 
as well, and protects against adipose tissue accrual within skeletal muscle (IMAT) and suppresses 




may predictably result in impairment in mitochondrial handling of fatty acid oxidation that may 
contribute to muscle adipose tissue accrual, and inflammatory pathway activation. Potential 
myocellular adipose accumulation may also be a consequence of the observed LDLR deficiency, 
STARD4, and ABCD2 downregulation, as all of these genes play key roles in fatty acid 
mitochondrial import and lipid metabolism (106, 107, 108) . Such alterations in mitochondrial 
metabolism may promote a different set of muscle health issues in middle-stage CKD. 
 Lastly however, muscle and mitochondrial health depends on a balance between 
mitochondrial synthesis and degradation (mitophagy). Our respiration results demonstrate increased 
LEAK-state respiration, and poor coupled respiration (Figure 5A, Table 4) that suggests these 
mitochondria may have a deregulation of membrane potential. With loss of membrane potential or 
increased ROS production, PINK1 protein is stabilized on the mitochondrial membrane, whereby it 
recruits Parkin to ubiquitinate and degrade defective mitochondrial proteins and also signal the 
autophagasome to sequester and degrade the defective mitochondria (109). This autophagasome is 
formulated, in-part through the interaction of BCL2 and BECN1 (Beclin-1) protein, with Beclin-1 
dissociation from BCL2 activating autophagasome formation and autophagy of deficient 
mitochondria (109). However, we observe significant reductions in expression of PINK, and BECN1 
and BCL2 genes in stages 4&5 CKD muscle, suggesting mitophagy and general autophagy may be 
attenuated in late-stage CKD (Figure 7A, Table 5). This may promote accumulation of defective 
mitochondria, and could partially explain the non-significant difference in mitochondrial abundance 
in this stage (Figure 4A,B), as mitochondria are not being degraded, and deficient mitochondria 
accumulate to result in poor muscle respiration (109). However, in such an environment with 
increased concentration of deficient mitochondria, cells may upregulate mitochondrial fusion genes 




observe significantly increased expression of mitochondrial-membrane protein MSTO1, a newly 
discovered player in mitochondrial fusion (Figure 7A, Table 5) (110,111). Similarly, we also 
observe reduced expression of PINK1 in stage 3 CKD. Interestingly, in stage 3 CKD, we also 
observe reduced BAG4 expression – an anti-apoptotic stress protein that negatively regulates 
PARKIN, a PINK-ligand that assists in autophagy of mitochondrial proteins and whole-
mitochondria (112). The downregulation of BAG4 may be in response to mitochondrial damage, to 
activate mitophagy, however, with insufficient PINK transcription, mitophagy may be deficient in 
stage 3 CKD muscle. However, further investigation is required to followup on these findings to 
determine the effects of CKD on mitochondrial turnover and quality control pathways.   
 Divergent from late-stage transcriptome changes, middle-stage CKD exhibits consistently 
downregulated genes that play a role in mitochondrial and nuclear DNA maintenance. Specifically, 
we observe deficits in RRM2B, DNA2, and SLC25A33 gene expression – all genes that participate 
in mitochondrial genome maintenance, and repair, and govern mtDNA stability, with DNA2 
specifically serving as the predominant means of repairing small mitochondrial DNA lesions 
induced via oxidative stress (113, 114, 115) (Figure 7B, Table 6). SLC25A33 is of particular interest 
in that it also plays a key role in regulation of mitochondrial membrane potential and regulates 
mitochondrial DNA replication/transcription, and governs the ratio of mitochondrial:nuclear 
encoded protein components of the ETC (115, 116). Its downregulation may promote an 
environment of dysregulated mitochondrial membrane potential, dynamics, and altered protein 
incorporation. Mitochondrial regulation requires maintenance of the mitochondrial membrane 
potential for importing nuclear encoded proteins involved in mitochondrial respiration, DNA 
replication and transcription, and similar to late-stage CKD muscle, we find reductions in gene 




 SLC35F6, dowregulated in stage 3 CKD muscle, stimulates mitochondrial membrane 
potential via interaction with inner-membrane bound ATP transporter ANT2, to transport ATP out of 
the cytosol and ADP into the matrix (117). Its reduced expression may result in poor membrane 
potential regulation, and altered ATP:ADP ratios that may promote shifts in metabolism and altered 
respiration. This de-regulation of mitochondrial membrane potential may be exacerbated by our 
findings of reduced BCL2L1, a BCL2 family member, located in the outer membrane to regulate 
mitochondrial VDAC opening. VDAC opening controls the production of ROS and release of 
cytochrome C, and inducers of apoptosis, with a loss of BCL2L1 regulation resulting in increased 
VDAC opening and subsequent permeation pathway creation for metabolites, electrons, and 
apoptotic proteins into and out of the mitochondria (118). This pathway constitutes a potential 
theoretical mechanism for the uremic milleui to infiltrate and negatively influence mitochondrial 
function, and for electron slippage and ROS generation. 
Thus, the skeletal muscle transcriptome highlights mitochondrial structure, function, and 
signaling as significant downregulated processes in both middle and late-stage CKD muscle. These 
findings lend potential mechanistic insights to support the respiratory deficits and coupling 
inefficiency observed in mitochondria with CKD progression. While this study marks the first use of 
transcriptomics to track skeletal muscle biological changes in CKD stages, these gene pathways 
require further study to more completely elucidate the direct connections between gene expression 
and mitochondrial function in this disease. 
 Conclusion- 
T2DM-induced CKD progression, and its associated uremic environment, independent of 




muscle force generation, power, and reduced fatigue resistance. We demonstrate, for the first time, 
that these muscle performance decrements strongly relate to intrinsic mitochondrial functional 
deficits that begin early in stage 3 CKD, which may in-turn, derive from altered expression of gene 
networks involved in mitochondrial respiration, structure, and turnover pathways. Further 
investigation is needed to probe the quality of skeletal muscle in CKD and its progression, and 
investigations aimed at determining the precise genomic and epigenetic influences of the uremic 










































(<29 mL/min) P-value 
Gender (M,F) 7,2 6,3 5,4 Fishers Exact (p=.47) 
Age (SD) 55 (9.8) 61 (6.4) 62 (7.3) 1-way ANOVA (p=.13) 
BMI (SD) 33.5 (5.6) 33.7 (5.6) 38.9 (6.3) 1-way ANOVA (p=.10) 
Years of DM (SD) 14 (6.3) 13 (7.6) 17 (7) 1-way ANOVA (p=.37) 
HbA1c (SD) 8.01 (2.1) 7.85 (1.8) 7.5 (2.1) 1-way ANOVA (p=.88) 
Neuropathy 




mass (kg) 59.24 (10.1) 55.64 (14.7) 57.08 (9) 
1-way ANOVA 
(p=.8) 
OGTT AUC (SD) 
 
 
40180 (10911) 47394 (11510) 39752 (12010) 1-way ANOVA (p=.37) 





31.2 (6.55) 58.2 (21) 
1-way ANOVA 
(p<.001) 
*Stage 1&2 vs. Stage 3 
^Stage 1&2 vs. Stage 4&5 










(eGFR) 87.8 (20.1) 46.3 (7.4) 18.9 (7.6) 
1-way ANOVA 
(p<.01) 
*Stage 1&2 vs. Stage 3 
^Stage 1&2 vs. Stage 4&5 
#Stage 3 vs. Stage 4&5 
 
TABLE1 – Demographics.  
Participant demographics were compared using 1-way ANOVA, and chi-square was used for sex 
distribution, and peripheral neuropathy status between groups. Values listed are mean and standard 
deviation in (). The following symbols represent post-hoc pairwise comparisons in the event of 
significant F-test - *(between Stage 1&2 and Stage 3), ^(between stage 1&2 and Stage 4&5), 




















BUN Chair Rise Score 
50-ft walk 
time  

















































































































































TABLE 2- Correlation Matrix. Bivariate pearson correlation coefficients were calculated between 
measures of physical function (PPT score, Chair Rise Score, 50-ft. walk time), muscle performance 
(Hip and knee extensor torque, knee extensor work fatigue), and serum chemistries (eGFR, BUN). 
Color coding is as follows --  















LEAK (L) respiration 




.325 (.06) .44 (.06) .82 (.12) 
1-way ANOVA 
(p<.05) 
^Stage 1&2 vs. Stage 4&5 
#Stage 3 vs. Stage 4&5 
Complex 1 respiration  
(normalized to CS activity 
– pmol/sec/mg/CS) 
 
4.3(.54) 3.46(.46) 2.9(.6) 
1-way ANOVA 
(p=.018) 
^Stage 1&2 vs. Stage 4&5 
-power analysis: 10 
subjects needed per stage 
to reach stage-wise 
significance 
Max Oxphos Capacity (P) 
(normalized to CS activity 
– pmol/sec/mg/CS) 
 
7.52(.87) 5.7(.72) 5.4(.55) 
1-way ANOVA 
(p=.004) 
*Stage 1&2 vs. Stage 3 
^Stage 1&2 vs. Stage 4&5 
 
Max ETS Capacity (E) 
(normalized to CS activity 
– pmol/sec/mg/CS) 
 
9.3(1.3) 6.9(.97) 7.2(.31) 
1-way ANOVA 
(p=.001) 
^Stage 1&2 vs. Stage 4&5 
#Stage 3 vs. Stage 4&5 
Correlations 
 eGFR (mL/min)  
LEAK (normalized to CS) r=-.75 (p<.001)  
Complex 4 Enzyme Activity r=.53 (p=.02)  
Complex 1 respiration (normalized to CS) r=.82 (p<.001) 
Max Oxphos (P) (normalized to CS) r=.81 (p<.001) 
TABLE 3- Top: Mitochondrial respiration normalized to mitochondrial content (citrate synthase 
activity) performed on a 13-participant subset of the study population, was compared across stage 
groups using 1-way ANOVA. Values listed are mean and standard deviation in (). The following 
symbols represent post-hoc pairwise comparisons in the event of significant F-test - *(between Stage 
1&2 and Stage 3), ^(between stage 1&2 and Stage 4&5), #(Between stage 3 and Stage 4&5). 
Bottom: Bivariate Pearson Correlations were calculated to compare respiration measures/states 
normalized to mitochondrial content (citrate synthase activity) with renal filtration rate (eGFR), and 










(<29 mL/min) P-value 
Oxidative phosphorylation 




.79 (.07) .81(.036) .67(.15) 
1-way ANOVA 
(p=.017) 
^Stage 1&2 vs. Stage 4&5 
#Stage 3 vs. Stage 4&5 





22 (4.3) 13.1 (2.4) 7.9 (3.2) 
1-way ANOVA 
(p<.001) 
*Stage 1&2 vs. Stage 3 
^Stage 1&2 vs. Stage 4&5 






.047 (.007) .078 (.015) .15 (.08) 
1-way ANOVA 
(p=.001) 
*Stage 1&2 vs. Stage 3 
^Stage 1&2 vs. Stage 4&5 
 
Oxidative Phosphorylation 





-.95 (.007) -.92 (.015) -.84(.08) 
1-way ANOVA 
(p=.001) 
^Stage 1&2 vs. Stage 4&5 
#Stage 3 vs. Stage 4&5 




.963 (.007) .936 (.01) .908 (.026) 
1-way ANOVA 
(p<.001) 
*Stage 1&2 vs. Stage 3 
^Stage 1&2 vs. Stage 4&5 
#Stage 3 vs. Stage 4&5 
 
TABLE 4- CKD-stage groups were compared in mitochondrial flux control ratios using 1-way 
ANOVA. Letters denote the following – P = max oxidative phosphorylation capacity (State 3-
C1+C2), E = ETS capacity, L = state2-C1 (LEAK). Values listed are mean and standard deviation in 
(). The following symbols represent post-hoc pairwise comparisons in the event of significant F-test 
- *(between Stage 1&2 and Stage 3), ^(between stage 1&2 and Stage 4&5), #(Between stage 3 and 












Table 5 (above) 
Table of significantly differentially expressed genes from Figure 7A (genes down or upregulated in 































Table 6 (above) 
Table of significantly differentially expressed genes from Figure 7B (genes down or upregulated in 



























Figures for Chapter 2: 
Figure 1 
 
FIGURE 1 – Physical function capacity was assessed across CKD-stage groups with 1-way 
ANOVAs. Bar heights represent group mean and error bars represent + SD. The following symbols 
represent significant post-hoc tests of pairwise comparisons:  *(between Stage 1&2 and Stage 3), 
^(between stage 1&2 and Stage 4&5), #(Between stage 3 and Stage 4&5). A. Pearson Bivariate 
Correlation with eGFR (glomerular filtration rate) plotted on the x-axis, and PPT score (0-36) 
plotted on the y-axis (higher scores indicate better functional performance) (not pictured – p<.001). 
B. 50-ft walk time, higher values indicate slower gait speed. C. PPT (physical performance test) 








FIGURE 2-  
Lower extremity muscle strength (hip extensor, knee extensor torque), and knee extensor power 
were assessed across CKD-stage groups with 1-way ANOVAs. Bar heights indicate group means, 
with errors bars indicating + SD. The following symbols represent significant post-hoc tests of 
pairwise comparisons:  *(between Stage 1&2 and Stage 3), ^(between stage 1&2 and Stage 4&5), 
#(Between stage 3 and Stage 4&5).  A. Group differences in knee extensor torque (assessed at 
isokinetic speed of 1200/sec, knee extensor torque measured in ft-lbs) (F=20, p<.001). B. Hip 
extensor torque (300/sec, ft-lbs) (F=22, p<.001). D. Knee extensor power (300/sec, measured in 
watts) (F=11, p<.001). C. Pearson correlation plotting total knee extensor work over fatigue task (50 








FIGURE 3- Bivariate pearson correlation plots depicting interrelationships between mitochondrial 
respiration states, muscle performance, and physical function. All depicted correlations are 
significant (p<.05). Abbreviations: Max Oxphos (State3-C1+C2), Complex-1 respiration (State3-
C1), ETS coupling efficiency (ETS capacity/ aka E). Knee extensor power was assessed as in Figure 










FIGURE 4 – Analysis of mitochondrial density, number, and ETC complex enzyme activity. A. 
Mitochondrial DNA copy number, y-axis is unitless (F=3, p=.07), all samples were included in 
mtDNA copy number analysis (n=26) depicting no significant difference between CKD stage 
groups. For remaining analysis  (B-D), analysis was performed on a 13-participant subset of samples 
(Stage 1&2 n=5, Stage 3 n=5, Stage 4&5 n=3). B. Citrate synthase enzyme activity assessment. Y-
axis = umol/min/gram muscle. as in A, no significant differences were observed between groups 
(F=1.2, p=.33). C. Mitochondrial ETC complex 2 (Succinate Dehydrogenase – SDH) enzyme 
activity measured in umol/min/g (y-axis), an assessment of complex-2 specific function in isolation. 
Although there appears to be a trend, there is no significant difference between CKD stage groups in 
complex 2 function (F=3, p=.08). D. Mitochondrial ETC complex 4 (Cytochrome Oxidase - COX) 
enzyme activity measured as in C (umol/min/g). The 1-way ANOVA F-test was significant (F=5.1, 
p=.02), with post-hoc tests revealing significant differences between stages 1&2 and 3 (*, p<.05), 









FIGURE 5 (above) - Mitochondrial respiration assessment. across CKD-stage groups with 1-way 
ANOVAs. Bar heights indicate group means, with errors bars indicating + SD. The following 
symbols represent significant post-hoc tests of pairwise comparisons:  *(between Stage 1&2 and 
Stage 3), ^(between stage 1&2 and Stage 4&5), #(Between stage 3 and Stage 4&5). All respiration 
measures are depicted in rate of oxygen consumption per second per mg of tissue wet weight (Y-
axis: pmol/s/mg). A. LEAK-state respiration between CKD stages (F=8, p=.002), with stage 1&2 (*) 
and stage 3 (#) exhibiting significantly less LEAK than late-stage 4&5 (p<.05). B. Complex 1 
respiration (State3-C1) between CKD stages (F=21, p<.001), with stage 1&2 (^), stage 3(#) 
significantly higher than late-stage (4&5), and stage 1&2 (*) higher than stage 3. C. Maximal ox-
phos (State3-C1+C2) between CKD stages (F=21, p<.001), with stage 1&2(*) being higher than 
stage 3, and stage 1&2 (^) being higher than stage 4&5 (p<.05). D. Maximal ETS respiration 
between stages (F=15.5, p<.001) with stage 1&2(*) being higher than stage 3, and stage 1&2 (^) 
being higher than stage 4&5 (p<.05). E. Representative oxygraph tracings depicting mitochondrial 
respiration (pmol/s/mg – red trace) over the experimental protocol between mitochondria in early 
(stage 1) CKD and late (stage 5) CKD, with plateaus labeled according to their respective respiration 
state (Complex 1 respiration, Maximal oxidative phosphorylation, and maximal ETS). Also depicted 




















FIGURE 6  
RNA-sequencing output detaling overall transcript differences between samples and CKD-stages. A. 
Heat-map depicting significantly differentially expressed genes (p<.05) across all samples. Columns 
represent participant muscle samples, rows depict genes. Color scheme is shown in the upper left, 
with increasing shade of red depicting relative upregulated genes, and increasing shade of blue 
depicting downregulated genes (scale = mean log 2-fold change). The heat map clusters on CKD 
stage, as shown at top. C. Venn diagram depicting the number of significantly differentially 
expressed genes per condition comparison (green circle = stage 4&5 vs. stage 1 – 448 differentially 
expressed transcripts) (blue circle = stage 3 vs. stage 1&2 – 440 differentially expressed transcripts) 
(red circle = stage 3 vs. 4&5 – 1775 differentially expressed transcripts). C. Bar graph depicting total 
gene counts per biotype. Each bar represents the biotype breakdown per participant. The transcripts 
analyzed contained mostly protein-coding mRNA (teal) across all samples, followed by 








Selected GO terms and KEGG pathways from a larger list of top 25 down and upregulated gene 
networks across stage-wise transcript analysis. Bar charts depict top downregulated (blue bars) or 
upregulated (red bars) gene networks, with their accompanying network label listed next to its 
corresponding bar (all GO terms list have FDR <.05, and all KEGG terms have p-value <.05). 
Pathway up or downregulation is expressed in mean log-fold-change units, and was determined to be 
significant when compared to background log 2 fold change for genes not contained within the 
network/pathway. Below/bottom are selected genes from the significant GO or KEGG pathways that 
are differentially expressed, and the fold change listed in parentheses next to the gene term. A. 
Comparing late-stage CKD muscle transcriptome to early stage 1&2 (early CKD is the reference). 
Oxidative phosphorylation and mitochondrial ATP-synthesis components were significantly 
downregulated in late-stage CKD compared to early, with specific genes listed at the bottom. B. 
Comparing middle-stage CKD to early stage 1&2 (early is the reference). Metabolic pathways 
including PI3K-Akt signaling, lipid handling and localization, and oxidative phosphorylation were 









KEGG oxidative phosphorylation pathway annotation for stage 4&5 CKD muscle. Significant 
selected downregulated genes in the electron transport chain GO term were used to annotate the 
mitochondrial electron transport chain subunits they encode (subunits circled in yellow, and 
connected to their corresponding gene with black arrow, and highlighted in blue). Not pictured – 
NDUFAF2 (complex 1 assembly factor) and SURF1 (complex 4 assembly factor). All listed genes 
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Chronic Kidney Disease (CKD) affects nearly two thirds of those with diabetes, and is an early 
complication of type 2 diabetes, a population exceeding 29 million persons in the United States (1). 
CKD, or diabetic nephropathy, is characterized by a progressive and persistent decline in kidney 
function, categorized into 5 stages defined by the degree of renal filtration rate impairment (2). CKD 
configures well to a geriatric syndrome model, specifically in its propensity to promote a physical 
frailty state. Reduced renal filtration rate is associated with marked muscle impairment and 
heightened risk for functional limitations (3). Many have theorized that such functional mobility 
limitations and exercise capacity deficits in this population are secondary to poor muscle 
performance and strength (4,5). Indeed, work by Diesel and colleagues (1990) find that skeletal 
muscle strength predicts exercise capacity, as opposed to blood-oxygen carrying capacity, and that 
altered skeletal muscle function explains the observed exercise and mobility intolerance in those 
with CKD (6). Given that skeletal muscle tissue is critical for many functions in the body and is 
responsible for movement, impairments in skeletal muscle may be the focal point of CKD-induced 
functional and exercise capacity deficits. Indeed, reduced kidney function leads to the retention of 
uremic solutes, promoting inflammation, hypercatabolism, oxidative stress, and insulin resistance 
contributing to skeletal muscle dysfunction (7). Given that muscle size, among other factors, is 
critical for muscle strength and performance, loss of muscle mass may explain some of these 
mobility deficits and intolerance to exercise (7). Indeed, even minor losses of muscle contractile 
proteins (ie. Myosin, actin) can be associated with large decrements in force generation due to 
consequential reduction in cross-bridge formation with contraction (7). In support of this 
observation, decreased muscle fiber size and number observed in CKD is due in large part to the 
synergistic proteolytic effects of uremia-induced inflammatory cytokines (IL-6, TNFa, CRP) and 




risk of morbidity and mortality in CKD and hampers muscle performance and mobility (10,9). 
However, skeletal muscle is a highly plastic tissue that responds to a variety of physiological and 
pathological stimuli due, in part, to the constant turnover or remodeling of muscle proteins, 
organelles and cell populations. Given the muscle degradation and multifactorial metabolic 
impairments in CKD, it is not surprising that investigators have observed a myriad abberant 
morphological features of skeletal muscle in CKD beyond atrophy alone, including – loss of 
myofiber myofilaments, reduced mitochondrial content with mitochondrial damage and reduced 
muscle density, and internalized nuclei with z-band damage and cellular degeneration (11,12). This 
constellation of muscle cellular alterations implicates not only dysfunction of systems governing 
muscle protein degradation and mitochondrial dysfunction, but also systems governing new muscle 
fiber formation and injury repair. 
Skeletal muscle is composed of multinucleated contractile muscle cells called myofibers. As 
the nuclei of myofibers are terminally differentiated in mature muscle (unable to divide, proliferate, 
or regenerate), a distinct cell population - the satellite cell (SC), residing on the periphery of the 
fiber, between its sarcolemma and basal lamina, is charged with repair, regeneration, and 
maintenance of muscle tissue (13). The fundamental process by which SCs perform these duties, is 
via a transition of specific yet overlapping steps that proceed from quiescence, to activation, 
proliferation, differentiation, and finally muscle cell fusion (13). 
 One primary means by which SCs “maintain” myofibers, including protein synthesis and 
breakdown, is through myonuclear domain maintenance. Each of the several hundred myonuclei of a 
myofiber regulates the gene products and cellular signaling networks in a finite volume of cytoplasm 
– termed its myonuclear domain (MND) (14). This has been demonstrated through findings that 




encoded and synthesized proteins are restricted to specific targets immediate to its parent nucleus 
(14). SCs provide a continual source for new myonuclei at a rate sufficient to maintain constant 
MND size during skeletal muscle growth, and degradation (15). Moreover, MND size relates to the 
amount or capacity for protein synthesis, and if SCs are deficient in nuclear addition (via fusion), 
myonuclei may be overwhelmed, resulting in deficient protein synthesis for their cytoplasmic 
domain, resulting in dysfunctional proteostasis (15). It has also been postulated that mitochondrial 
content and demand may also require dynamic myonuclear addition via SC activation and fusion. 
Indeed, it is now well established that anterograde and retrograde signaling between nucleus and 
surrounding mitochondria is crucial for many fundamental cellular processes, especially proper 
mitochondrial function. Roughly 1500 proteins necessary for mitochondrial function are nucleus-
encoded, and are then imported into the mitochondria to perform their functions (eg. NRF-1 
stimulates mitochondrial DNA replication, PGC-1a, electron transport chain proteins and subunits, 
and mitochondrial turnover genes). Thus, SC function may be crucial in dictating the metabolic 
capacity, both for protein synthesis and maintenance, and energetic efficiency of myofibers. This is 
supported by recent elegant work by Fry and colleagues (16) who demonstrate that by inhibiting SC 
fusion (via genetic deletion of a key fusion protein-- myomaker), overload-induced muscle 
hypertrophy was attenuated, along with protein synthesis. The authors argue that this is likely due to 
the inability to add myonuclei to the muscle fiber, and thus, transcription of contractile proteins is 
blunted, while additional protein synthetic factors – ribosomes for protein translation or secondary 
signaling molecules secreted by SCs – are also diminished (16). Interestingly, other work also 
demonstrates that SC deficiency leads to diminished muscle performance (17). This may be due to 
impairments in nuclear metabolic and protein synthesis capacity, but this may also result from poor 




 SCs reside underneath the basal lamina in a quiescent state, and upon injury, become 
activated to generate a pool of myogenic progenitors (MPs) that differentiate and fuse to each other 
or existing myofibers to restore structure and function to muscle (16). Every functional satellite cell 
is critical for the repair of subtle and focal damages that occur in normal day-to-day muscle 
utilization. This injury triggered repair process occurs in 3 sequential and overlapping stages – 1. an 
inflammatory response, 2. activation, differentiation, and fusion of SCs, and 3. maturation and 
remodeling of newly formed myofibers. This injury-SC-repair process begins with sarcolemmal 
disruption, resulting in increased myofiber permeability that upregulates calcium-dependent 
proteolysis of myofibrillar and cytoskeletal proteins along with activation of the complement 
cascade and inflammatory response (18). This inflammatory response recruits leukocytes to the cite 
of myofiber damage, followed by pro-inflammatory (M1) macrophages that phagocytose debris, and 
anti-inflammatory (M2) macrophages that promote SC proliferation and differentiation (18). The SC 
activation, proliferation, and differentiation is driven by myogenic regulatory factors, where SCs are 
progressed down the myogenic pathway, starting with their expression of Myogenic factor 5 (Myf5 -
- drives SC proliferation and amplifies SC number), and MyoD which commits these SC to a 
myogenic end-point as they form myoblasts (13). These myoblasts then differentiate and fuse under 
the direction of Myogenin, to create myotubes and synthesize the major muscle contractile protein -- 
myosin heavy chain, after which, myotubes fuse with existing myofibers in both growth and repair 
(13). How SC proliferation and differentiation is balanced is poorly understood, but is known to 
involve extrinsic signals from muscle and non-muscle cell types (19). SC, not surprisingly, are 
regulated by their surrounding niche that consists of endothelial cells, inflammatory cells, 




factors, in addition to mechanical cues (19). Thus, impairments and/or disruptions in any of these 
factors may predictably alter SC function, and proper myofiber repair and maintenance. 
The initiating inflammatory response of myofiber repair, requires an orchestrated response 
consisting of leukocyte infiltration signaling circulatory monocytes and chemoattractant molecules 
that produce downstream inflammatory cytokines and extracellular matrix proteins (ie. fibronectin, 
collagen 6) (20). It has been clearly shown that even slight imbalances in immune cell populations 
due to sustained and excessive inflammatory signals in muscles, can disrupt the cellular dynamics of 
the niche, and provide inappropriate environmental cues to SCs (20). In fact, sustained inflammation 
and accompanying persistent expression of ECM proteins impairs the differentiation capacity of SCs 
(21). Moreover, the ECM remodeling in such an environment alters elastic properties of muscle 
tissue, making it more fibrotic, stiff, and negatively impacting SC capacity to proliferate, fuse, and 
self-renew (22). However, persistent inflammation may not be the only factor that impairs SC 
reparative processes. 
 As demonstrated in several studies, fibrosis, and poor muscle quality may best be attributed 
to inability to maintain myofiber integrity due to a loss or imbalance of SC-fibroblast paracrine 
communication (16). Fibroblasts regulate expansion of SCs by preventing their premature 
differentiation (23), while SCs secrete micro-RNAs (ie. MiR-206) that regulate fibroblast collagen 
production and ECM deposition, while also possessing the capacity to remodel the basal lamina 
constituents directly (23,24,25). However, increased ECM is characteristic of regenerating muscle, 
and is synthesized by muscle-resident fibroblasts, largely to serve as scaffolds to maintain structural 
and functional integrity, myofiber orientation, and to sequester and present growth factors necessary 
for SC repair (26). Yet, excessive ECM with regeneration can impede muscle function and hinder 




noticeable increase in fibroblast density and ECM deposition in muscle, and these fibroblasts retain a 
multipotent capacity, as certain subpopulations can differentiate into adipocytes, thus promoting 
intramuscular adipose tissue infiltration in addition to unchecked fibrosis (19). Thus, pathological 
deterioration of the SC niche or systemic changes can influence SC fate decision and disrupt normal 
cellular responses to injury, and attenuate the formation of healthy or even new myofibers that leads 
to loss of muscle function and mass (27,28). However, aside from inflammatory and neighboring 
cell paracrine interaction potentially impairing SC reparative function, second-messenger signaling 
factors also play a large role in the SC niche.  
 Notch signaling regulates SC proliferation, differentiation, and cell fate determination (29). 
Delta and Jagged family ligands bind to SC transmembrane Notch receptors resulting in cleavage 
and nuclear translocation of the Notch intracellular domain to activate MRF and gene expression 
(29). However, for SCs to progress from proliferation to differentiation, signaling must switch from 
notch to Wnt, with Wnt and notch signaling interacting to promote efficient transition between these 
two cellular states and proper progression down the myogenic lineage (30). However, in aging 
studies, increased Wnt signaling during SC proliferation can convert SCs myogenic lineage to a 
fibrogenic one, resulting in further fibrosis (27). Conversely, the age-related deficiency in Notch 
signaling in SCs impairs their activation, proliferation, and muscle repair following injury (31). 
Similar to Notch signaling, insulin-like growth factor 1 (IGF-1) binds to, and activates IGF-1R in 
SCs to induce expression of MRFs and SC activation (32). These co-regulating signaling molecules 
add another level of complexity to the control mechanisms that dictate SC-mediate muscle 
maintenance. 
 Thus, SCs play a vital role in maintaining myofiber protein synthesis rates, energetic 




deteriorating health state characterized by elevated inflammation, contractile protein catabolism, 
skeletal muscle mitochondrial/energetic deficiencies, and systemic signaling factor alterations (ie. 
increased Angiotensin-2 production that may suppress SC MRF gene transcription via SC 
angiotensin receptors). Given this physiological imbalance and the aforementioned muscle 
morphological alterations in CKD - fiber atrophy, loss of myofilaments, reduced mitochondrial 
content, mitochondrial damage, reduced muscle density, and z-band damage and myocellular 
degeneration - SC function represents a critical area of research that may provide key mechanistic 
insights into skeletal muscle impairments that are so prevalent in this population. As satellite cells 
are controlled by both intrinsic and extrinsic regulatory cues and relate to both muscle degenerative 
disease and sarcopenia, novel discoveries in this area may bring new opportunities to enhance 
muscle function and mass in the uremic environment of CKD (33). Based on studies demonstrating 
the negative impact of the uremic milleui on mesenchymal stem cells (34), endothelial progenitor 
cells (35), bone marrow-derived stromal cells (34), investigation into the effect of CKD on SCs is 
needed. However, to-date, no studies have evaluated the impact of CKD or its progression on 
satellite cell function and muscle health in humans, nor have the muscle and whole-body functional 
relationships to SC function been explored in this population.  
 Thus, the purpose of this study is to determine how skeletal muscle SC abundance and 
function is affected by CKD progression and its associated systemic milleui in those with T2DM, 
and subsequently, how SC alterations relate to muscle health, quality, performance, and overall 
physical mobility across the spectrum of CKD severity. In understanding the functional status of this 
key skeletal muscle regulatory cell population, we may gain new insights not only into the biological 
underpinnings of skeletal muscle impairment in those with CKD, but also when these mechanisms 




treatments to improve muscle health and remedy functional deficits to improve activity 
engagement/tolerance and attenuate CKD progression in those most vulnerable – those with T2DM. 
Methods  
Participants 
Twenty seven subjects participated in this study – all were diagnosed with T2DM, 12 with diagnosed 
and clinically confirmed peripheral neuropathy (PN), and all with clinically diagnosed diabetic 
nephropathy (diabetes-induced CKD) by a nephrologist. Participants were categorized into early 
CKD stage (eGFR >60 mL/min, stages 1 and 2), middle-stage CKD (eGFR 30-59 mL/min, stage 3), 
and late CKD (eGFR<29 mL/min, stages 4 and5). Participants of each categorical stage/group of 
CKD progression were – n = 9 in early CKD (stage 1 and 2 - 7 male, 2 female), n=9 in middle-stage  
CKD (stage 3 - 6 male, 3 female), and n=9 in late-CKD (stages 4 and 5 - 5 male, 4 female). The 
groups were matched for gender composition, age, BMI, duration of T2DM, glycemic control 
(HbA1c, OGTT AUC), diabetes severity (presence of PN) (Table 1). Participants were recruited 
from the Washington University Volunteers for Health, the Center for Community Based Research, 
the Washington University Medical School Renal Clinic, and from the surrounding St. Louis 
community.  
Study inclusion criteria included a diagnosis of T2DM based on clinical report of a diagnosis 
of DM from a physician, confirmation of medication usage for DM (insulin, oral hypoglycemic 
agents or both) and verification of HbA1c levels either currently or at the time of diagnosis >6.5%, 
and/or OGTT >200 mg/dL. A diagnosis, particularly for those with eGFR <60 mL/min, of diabetic 
nephropathy based on nephrologist clinical assessment of patient medical history, degree of 




glycemic control, diabetic medication use, hypertension status, and rate of kidney decline (eGFR 
utilizing creatinine), all according to KDIGO guidelines (35) 
Participants were excluded from the study if they weighed more than 350 pounds (equipment 
weight limit), had any infection or ulceration of either foot, severe foot deformity or amputation, or 
any serious medical co-morbidity. Serious medical comorbidities included - dialysis treatment, heart 
failure requiring medications, or New York Heart Association class 3 or class 4 heart failure, 
coagulation disorders (platelets <100,000, PT > 2 seconds above control, or INR >1.5), anemia (Hbg 
< 10g/dL), uncontrolled proliferative diabetic retinopathy, joint replacement or musculoskeletal 
injury that precludes intense muscular contraction, within 1 year of enrollment, symptoms that meet 
the requirement for class C or class D of the AHA risk stratification criteria, individuals who are 
participating in regular structured exercise programs, or may be pregnant or breast feeding, current 
cancer treatment, and organ transplant requiring immunosuppressant therapy. Each participant read 
and signed an IRB-approved protocol and informed consent that was approved by the Human 
Research Protection Office at Washington University in St. Louis, MO. 
CKD Staging (eGFR): 
CKD staging was performed using serum creatinine concentrations. Serum creatinine was measured 
with a standardized assay, and used to estimate GFR (eGFR) - computed based on the Chronic 
Kidney Disease Epidemiology Collaboration equation and was classified into 5 stages: eGFR > 90 
mL/min per 1.73 m2 (stage 1 CKD), 60-90 mL/min (stage 2 CKD), 30-60 mL/min (stage 3 CKD), 





Laboratory measures including serum creatinine (mg/dl) as above, blood-urea nitrogen -- BUN 
(mg/dl), HbA1c (%), oral glucose tolerance test – OGTT area under the glucose curve (AUC), and 
urine albumin:creatinine ratio (ACR – mg/g) to quantify degree of proteinuria. 
Participant Demographics: 
Participants age, duration of T2DM, weight, height, and BMI (calculated as weight in kg divided by 
the square of height in meters, used to define obesity) were collected through participant interview, 
weight balance, and stadiometer, respectively at the initial visit, prior to any dynamometry or 
physical performance testing. 
Neuropathy Assessment: 
Peripheral neuropathy was determined by diminished or absent plantar sensation to light touch or 
pressure or vibration perception. Lower extremity sensation was assessed via biothesiometry and 
semmes Weinstein monofilament testing. Peripheral neuropathy was defined clinically as the 
inability to feel the 5.07 (10 gram) monofilament on at least one non-callused site on the plantar 
aspect of either foot or the inability to perceive vibration threshold <25 volts on the biothesiometer 
(Biomedical Instrument, Newbury, OH, USA) applied to the hallux (36). 
Physical Function: 
Functional physical performance was assessed using the 9-item modified physical performance test 
(PPT). The PPT is a timed observational assessment of performance on nine daily physical activities 
including: 5 consecutive sit-to-stand transfers without arm assistance, climbing a flight of stairs with 
10 steps, a 50-ft. walk test, turning 360 degrees, picking up a coin from the floor, donning/doffing a 




open, and ability to ascend 4 flights of stairs (36). Each item is scored from 0-4 based on the time 
taken to complete each task, with a maximum score of 36 (higher scores indicate better physical 
function/performance). Each task is performed twice with the average time used to score the task. 
Interrater reliability, validity with other functional assessments, and predictive validity of lack of 
independence and mortality have all been well established for the mPPT (36,37,38,39). The mPPT 
possesses a test-retest reliability of .964, while individual sub-items have reliability ranging from 
.51-.99, and Cronbach alpha of .785 (38,39). 
Stair Vertical Power- 
Stair vertical power was calculated from the stair-climbing component of the PPT, using the 
equation as previously described (36) 
Stair Power = [(weight in Kg)(9.8)(1.95)] / (avg. stair climb time in seconds) 
1.95 à cumulative height of the 10 steps (each step is 19.5 cm), in meters 
Muscle Performance Assessment: 
Muscle performance of lower extremity major muscle groups was assessed via Biodex System 3 
isokinetic dynamometer as described previously (40,41,42,43). Major muscle groups assessed were 
hip extensors and knee extensors as these muscle groups are critical to ambulation and functional 
mobility (44). For each movement, the anatomical axis of rotation (ie. hip joint center/greater 
trochanter, knee joint femoral condyles) was aligned to the dynamometer axis using visual 
inspection and manual palpation.  
Participants upper extremities, trunk, and contralateral limb were secured with padded straps 




participants became familiar with procedures by performing 3-5 submaximal contractions, and the 
tested leg was weighted to correct for the effects of gravity on the torque measured, according to the 
specifications of the Biodex Manual. Range of motion was set for each movement to obtain ~110 
degrees of hip flexion (from ~5° of hip extension), ~90 degrees of knee flexion (from terminal 
extension). The isokinetic tests for each muscle group included 5 maximal concentric contractions 
each separated by 5 seconds. Isometric tests consisted of 4 maximal contractions held for 5 seconds 
each, separated by 10 seconds rest between repetitions. Isometric force production was assessed at 
60 degrees of hip flexion, 60 degrees of knee flexion, to achieve optimal muscle-specific sarcomere 
length (45,46). 3 minutes rest separated each test. Isokinetic strength was assessed for each joint 
extensor movement at 30°/sec and 120°/sec. To assess peak torque production (ft-lbs) as a measure 
of maximal muscle strength, the highest 3 repetitions were selected and averaged for each joint at 
each repetition speed. At each selected repetition, rate of torque production, seconds to peak torque, 
total work, and power was also assessed and averaged. Power was determined by the time-averaged 
integrated area under the curve at the constant velocity of movement in the available range of motion 
(40,41) To avoid sub-maximal performance or outliers, tests were re-done or data discarded if the 
coefficient of variation exceeded 10% for the knee and ankle, and 15% for the hip (47).  
Finally, we also assessed muscle fatigueability/fatigue resistance of the aforementioned 
muscle groups using a fatigue protocol detailed as follows – participants performed 50 maximal 
repetitions at 90 degrees per second, with 2 second rest period between repetitions. Torque 
production was assessed for each repetition, and work was calculated across the first, second, and 
third portion of the fatigue set, and totaled for an index of fatigue resistance as detailed previously 
(48,49). Recovery from this fatigue task was tracked over 2 recovery phases. In phase 1, participants 




set. In phase 2, participants performed 5 maximal repetitions separated by 25 seconds of rest. Torque 
production for each recovery repetition was recorded.  
Fasting/medication/OGTT: 
As renal decline can contribute to skeletal muscle insulin resistance, an oral glucose tolerance test 
and fasting glucose and insulin values were obtained to assess and control for any differences in 
insulin sensitivity, as this may confound the relationship between mitochondrial function and muscle 
performance. All diabetes medications (except insulin) were stopped 2 days before admission to the 
Clinical Research Unit (CRU) to decrease residual drug effects on the metabolic measurements 
(long-acting GLP-1 agonist and thiazolidinediones were stopped 7 days before admission). 
Subcutaneous insulin was stopped after the final dose on the day prior to admission to the CRU. 
Blood glucose concentration was checked by fingerstick twice daily at home (once before breakfast, 
and once posprandially after dinner before bedtime) for 2 days before admission (7 days before 
admission in subjects taking long-acting GLP-1 agonist or thiazolidinediones) to ensure adequate 
glycemic control was maintained prior to metabolic testing. Participants refrained from eating for 10 
hours prior to administration of the 3-hour oral glucose tolerance test as previously described (50).  
Participants fasting plasma glucose was assessed 10 minutes prior to administration of a 75g 
glucose drink. Plasma samples were subsequently obtained at the time of drink ingestion, and at 10, 
20, 30 minutes, and then every half hour until 3 hours post-ingestion. Plasma glucose was assayed 
by automated glucose analyzer (Yellow Spring Instruments), and plasma insulin by ELISA (51). 
Insulin sensitivity as a measure of basal insulin sensitivity during an OGTT was estimated using 
homeostasis model assessment of insulin resistance (HOMA-IR), calculated as [(fasting glucose 





Fasting blood samples for cytokine measurement were drawn prior to the glucose challenge, into 
pre-cooled glass tubes containing EDTA and gently inverted 10x to mix. Samples were subsequently 
spun at 1300g, at 4°C for 10 minutes, and the supernatant aliquoted as plasma and stored at -80°C 
for future analysis. IL-6 and TNF-alpha concentrations (pg/mL) were assessed via high-sensitivity 
ELISA from R&D Systems (Minneapolis, MN, USA) (53,54). 
Body Composition: 
Each participant was assessed for body composition with a whole-body, dual energy x-ray 
absorptiometry (DXA) (Hologic GDR 1000/W, software version 6.2 OD; Waltham MA) scan to 
assess composite and regional lean and fat mass as described previously (55). Bilateral upper and 
lower extremity fat-free masses, region-specific lean mass (ie. thigh region), whole-body lean mass 
and fat masses were assessed.  
Muscle Biopsy: 
Participants were positioned supine in a hospital bed with the thigh of their dominant leg exposed. 
Participants were then asked to contract the thigh so as to visualize the vastus lateralis (anterior to 
fascia lata, approximately 1/3rd of the distance from patella to great trochanter). The area was 
prepped and cleaned with iodine, and draped. The skin was anesthetized with 2% lidocaine solution 
injected into the dermis and allowed to take effect over a 3 minute period. A 1-2 cm incision was 
made through the skin and subcutaneous tissue, and a 5 mm Bergstrom needle was introduced with 
vacuum suction into the vastus lateralis. Two passes of the biopsy needle were performed for each 




A 50-75 mg portion of the sample were immediately snap-frozen in liquid nitrogen and 
stored at -80°C until further analysis (RNA-sequencing), while 50-120 mg of  muscle tissue were 
prepared for immediate flow cytometry analysis and muscle SC isolation. When enough sample 
remained, 50 additional mg of tissue were blotted with gauze to remove excess moisture, and 
oriented with fibers directed vertically and embedded in cork-mounted tragacanth gum and frozen in 
liquid-nitrogen-cooled isopentane for 10-20 seconds for cryosectioning and histology. 
Muscle Morphology (H&E staining): 
Samples frozen for histology were sectioned at 8um with a Leica Cryostat on Superfrost Plus slides, 
and fixed for 5 minutes with ice-cold acetone and stained with Harris haematoxylin and eosin (H&E) 
according to standard procedures as previously described (57). Briefly, mounted cryosectioned 
samples were immersed in filtered Harris Hematoxylin for 1 minute, followed by tap water rinse, 
and subsequent immersion in EOSIN stain for 1-2 minutes. After thorough rinsing, the sample was 
dehydrated in ascending alcohol solutions (50,70,80,95%x2,100%x2) in Columbia staining dish. 
Samples were then cleaned with xylene (3-4x), and mounted with coverslips with Permount for non-
contractile tissue quantification.  
 Sections were examined at 10x magnification at 5 representative locations in the muscle 
cross section by a blinded rater. Images were captured with a Leica DC500 camera and Leica IM50 
software. Subsequently, ImageJ software was used with the haeomatoxylin/eosin (H&E) color 
deconvolution plugin (Rasband, W.S., ImageJ, US National Institutes of Health, Bethesda, 
Maryland, USA http://rsb.info.nih.gov/ij/, 1997–2008) to determine the fibrotic/non-contractile 
percentage of the entire cross section of each image per sample. This plugin was used as it is 




based on the primary and secondary 3D colour space (RGB and CYM) 
(http://www.dentistry.bham.ac.uk/landinig/software/cdeconv/cdeconv.html). Healthy contractile 
tissue was separated from non-contractile using ImageJs automatic threshold on the eosin component 
(obtained after H&E color deconvolution). This allowed for calculation of the percentage of 
fibrotic/non-contractile tissue ((whole area – muscle occupied area)/whole area) as described 
previously (58). 
Satellite Cell Isolation/Cell quantification –  
Muscle SC isolation was adapted from standard methods and criteria (59,60). Briefly, muscle 
samples were immediately placed in a 15 mL conical tube containing pre-warmed (370C) digestion 
buffer (Dulbecco’s Modified Eagle Medium [DMEM; Gibco/Invitrogen, Carlsbad, CA, USA]; 20 
mg/mL collagenase type 1 [Sigma, St. Louis, MO, USA]; 6mg/mL dispase II [Roche, Mannheim, 
Germany]; 6ku/mL penicillin [Gibco/Invitrogen]; 5mg/mL streptomycin [Gibco/Invitrogen]), and 
placed in a 370C water bath for 30 minutes, with agitation every 10 minutes. Samples were 
transferred to a 21cm2 tissue culture plate and fibers were visualized and pulled apart using surgical 
fine-tip forceps in a sterile tissue culture hood. After the tissue was sufficiently broken apart, the dish 
was placed in an incubator for 50 minutes (5% CO2, 370C), with gentle agitation every 10 minutes. 
The plate and mixture were then manually triturated through a 5mL plastic serological pipette to 
further disrupt the tissue, and incubated for an additional 10 minutes. Following incubation, the 
mixture was filtered through a 70 um mesh cell strainer (VWR #352350) into a 50-mL conical tube. 
The plate was subsequently washed with 4 mL of low-glucose DMEM (1g/L) and passed through 
the filter. The mixture was then passed through a 40 um mesh cell strainer (VWR #352340) into a 
new 50-mL conical tube and transferred to a 15-mL conical tube. The mixture was centrifuged at 




suspended in 1 mL of fluorescence-activated cell sorting (FACS) buffer (2.5% goat serum; 1mmol/l 
ethylenediaminetetraacetic acid in phosphate buffer saline [PBS] at pH 7.4). 20 uL of the cell 
suspension was then added to 980 uL of FACS buffer for 4 conditions (1 for each cell surface 
marker probe, and 1 for unstained cell control) for fluorescence minus-one controls (FMO). 200 uL 
of FACS buffer was used to restore the original cell suspension to 1 mL volume. Cell-surface 
markers were then labeled by adding the following fluorophore conjugated antibodies to the cell 
suspensions: NCAM (unconjugated, BD Biosciences, #561903, San Jose, CA, USA, 1:200), CD31 
(FITC, eBioscience/ThermoFisher Scientific, #11031941, Grand Island, NY, USA, 1:200), and 
CD45 (Pac-Blue, Biolegend, #304022, San Diego, CA, USA, 1:200), and secondary antibody goat 
anti-mouse IgG (Alexa-Fluor 647, ThermoFisher, #A21236, Grand Island, NY, USA, 1:200). Cell 
suspensions with primary antibodies were incubated for 20 minutes on a rocker, in a 40C  cold room, 
and pelleted, and washed with 3 mL of FACS buffer. Cells were then pelleted and re-suspended in 1 
mL of FACS buffer (5 suspensions total – 3 FMOs, 1 unstained control, and sample suspension).   
Secondary antibody was then added to conjugate to the NCAM (CD56) antibody, and incubated for 
20 minutes on a rocker in a 40C cold room, after which, cells were pelleted, washed, and re-
suspended as previously, and ready for FACS sorting. 
Flow cytometry was conducted using a FACS Aria II-1 (BD Biosciences, San Jose, CA, 
USA) instrument at the Washington University School of Medicine Pathology Department Flow 
Cytometry Core (St. Louis, MO, USA; https://pathology.wustl.edu/research/core-facilities/flow-
cytometry-fluorescence-activated-cell-sorting/). Optical alignment and fluidics of the cytometer 
were verified daily by a trained technician using BD Cytometer Setup and Tracking Software (BD 




excitation=650 nm, emission=668 nm, CD31 (FITC) excitation=494, emission=519, and CD45 (Pac-
Blue) excitation=401, emission=452.  
Gating strategies were optimized using multiple preliminary experiments that included 
unstained and FMO controls. Initial gaiting was set based on two-dimensional plot of forward scatter 
(FWSC – indicative of cell size) and side scatter (SSC – indicative of internal cell 
complexity/granularity) to focus on intact cells while excluding cell debris. Next, gating was 
established on two-dimensional plotting of the intact cells on forward scatter area (FSC-A) and 
forward scatter width (FSC-W) to remove any dublets, debris clumps and non-single-cells. This 
single-cell population was further refined by establishing a gate set on two-dimensional plotting of 
side-scatter area (SSC-A) and side-scatter width (SSC-W), to ensure that mononuclear single cell 
population was being applied to the established antibody gating scheme for cell quantification. From 
this established population, satellite cell (NCAM+) gating was performed with a 1-dimensional gate 
placed so that <1% of cells within the FMO suspensions were positive, and a confirmatory gate was 
placed on a two-dimensional plot of CD45 and CD31, to ensure that Satellite Cells were CD31-
/CD45-/NCAM+. Gating for endothelial cells and inflammatory cells was performed on a 2-
dimensional plot of CD31 and CD45, with CD34+/CD45- cells demarcated as endothelial cells, and 
CD45+/CD31- cells designated as inflammatory cells (leukocytes). All samples - FMOs, unstained 
suspension, and labeled biopsy sample were run in the same session, and the established gating 
parameters were applied to every sample sorted. All cell population were expressed as a percentage 
of the total mononuclear cell population, and compared via 1-way ANOVA between CKD groups. 
Sorted satellite cells (NCAM+) were collected in FBS and immediately plated in 21cm2 collagen-




#C3867, St. Louis, MO, USA) with growth media (20% FBS, 1% Pen/Strep, 1:1 low glucose 
DMEM to Hams F10, 4 ng/mL bFGF) in a cell culture incubator (370C in 5% CO2-95% air). 
Satellite Cell Culturing- 
Once plated, isolated satellite cells were left to proliferate and expand, with growth media changed 
every 4 days, until the contents of the 21 cm2 dish were ~75% confluent (~5 days - 1 week). Once 
75% confluent, cells were split into two collagen-coated 21 cm2 dishes for expansion. After ~3 days 
(~75% confluency), cells were split further (passage 2) into two 60 cm2 collagen-coated dishes for 
final expansion to ~75% confluence (~3-5 days), at which time, cells were trypsinized (.25% trypsin-
EDTA, Simga-Aldrich, #T4049, St. Louis, MO, USA), pelleted and frozen for later analysis (freeze 
media – 90% FBS+10% dimethylsulfoxide/DMSO).  
For cell culture studies, frozen primary satellite cells were thawed and expanded in collagen-
coated 60 cm2 dishes (each passage split 1:4 in dishes). All subsequent experiments were performed 
with cells at passage 3-4. Cells were fed growth media every 3 days, until ~75% confluent, at which 
time, cells were trypsinized, pelleted, counted and plated into 16 matrigel-coated 9.6 cm2 dishes 
(matrigel concentration – 200 ug/mL, or 26.7 ug/cm2) (GFR-phenol-red-free, Corning, #356231, 
Bedford, MA, USA). 14 dishes were plated with 100,000 cells (~10,400 cells per cm2) for myogenic 
analysis, while 2 dishes were plated with 30,000 cells each (~3,125 cells per cm2) for cell 
proliferation assay. 
Cellular proliferation was measured with the Click-iT ethynyl-2’-deoxyuridine (EdU) 
imaging kit (Invitrogen) following the manufacturers protocol. EdU is a nucleoside analog of 
thymidine, and is incorporated into DNA during DNA synthesis, thus preferentially staining the 




growth media containing 1 mM EdU solution, after which, cells were fixed in 3.7% formaldehyde 
solution for 15 minutes, and rinsed with PBS. Fixed cells were then permeabilized with 1% Triton-X 
solution for 15 minutes and rinsed with PBS, and subsequently incubated for 40 minutes at room 
temperature in EdU reaction cocktail. Detection of EdU occurs through a click reaction (copper-
catalyzed covalent reaction between azide and an alkyne). Labelled cells were then incubated at 
room temperature for 10 minutes, with Hoechst 33342 to stain cell nuclei blue. Cells were finally 
rinsed with PBS and imaged using a dual purpose phase contrast and fluorescence microscope 
(EVOS FL Cell Imaging System, Life Technologies, Paisley, UK) at 10x magnification at 5 random 
locations per dish (2 dishes total). EdU-stained cells were counted with ImageJ software and 
quantified as a fraction of the total number of cells in the field of view per image, and averaged over 
all images and expressed as a percentage (61). 
Myogenic analysis was performed over a 5-day period. Plated cells were allowed to grow to 
confluence (~2-3 days), at which time, to promote differentiation of confluent satellite cells into 
myotubes, growth media was changed to differentiation media consisting of low-glucose DMEM 
(1g/L) (GIBCO/Invitrogen) supplemented with 5% horse serum (ThermoFisher #16050-122) and 1% 
pen/streptomycin antibiotic, denoted as day 0. To assess the timeline and myogenic capacity of 
primary satellite cells, 2 plates were fixed in ice-cold 100% methanol at days 1 (24 hours post 
differentiation media administration), day 2, day 3, and day 5. Fixed cells were subsequently stained 
for constituent protein myosin heavy-chain (MyHC) (MF-20, mouse anti-human, Developmental 
Studies Hybridoma Bank, Iowa, USA), and nuclei (Hoechst 33342, Invitrogen). Briefly, fixed cells 
were washed twice with 1x PBS, and blocked in 2% BSA with primary antibody against myosin 
heavy chain protein (MF-20, diluted 1:30) for 1 hour at room temperature. Cells were then washed 




ThermoFisher, #A21236, Grand Island, NY, USA, diluted 1:400 in 2% BSA) for 20 minutes at room 
temperature, protected from light. Cells were then washed thrice with PBS, and finally incubated in 
Hoechst nuclear stain (diluted 1:1000 in 1x PBS) for 2 minutes at room temperature. Cells were 
thoroughly rinsed with PBS and viewed on a dual purpose phase contrast and fluorescence 
microscope (EVOS FL Cell Imaging System, Life Technologies, Paisley, UK). At each day, 5 
representative images were taken at random locations in each of the two plates (10 total images per 
day) at 20x magnification, and the proportion of cells that had fused into multinucleated MyHC+ 
myotubes were expressed as a percentage of total nuclei in the field of view, averaged over all 10 
images per day, per participant, and reported as the fusion index as previously described (61). 
Simultaneously, to examine the coordination of myogenic regulatory factor (MRF) gene 
program, 2 plates of cells were extracted for gene expression profiling using Trizol reagent 
(Invitrogen # 15596026) at day 1, day 3, and day 5. Quantitative RT-PCR was used to assess mRNA 
expression of chief MRF genes that drive differentiation (myod, myogenin, MyHC). Briefly, trizoled 
cells were thawed and incubated with 20 mg/mL glycogen for 10 minutes, and precipitated with 
chloroform, centrifuged at 13200 rpm (16000g) for 15 minutes, and the aqueous layer was 
transferred, precipitated with isopropanol and centrifuged at 13200 rpm (1600g) for 10 minutes, and 
finally the pellet was re-suspended in 75% ethanol and centrifuged at 11000 rpm for 5 minutes and 
allowed to air dry for 15 minutes and re-suspended in DEPC water. Concentration and quality of 
mRNA were measured using a nanodrop spectrophotometer. qPCR was subsequently performed on 
isolated RNA as described previously (62). Briefly, 1 ug of RNA was diluted in DEPC water and 
combined with reverse-transcription master mix (consisting of dNTP, 100 mM DTT, 5x buffer, 
random hexamers and RTase) per sample and subsequently cycled at 370C for 60 minutes, 990C for 




(consisting of 12.5 uL SYBR Grenn, 6.5 uL DEPC water, and 2.5 uL of forward and reverse primer) 
per well in a 96-well plate and covered with optical adhesive. Sample PCRs were run in duplicate 
per gene probe. PCR was carried out at 500C for 2 min, 950C for 10 min., 950C for 15 sec., and 600C 
for 1 minute for 40 cycles. (PRIMERS LISTED BELOW). The cycle threshold (Ct) value for 
detection of gene of interest was normalized against the Ct value of GAPDH, and relative changes 
compared to stage 1&2 SCs were calculated according the ΔΔCt method.  
Primers-  
MyoD:  Forward 5’ - ACTTTGCTATCTACAGCCGGG- 3' 
   Reverse 5'- TAGAAGTCGTCCGTTGTGGC- 3'  
Myogenin:  Forward 5’ - CAGTGCACTGGAGTTCAGCG- 3' 
           Reverse 5'- TTCATCTGGGAAGGCCACAGA- 3'  
Myosin HC:  Forward 5’ - TTGCTGTCTTCTGCTCTCATC- 3' 
 Reverse 5'- GGAGCAGCTATGCCGAACAC - 3'  
GAPDH:  Forward 5’ - CTCTGACTTCAACAGCGACA- 3' 
 Reverse 5'- TCTCTCTCTTCCTCTTGTGC- 3'  
 
Transcriptome Analysis (RNA-sequencing)- 
Approximately 20 mg of snap frozen tissue per participant, was ground into a fine powder in a 
liquid-nitrogen cooled mortar and pestal system. Ground samples were subsequently emptied into a 
vial containing 1mL of Trizol reagent (Invitrogen # 15596026) supplemented with 20 mg/mL 
glycogen and incubated for 10 minutes, and precipitated with chloroform, centrifuged at 13200 rpm 
(16000g) for 15 minutes, and the aqueous layer was transferred, precipitated with isopropanol and 
centrifuged at 13200 rpm (1600g) for 10 minutes, and finally the pellet was re-suspended in 75% 




suspended in DEPC water. Concentration and quality of mRNA were measured using a nanodrop 
spectrophotometer. 1 ug of total RNA was subsequently utilized for RNA-sequencing and library 
preparation. Library preparation was performed using a Clontech SMARTER kit according to the 
manufacturer’s protocol. The resulting cDNA ends were rendered blunt, an A base was added to the 
3’ ends, and Illumina sequencing adapters were ligated to the ends. The ligated fragments were then 
amplified for 12 cycles using primers that incorporated unique index tags, and the resulting 
fragments were sequenced on an Illumina HiSeq 2500 sequencing system using single reads that 
extended 50 bases and targeted 30M reads per sample as previously described (63). Briefly, RNA-
seq reads were aligned to the Ensembl top-level assembly with STAR version 2.0.4b.  Gene counts 
were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount 
version 1.4.5.  Transcript counts were produced by Sailfish version 0.6.3.  Sequencing performance 
was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and 
transcripts detected, ribosomal fraction known junction saturation and read distribution over known 
gene models with RSeQC version 2.3. 
All gene-level and transcript counts were then imported into the R/Bioconductor package 
EdgeR and TMM normalization size factors were calculated to adjust for samples for differences in 
library size.  Ribosomal features as well as any feature not expressed in at least the smallest 
condition size minus one sample were excluded from further analysis and TMM size factors were 
recalculated to created effective TMM size factors.  The TMM size factors and the matrix of counts 
were then imported into R/Bioconductor package Limma and weighted likelihoods based on the 
observed mean-variance relationship of every gene/transcript and sample were then calculated for all 
samples with the voomWithQualityWeights function.  Performance of the samples was assessed 




performance was assessed with plots of residual standard deviation of every gene to their average 
log-count with a robustly fitted trend line of the residuals. Generalized linear models were then 
created to test for gene/transcript level differential expression. Differentially expressed genes and 
transcripts were then filtered for FDR adjusted p-values less than or equal to 0.05. 
The biological interpretation of the large set of features found in the Limma results were then 
elucidated for global transcriptomic changes in known Gene Ontology (GO) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) terms with the R/Bioconductor packages GAGE and 
Pathview. Briefly, GAGE measures for perturbations in GO or KEGG terms based on changes in 
observed log 2 fold-changes for the genes within that term versus the background log 2 fold-changes 
observed across features not contained in the respective term as reported by Limma. For GO terms 
with an adjusted statistical significance of FDR <= 0.05, heatmaps were automatically generated for 
each respective term to show how genes co-vary or co-express across the term in relation to a given 
biological process or molecular function.  In the case of KEGG curated signaling and metabolism 
pathways, Pathview was used to generate annotated pathway maps of any perturbed pathway with an 
unadjusted statistical significance of p-value <= 0.05. 
Statistics- 
Pearson Chi-square test for equality of proportions was used to determine the homogeneity of sex 
distribution, and neuropathy status between CKD-staged groups (stages 1 and 2, stage 3, and stages 
4 and 5). CKD group baseline demographic variables (age, BMI, duration of diabetes, glycemic 
control – HbA1c, total body lean mass, and eGFR) were analyzed and compared via 1-way analysis 
of variance (ANOVA). CKD-group differences were also assessed via 1-way ANOVA for OGTT 
area under the curve and HOMA-IR (measures of insulin resistance), PPT score, PPT sub-items stair 




extensors, hip extensors), SC quantification, SC proliferation capacity (EDU+ %), SC myogenic 
capacity (fusion index %) at differentiation days 1,2,3, and 5, and all gene expression measures. 
Post-hoc testing for CKD-staged group differences was determined using Tukey’s HSD or Games-
Howell in the event of a violation of homogeneity of variance. Bivariate pearson correlation 
coefficients were used to assess relationships between eGFR and the aforementioned measures, 
including lab measures, and between SC function/abundance measures and muscle quality, muscle 
performance and PPT scores. All analyses were evaluated at an alpha level set at .05.  
Results 
Group Demographics- 
As shown in Table 1, there were no group differences in gender composition, PN status, BMI, age, 
duration of diabetes, whole-body lean mass, glycemic control (HbA1c), insulin sensitivity (OGTT 
AUC) or albuminuria, though stages 3 and 4&5 CKD groups on average presented with macro-
albuminuria (>300 mg/dL), while early stage CKD presented with microalbuminuria (30-300 
mg/dL).  The groups inherently differed in eGFR, as this was the defining criteria of the groups 
(early, middle, and late-stage CKD) (p<.001), and also differed in BUN, a measure of uremia 
(p<.001). 
Physical Function- 
As shown in Figure 1, eGFR was significantly positively correlated with PPT score (r=.8, p<.001), 
along with other functional measures -- lower extremity power output while climbing stairs (Figure 
2), or in other words, worse kidney function was associated with impaired functional mobility, and 
muscle power output to propel stair climbing. Similarly, PPT score (F=36.1, stage 1&2 vs. stage 3-




vs. stage 3-p=.02, stage 1&2 vs. stage 4&5-p<.001, stage 3 vs. 4&5-p=.047), and chair rise score 
(F=13.9, stage 1&2 vs. stage 3-p=.048, stage 1&2 vs. stage 4&5-p<.001, stage 3 vs. 4&5-p=.027) 
significantly declined with stage-wise progression of CKD (Figure.1 B,C). 
Muscle Performance- 
As shown in Figure 3, knee extensor torque (Figure.3A, F= 16.9, stage 1&2 vs. stage 3- p=.014, 
stage 1&2 vs. stage 4&5- p=.001, stage 3 vs. 4&5- p=.037) and power (Figure.3C, F=11.4, stage 
1&2 vs. stage 3- p=.04, stage 1&2 vs. stage 4&5- p=.002, stage 3 vs. 4&5- p=.023) significantly 
decline across CKD stages. Similar relationships were observed for hip extensor torque (Figure.3B, 
F=10.1, stage 1&2 vs. stage 3- p=.01, stage 1&2 vs. stage 4&5- p=.01, stage 3 vs. 4&5- p=.07), and 
hip extensor power (Figure.3D, F=19.36, stage 1&2 vs. stage 3- p=.009, stage 1&2 vs. stage 4&5- 
p=.003, stage 3 vs. 4&5- p=.014). Moreover, as shown in Figure 2, eGFR was strongly and 
significantly positively correlated with knee extensor torque (r=.79, p<.001) and power (r=.84, 
p<.001) production. Not surprisingly, knee extensor torque and power production significantly 
positively correlated with stair power production in the functional PPT assessment (r=.78, r=.87, 
p<.001 respectively) (Figure.2). Importantly, these muscle performance changes were not 
attributable to altered neuromuscular properties, as no differences were found between staged groups 
in regards to seconds-to-peak torque (a measure of muscle activation capacity) (knee extensors p=.4, 
hip extensors p=.18, not shown). 
Laboratory Measures (blood chemistries)- 
As demonstrated in Figure.2, eGFR was significantly strongly negatively correlated with BUN levels 
(r=-.77, p<.001). Similarly, eGFR was moderately negatively correlated with plasma inflammatory 




systemic IL-6 concentration is slightly elevated in stage 3, but exhibits a robust and significant 
increase in later stages of disease (stages 4&5, F=6.8, stage 1&2 vs. stage 3- p=.5, stage 1&2 vs. 
stage 4&5- p=.034, stage 3 vs. stage 4&5- p=.08). The same relationship is demonstrated in TNF-a 
concentration, though a more noticeable increased in stage 3 is seen with this pro-inflammatory 
cytokine (F=3.9, stage 1&2 vs. stage 3- p=.6, stage 1&2 vs. stage 4&5- p=.03, stage 3 vs. stage 4&5- 
p=.1). In examining the interrelationships between these cytokines with BUN levels and functional 
and muscle performance, Figure 2 shows that both IL-6 and TNF-a cytokine concentrations are 
significantly strongly positively correlated with BUN (r=.71, r-.56 for IL-6 and TNF-a respectively), 
however, while both cytokines were negatively correlated with knee extensor torque and power 
production, only IL-6 cytokine concentrations was significant (r=-.4, r=-.46 with knee extensor 
torque and power respectively). However, both IL-6 (r=-.54) and TNFa (r=-.37) were negatively 
correlated with functional stair power production (Figure.2). 
Satellite Cell and Inflammatory cell abundance- 
SC count (% of mononuclear cell population) significantly declines from early to middle and late 
CKD stages, as demonstrated in Figure 5A. (F=9.6, stage 1&2 vs. stage 3- p=.015, stage 1&2 vs. 
stage 4&5- p=.001, stage 3 vs. stage 4&5- p=.47). Additionally, renal filtration rate (eGFR) was 
significantly positively correlated with SC pool size (r=.707, p<.001, Fig.5B). Conversely, filtration 
rate was significantly negatively correlated with CD45+ muscle-resident inflammatory cell 
population (leukocytes) (r=-.695, p<.001, Figure.5D). Interestingly, SC pool size/count was 
significantly positively correlated with functional stair power production (r=.57, p=.004), knee 




 Figure 2 further shows that SC count within skeletal muscle was also negatively correlated 
with the uremic environment (BUN – r=-.45, p<.001), and moderately negatively correlated with 
inflammatory cytokine concentration IL-6 (r=-.39) and TNF-a (r=-.33, not-significant). However, 
CD45 population size did not reach significance in its relationships to any of the other measures, 
aside from eGFR. 
Satellite Cell Proliferative Capacity – 
Subsequent to the above findings that SC content is reduced with stage-wise progression of CKD, 
EdU click-it reaction analysis was performed on selected primary SCs from individuals of each stage 
as shown in Figure 6A, to determine if cell proliferation may be a potential mechanism driving SC 
loss in this population. As demonstrated in Figure.6B, SC proliferation, demarcated as % of EdU+ 
cells after 12 hour incubation period, significantly declines as early as stage 3 CKD, and remains 
attenuated in later stages. Representative EdU images are shown in Figure.6C (F=27.1, stage 1&2 
vs. stage 3 – p=.01, stage 1&2 vs. stage 4&5- p=.001, stage 3 vs. 4&5- p=.058). In light of these 
findings, it was not surprising that SC proliferative capacity was significantly positively correlated 
with eGFR (r=.83, p<.001), SC count (r=.71, p=.01), negatively correlated with uremia (BUN – r=-
.85, p<.001), IL-6 concentration (r=-.57, p=.03), TNF-a (-.51, p=.048), and was also strongly 
associated with knee extensor torque and power production (r=.93, r=.87, p<.001) (Fig.2). 
Muscle Quality – 
With the above findings of reduced SC pool size, and impaired proliferative capacity in-vitro, we 
sought to characterize the morphological quality of skeletal muscle in this population as shown in 




however, stage 3 CKD muscle was characterized by increased presence of fibrotic and adipose tissue 
infiltration (black arrows), which was exacerbated in later stages of disease (Figure.7B). As shown 
in Figure.7A, when plotted relative to renal function, non-contractile tissue infiltration of skeletal 
muscle of the quadriceps increases with worsening kidney function (lower eGFR), and this 
relationship was strongly negative and significant (r=-.75, p<.001). Not surprisingly, the degree of 
non-contractile tissue infiltration in the quadriceps was strongly and significantly negatively 
correlated with knee extensor torque production and power (r=-.72, r=-.75, p=.005, p=.003 
respectively) (Figure.2). Similarly, non-contractile tissue infiltration significantly negatively 
correlated with functional stair power (r=-.51, p=.044). While the degree of non-contractile tissue 
infiltration was significantly positively correlated with CKD-associated systemic factors (BUN: 
r=.79, IL-6: r=.57, TNF-a: r=.67, p=.001, p=.042, p=.012 respectively), one of its strongest 
relationships was to SC proliferative capacity (r=-.81, p<.001), but not SC number (r=-.2, p>.05). 
Satellite Cell Myogenic Capacity- 
Due to the striking degree of non-contractile infiltration in the vastus lateralis with progressive CKD, 
and its strong relationship to SC proliferative function, we sought to examine the myogenic capacity 
of these SCs in-vitro by inducing differentiation into myotubes and tracking both the myogenic gene 
program (MRF expression patterns), and fusion capacity with immunostaining and microscopy 
(Figure.8A). As demonstrated in Figure.8B, SCs from those in early-stage CKD demonstrated strong 
myogenic capacity, with myosin-expressing myotube formation and ~38% cell fusion after only 1 
day of differentiation, while those in stage 3 and 4&5 CKD exhibit little to no myotube formation in 
this time period (stage 1 vs. stage 3, p=.006, stage 1 vs. 4&5 – p<.001). This is also visualized in 




completely absent in middle and fully absent in late-stage disease (not shown). This relationship 
continues over the course of differentiation, where robust myotube formation, with a surprising 
~95% fusion, was achieved in early-stage SCs by day 2 of differentiation (Figure.8B,C), while 
myotube formation was significantly less robust with reduced fusion in middle and late stage CKD 
(stage 1 vs. stage 3, p=.041, stage 1 vs. 4&5 – p=.005) (Figure.8B,C). At day 3, where the myogenic 
program slows down considerably, and all stages begin to plateau, early-stage CKD SCs maintain 
their thick, fusion-laden myotube morphology, while middle-stage CKD is not significantly different 
in their degree of fusion at this time, and late-stage SCs demonstrate slightly improved myotube 
formation from day 2 albeit with significantly less fusion and myotubes that are not as robust as 
early-stage cells (stage 1 vs. stage 3, p=.18, stage 1 vs. 4&5 – p=.02). Although not depicted in part 
C, at day 5, early-stage SCs maintain their morphology achieved at day 2, and this is significantly 
larger than middle-stage SCs (p=.043), and later-stage (p=.015). Interestingly, at no point during the 
5-day differentiation experiment did the degree of fusion between middle stage CKD (stage 3) and 
later-stage (stage 4&5) differ significantly in their fusion capacity (all days – p>.05). The degree of 
SC fusion at day 5, was subsequently correlated with the aforementioned measures, and shown in 
Fig.2. Not surprisingly, the degree of SC fusion was the strongest relationship of all measures to the 
degree of non-contractile tissue infiltration in muscle (r=-.9, p<.001). The fusion index also strongly 
correlated with SC proliferative capacity (r=.83, p<.001), and is negatively related to the systemic 
milleui of CKD (BUN: r=-.73, IL-6: r=-.40, TNF-a: r=-.35, p=.003, p=.15, p=.22 respectively). 
Interestingly, SC fusion index significantly related to knee extensor torque and power production 
(r=.81, r=.86, p<.001 respectively), though this may be an indirect relationship mediated through 
non-contractile tissue accrual secondary to poor SC-mediated myogenesis. 




Given the SC myogenic deficits, we sought to determine the expression pattern of key MRFs over 
the 5-day SC differentiation period. As shown in Figure 9A, MyoD expression was attenuated in 
stage 3 CKD across all studied days (day 1: -31%, day 3: -46%, day5: -57%), and was even more 
attenuated in late-stage SCs (day 1: -53%, day 3: -64%, day5: -63%), though only MyoD expression 
on day 1 of differentiation significantly differed between middle and late-stage cells. Myogenin 
expression was similarly attenuated across all days studied, in both middle (day 1: -52%, day 3: -
38%, day5: -62%) and late-stage SCs (day 1: -62%, day 3: -36%, day5: -47%), with no differences 
observed between middle and late-stage cells (Figure 9B). Myosin heavy chain gene expression was 
attenuated in middle-stage CKD only after day 1 of differentiation (day 1: -90%), with no difference 
observed in days 3 or 5 compared to early-stage SCs (Figure 8C). However, myosin heavy chain 
expression was attenuated at all days in stage 4&5 cells compared to stage 1&2 cells (day 1: -80%, 
day3: -70%, day5: -68%) (Figure 9C).  
Skeletal Muscle Transcriptome- 
The RNA-seq analysis resulted in approximately 19–28 million raw sequence reads for each of the 
25 cDNA libraries generated from the human skeletal muscle samples. On average, 99% of the 
trimmed reads mapped to the human reference genome. The muscle samples contained 44,000–
66,000 transcripts, with ~5,000-8,000 genes detected. The ribosomal fraction was <5% across all 
samples. To determine the similarity between expression profiles, we used Pearson correlation plots. 
The correlation values indicate closely similar expression values for transcripts between biological 
samples. Differentially expressed genes in the stage 1&2 CKD group, stage 3 CKD group, and stage 
4&5 CKD were filtered based on the highest fold change and significant p-values and the genes were 




between stages of disease. As shown in Figure 10 (center graphic), there were 448 differentially 
expressed genes between early and late-stage CKD, 440 differentially expressed genes between early 
and middle-stage CKD, and 1775 differentially expressed genes between middle and late-stage 
CKD, all with p-value <.05.  
GO and KEGG gene pathways that differed between CKD stage groups are shown in Figure 
10. As demonstrated in Figure.10, A, extracellular matrix organization and structure, MAPK 
signaling, molecular transducer activity, growth factor activity, g-protine coupled receptor activity 
and ribosome constituted the most significant down-regulated gene pathways (GO and KEGG terms) 
(all FDR <.05) in late-stage CKD (stages 4&5) compared to early disease. Conversely, gene 
networks involved in miRNA bidning, phagasome, chromatin binding, mRNA transport, histone 
modification, mRNA processing, cytokine/cytokine-receptor interaction, DNA repair, and 
complement cascade were all the most significantly upregulated in late-stage disease. Shown in 
Figure.10, A, are selected genes from the above GO and KEGG terms that were significantly altered 
in expression. In (Figure.10, B), the significant down-regulated gene networks/pathways in stage 3 
CKD compared to early disease, include signaling receptor activity, molecular transducer activity, 
cell morphogenesis/differentiation, MAPK signaling, protein kinase activity, focal adhesion 
pathway, and hippo pathway signaling. Conversely, upregulated gene families were observed for the 
spliceosome, proteasome, transcription factor binding, and chromatin DNA binding networks. As in 
Figure 10, Tables 2 and 3 describe general functions of selected significantly differentially expressed 
genes from the selected GO and KEGG pathways. Figure 11 depicts a subunit visualization of the 





CKD represents a health state characterized by systemic hormonal, protein, metabolic bi-product and 
genetic alterations and imbalances, with resulting demonstrable muscle morphological 
characteristics. However, this study, for the first time, demonstrates the negative effect of CKD 
progression on skeletal muscle reparative and maintenance capacity – through loss of SCs, 
attenuated SC myogenic gene expression and myogenic capacity. Moreover, theses findings were 
strongly related to the progressive deterioration in muscle quality with CKD progression, that may 
serve as the connection between cellular dysfunction and altered muscle contractile performance and 
physical mobility deficits that are apparent even early in CKD. Our cohort of participants did not 
differ in any potential confounding variables (ie. age, gender, peripheral neuropathy, BMI, duration 
of diabetes, glycemic control, insulin sensitivity, or lean mass), lending strong support to the 
analyzed connections between renal dysfunction and skeletal muscle health, cellular regulation, and 
performance.  
Our findings that CKD progression – from early, to middle, to late-stages demonstrated 
impairments in physical function (PPT scores, ability to rise from a chair, power production to 
traverse stairs) that becomes significant upon stage 3 disease, is reflected in numerous other studies 
(7, 67, 68, 69). Moreover, as proximal lower extremity muscle performance (notably the quadriceps) 
is most strongly associated with functional limitation and mobility disability among those with CKD, 
our findings that quadriceps and hip extensor torque production and power were significantly 
reduced with disease progression, in parallel with reductions in function, is not surprising. A 
potential link between CKD progression and muscle performance impairments, may be the systemic 
milleui imparted by renal dysfunction. Urea, a major nitrogenous end product of protein and amino 
acid catabolism and filtered by the renal glomeruli, predictably increases in circulation and 




relationships between BUN levels and knee extensor power and strength, and functional stair power 
production suggest a possible negative influence of urea on muscle function. Indeed, elevated urea 
concentrations are known to disrupt proteins, and specifically alter the tertiary structure of skeletal 
muscle myosin. Moreover, urea targets the globular catalytic domain of myosin through ATPase 
interference at the myosin head, thereby interfering with ATP binding and cross-bridge cycling for 
contraction (70). The kidneys also play a major role in the clearance of pro-inflammatory cytokines, 
and thus, our findings of elevated circulating levels of IL-6 and TNF-a in later-stage non-dialyzed 
CKD patients is reflected in numerous other studies as well (71,72). These cytokines have a wide 
range of negative effects on skeletal muscle, as chronic low-level IL-6 exposure and TNF-a can 
upregulate skeletal muscle atrophy pathways. Specifically, these cytokines can phosphorylate 
ribosomal p70 S6 kinase to promote atrophy, activate caspase-3 to target myofibrillar proteins for 
breakdown, transcriptionally activate the ubiquitin proteasome system, upregulate atrogenes atrogin-
1 and MuRF1, and inhibit protein synthesis via phospho-inactivation of IRS-1 and 2 receptors (73). 
However, the negative effects of such cytokine exposure extend beyond atrophy-induction. 
Myofibers treated with TNF-a demonstrate failure to maintain contractile force, and both TNF-a and 
IL-6 have been associated with hand grip strength loss, and lower knee extensor strength 
(73,74,75,76). Thus, the systemic milleui of CKD – elevated urea, and pro-inflammatory cytokines, 
may combine to partially explain the skeletal muscle performance decrements with CKD progression 
that in-turn, impairs functional mobility. However, IL-6 cytokine concentration significantly 
correlated with muscle performance only to a moderate extent, while TNF-a did not, and BUN levels 
were only slightly stronger in their relationship. Moreover, lean mass assessment with DXA did not 
differ between stages. While not ruling out an active atrophy process, this suggests that the elevated 




significant. This suggests that the systemic factors of CKD do not fully explain the poor muscle 
performance and health with CKD progression. Thus, to further probe into the mechanistic causes of 
muscle dysfunction and poor health in CKD, we examined reparative SC function.  
 SCs are the engine of muscle regeneration and in healthy conditions, satellite cells possess a 
tremendous capacity to regenerate muscles with their ability to proliferate extensively, differentiate 
and self-renew (77). In muscle injury, induced experimentally or with exercise, sarcolemmal damage 
triggers SC activation by disturbing the niche of SC (78). Moreover, muscle injury not only activates 
SC locally, but also alerts SCs in distant, uninjured muscles via yet unknown circulating factors, 
transitioning them into a Galert phase (79). However, prolongued or chronic Galert leads to SC pool 
depletion and regenerative failure (79). CKD represents a state of repeated muscle damage, as 
evidenced by the pervasive findings of z-disc streaming, increased serum CK levels, and centrally 
nucleated myofibers in muscle biopsy analyses (11). Thus, our findings of reduced SC abundance in 
skeletal muscle with progressive CKD, may be due to SC exhaustion secondary to chronic 
activation. Such a phenomenon would be similar in mechanism to neuromuscular diseases such as 
DMD, metabolic myopathies like Pompe disease, and even natural aging, In these health conditions, 
SC depletion is due to continuous regeneration attempts, and subsequent exhaustion of the SCs (80). 
In such cases of exhaustion, as demonstrated in DMD (mdx mouse model), a subpopulation of SCs 
no longer proliferate to replenish the SC pool (80). In aging studies, reduced SC pool size has been 
attributed to reduced SC proliferative capacity and a switch to senescence, a finding suggested in our 
results as well (81,82). Indeed, aging studies have demonstrated a reduction in the SC pool size from 
4-5% in adulthood to ~1% in those 60-80 years old (83). We demonstrate a strikingly reduced SC 
pool (.866%) in those with advanced CKD, to levels that reflect an extremely aged condition, and 




precise mechanisms driving proliferative senescence remain poorly understood, a study by Collins 
and colleagues (2007) shows that when aged muscle stem cells were engrafted into young mice, their 
capacity to proliferate and re-populate the SC pool were partly restored – a finding that the authors 
suggested, points to circulating agents of the systemic environment as significant players that 
partially regulate SC abundance (84). In the only study to-date to examine SCs functionality in 
CKD, the authors, using a murine nephrectomy model that recapitulates ESRD, demonstrate a 44% 
decline in SC proliferative capacity as measured by SC BrDU incorporation, while we report a 
reasonably similar 27% decline in stage 4&5 SCs (33). Thus, the systemic milleui of CKD (elevated 
BUN and inflammatory cytokines) may in fact exert their negative effects on muscle performance 
indirectly through negative influence on the SC pool size and proliferative capacity, a hypothesis 
that is suggested in Figure 2. Indeed, while unconfirmed in our study, findings of disrupted cell 
division kinetics in endothelial cells in CKD lends theoretical support for this explanation (85). As 
other studies have demonstrated- there seems to be a negative impact of the uremic milleui on 
mesenchymal stem cell (MSC) proliferation, abundance, and overall competence. Work by Noh and 
colleagues (2011) clearly demonstrate reduction in mesenchymal stem cell proliferation by 50% in 
the presence of uremia-associated systemic bi-products p-crestol, and indoxyl sulfate (34). While we 
find a smaller, ~27% reduction in proliferative capacity in late-stage CKD SCs, our experiments 
were conducted on primary cells in ideal culture conditions. However, under experimental 
conditions similar to our own, the authors also found reduced MSC proliferation and differentiation 
under ideal in-vitro conditions in those cells obtained from CKD patients as well (34). Interestingly, 
the authors posit that this phenomenon is similar to cellular metabolic or hyperglycemic memory 
observed in diabetes, in that the uremic environment imparts a metabolic and epigenetic imprint on 




function (34). This point leads to one more potential explanation for the loss of SCs observed in this 
study, with CKD progression. A popular theory applied to the loss of SC with aging, is that SC 
intrinsic properties, determined via epigenetic mechanisms – ie. DNA methylation, play a large role. 
 DNA methylation can influence the accessibility of methylated enhancer regions to 
transcription factors, can alter histone deacetylases and methyltransfersases to promote tight DNA 
packing and prevent RNA polymerase or transcription factor binding and subsequently, repress gene 
expression. A recent study has shown that aged SCs present with different methylation patterns that 
are modified by the systemic environment and its constituent hormones, metabolites, and proteins, 
and that these methylation marks related to poor SC proliferation and abundance with age (86). 
Others have similarly found that SC hypermethylation in older age interferes with their capacity for 
self-renewal, leading to SC pool exhaustion (86,87). While we did not assess epigenetic alteration to 
SCs in CKD, this represents a promising area of future study. However, we have previously 
demonstrated evidence of increased mitochondrial ROS production and inefficient respiratory 
coupling in ATP production with progression of CKD. A consensus theory behind SC epigenetic 
alterations in other conditions involves continual ROS exposure through mitochondrial deficiencies 
in skeletal muscle that leads to SC DNA damage and recruitment of epigenetic machinery to repress 
gene transcription – a plausible and exciting area of future study (88, 89, 90, 91). Indeed, our 
transcriptomic analysis revealed epigenetic gene networks (histone modification, miRNA binding, 
chromatin binding) to be among the most significantly upregulated in middle and late-stage CKD 
compared to early CKD (Figure.10). However, aside from SC proliferation deficiency and loss of 
SCs, even in early CKD (stage 3), SC myogenic deficits were striking. The end-results of poor SC 




 As demonstrated in Figure 7, renal function and muscle quality deteriorate in-parallel . Of 
particular note, selected muscle of those with advanced CKD (eGFR <25 mL/min) demonstrated 
>25% non-contractile composition. The evident fibrotic and adipose tissue accrual, seen even in 
stage 3 CKD, strongly implicates deficient SC reparative function.  
Indeed, with loss of SCs, as shown in this study, there is noticeable increase in fibroblast 
density and ECM deposition in muscle, as muscle injury is repaired poorly and injured contractile 
tissue is replaced with non-contractile accumulation. Moreover, these fibroblasts retain a multipotent 
capacity and can differentiate into adipocytes, thus promoting intramuscular adipose tissue 
infiltration in addition to unchecked fibrosis, a possibility given our observations of adipose tissue 
infiltration as early as stage 3 CKD (Figure 8B, dark arrows) (19). However, it is difficult to discern 
the directionality of this relationship in our findings, as excessive ECM with regeneration can 
impede muscle function and hinder muscle regeneration, and prevent SC self-renewal to exhaust the 
SC pool as well (22). In any case, poor myofiber repair and subsequent poor muscle quality  
decreases specific tension generating capacity in skeletal muscle. This is supported in our findings 
that reduced SC proliferative and myogenic capacity is strongly related to non-contractile tissue 
deposition, which is in-turn strongly negatively related to muscle performance and mobility. 
Interestingly, SCs from middle and late-stage disease did not exhibit significant differences 
in their myogenic capacity or in their upregulation of the necessary MRFs, yet both were deficient 
when compared to early CKD (stages 1 &2). 
 With damage, SCs exit from quiescence and engage in a highly orchestrated and self-
regulating myogenic program. We report delayed and deficient myotube formation and SC fusion in-




expression patterns, beginning with MyoD and Myf5 to drive SC activation. In fact, deficient MyoD 
activation causes SC withdrawal from the cell cycle and attenuates progression to differentiation and 
repair, effectively delaying myogenic differentiation (92). We demonstrate, after 5 days of 
differentiation, a 58% reduction in MyoD expression in stage 3 disease, and 64% reduction in stages 
4&5. These findings are strikingly similar to the findings of Zhang et al (2010), that exhibit a ~55% 
reduction in MyoD expression in SCs from CKD mice after 5 days of differentiation (33). Moreover, 
we find attenuated MyoD expression 1 day and 3 days after differentiation induction as well (Figure 
9). This may be a potential genetic cause explaining the delayed and deficient myogenesis we 
observe in middle and late-disease SCs (Figure 8).  
Differentiating SCs fuse to each other or existing myofibers to restore structure and function 
to muscle (93,16,18). Thus fusion of myoblasts are crucial in muscle repair and maintenance, and 
altered fusion causes delayed, deficient, and inadequate regeneration (94). This fusion process is 
dependent upon genetic expression of Myogenin and Mrf4 – two immediate downstream targets of 
MyoD (18). Subsequently, a large portion of Myogenin and Mef2 target genes encode muscle-
specific structural, transmembrane, and contractile genes such as those encoding actins, myosins, 
and troponins, in addition to adhesion molecules, and binding factors that facilitate cell-cell 
communication and fusion (18 ,95). Similar to our MyoD expression results, SCs from middle and 
late-stage CKD exhibit attenuated myogenin expression across all studied days (1, 3, and 5 days 
post-differentiation). This strongly suggests that CKD progression may negatively influence the 
myogenic program to alter key MRF expression patterns, and hamper proper SC regenerative 
function. Of note however, were our findings that although deficient compared to early disease 
(stages 1&2 CKD), middle and late-stage SCs are still capable of producing myotubes in-vitro, with 




myogenic expression, contractile protein may not be properly transcribed, deficient, and muscle 
morphology may be altered as well.  
Interestingly, the fact that these cells demonstrate altered MRF expression and 
proliferation/fusion kinetics in-vitro, strongly suggests that the CKD environment may impose 
epigenetic alterations that are in-turn remembered by these cells and demonstrated in culture 
conditions (96). Indeed, the work by Zhang and colleagues (2010) also demonstrates in-vitro 
impairment in SC myotube formation and fusion with 30% reduction in Myogenin expression at 5-
days post-differentiation in a murine CKD model (33). While we found myogenin to be attenuated to 
a greater extent (~50% in middle and late stage CKD), both findings suggest that the systemic 
environment of CKD negatively influences genetic expression of SCs, and this is committed to 
cellular memory even outside this environment. While it is unclear what particular mechanisms or 
CKD-associated factors result in impaired MRF activation in these SCs, our findings of poor muscle 
quality with evidence of excess fibrosis and adipose tissue accumulation in progressively declining 
kidney function (Figure 8), suggests that SC dysfunction may stem from other muscle-resident 
sources.  
We demonstrate a progressive increase in muscle-resident leukocytes with worsening kidney 
function in CKD (Figure 5C). The injury-SC-repair process activates the complement cascade and 
inflammatory response that immediately recruits leukocytes to the muscle tissue (18). This is 
subsequently followed by signaling cascades that produce down-stream pro-inflammatory 
macrophages and cytokines and signal the production of extracellular matrix constituents like 
collagen and fibronectin from other cell types like fibroblasts (18). However, even slight imbalances 
in immune cell populations in muscle can disrupt cellular dynamics of the SC niche, as sustained 




proliferative function (97). While we demonstrate a kidney function-associated rise in the leukocyte 
population, and increased circulating inflammatory cytokines (IL-6 and TNF-a in late-stage CKD) 
others have demonstrated prolongued macrophage infiltration in CKD muscle after injury that 
persists beyond 2 weeks, with accompanying increase in IL-6 (2.5x) and TNF-a (5x) gene expression 
and increase muscle fibrosis (33). The authors conclude that CKD facilitates a “more intense” 
macrophage infiltration in muscle. Our data suggests that this may indeed be the case, and may be 
due to increased muscle resident leukocyte population (CD45+), even in non-injured CKD muscle.  
Thus, a potential explanation for the progressively poor muscle quality, even in middle-stage 
CKD, may be a cyclical process whereby the CKD environment and accompanying inflammation 
may impair SC proliferative function and myogenic capacity at a genetic level, to hinder adequate 
muscle repair. At this time other muscle-resident cell populations (ie. fibroblasts) contribute 
excessively and are disinhibited by the associated SC dysfunction. This creates a progressive 
thickening of the muscle ECM, and potentially promotes transdifferentiation of other cells (ie. fibro-
adipogenic progenitors -- FAPs) leading adipose tissue accrual, and muscle replacement with non-
contractile tissue. The resultant biophysical properties of the SC niche further negatively influence 
the remaining SCs to inhibit their function. While this is speculative, transcriptomic analysis via 
RNA-sequencing suggests this may indeed be the case. 
RNA-seq results demonstrate significant gene pathway alterations in CKD progression, 
beginning in stage 3 disease that lends further support to the morphological and functional 
differences demonstrated in this study. In both Stage 3 CKD, and later stages (4&5) of disease, gene 
pathways governing cell morphogenesis, focal adhesion and molecular transducer and cell signaling 
networks are negatively affected compared to early-stage CKD, and many genes within these 




 In stage-3 CKD, genes of particular interest included CDC42, CRKL, DOCK1, PTEN, Myf5, 
SKIL, EFNA5, WNT5A, FZD4, and TCF7 as all of these genes were significantly downregulated 
(Table 3), and all carry direct action on SC function. These genes govern a host of pro-SC-function 
duties ranging from -- actin-fiber recruitment to facilitate SC fusion and myogenesis; encoding SC 
adaptor proteins that facilitate growth-factor signaling networks (ie. MAPK) to fuel SC proliferation; 
encoding signaling proteins that activate key transcriptional networks (ie. Akt-mTOR pathway) to 
ensure adequate SC proliferation and self-renewal; direct MRFs (ie. Myf5) that guide SCs to 
myoblast lineage; transcription factors that alter epigenetic marks to promote myogenesis; interstitial 
second-messenger proteins that stimulate SC motility and regulate interstitial cell concentration; and 
SC Wnt signaling (Figure.10, Table 3) (98, 99, 100, 101, 79, 102, 103, 104, 105, 106, 107). 
Interestingly, cell signaling networks in later-stage disease were more strongly connected to 
inflammatory reactions, although within the molecular transducer gene network, we also found 
significant attenuation in expression of genes that govern SC function as well – with reductions in 
IGF-1 expression, but upregulation in RPTOR gene expression, a canonical mTOR signaling protein 
known to stimulate SC cycle shifts to Galert; upregulation in CDKN1A a pro-atrophy cyclin-
dependent kinase inhibitor that mediates p53 inhibition of SC proliferation while simultaneously 
stimulating protein degradation and inhibiting protein synthesis; and downregulation of BCL2, an 
anti-apoptotic gene that promotes autophagy and clearance of deficient or defective contractile 
proteins and organelles (Figure.10, Table 2) (108, 33, 109, 110). In this regard, early and late-stage 
CKD seem to have differential gene-driven negative effects on SC-mediate myogenesis and general 
muscle maintenance. This is perhaps best supported by the different gene pathways outside cell 




 Stage 3 CKD skeletal muscle demonstrated notable attenuation in gene expression of 
numerous muscle-integrity-related genes. For instance, the downregulation of the gene encoding 
cortactin (Table 3) may promote muscle fragility through inadequate transcription/translation of its 
actin binding filament that is important for muscle cytoskeletal structure (111). Similarly, the stage 3 
reduction in CAV3 expression (Table 3) suggests that there may be a significant loss of caveolin3 
protein, a key muscle membrane constituent that maintains sarcolemmal integrity in response to 
mechanical strain and aids in membrane repair, while also playing an important role in myoblast 
fusion (112, 113). Lastly, the finding of attenuated expression of fibronectin 1, a protein that 
contributes to myogenesis and SC differentiation, has also been shown, that when down-regulated, 
promotes myofiber disorganization (114, 115). Thus, in middle-stage CKD, there may be a shift in 
the transcriptome that promotes a loss of skeletal muscle architectural integrity, with simultaneous 
impairment in SC-response and SC signaling networks. However, we observe ECM-integrity genes 
to be upregulated in late-stage CKD, perhaps as an adaptive compensatory mechanism to bolster a 
more fragile architecture with disease progression. Specifically, we find upregulation of COL19A1, 
a collagen fibril-associated cross-bridge protein that serves as a scaffold for ECM deposition, along 
with increased expression of COL27A1 and TNC (116). Interestingly, TNC encodes an ECM protein 
expressed only in actively remodeling muscle tissue as a result of microdamage (117). TNC exerts a 
strong proliferative effect on interstitial cells, and has even been shown to make SCs de-adhesive to 
their niche, so as to engage in the myogenic program (117). However, we did observe reduced 
MYOC gene expression, a gene encoding the myocillin protein link between the dystrophin-
associated protein complex (DAPC) and intracellular signaling machinery. Myocillin not only acts 
as the bridge to translate extracellular mechanical signals into metabolic change (ie. Akt activation), 




that may partially explain the increase in fibrosis observed with CKD progression that warrants 
further study. Thus, there appears to be a significant alteration in key muscle integrity and ECM-
related genes in both middle and late-stage CKD that may help explain both the observed poor 
muscle quality (Figure.10, Tables 2 and 3) with worsening kidney function, but also the poor SC 
functional capacity. However, while middle and late-stage CKD skeletal muscle seem to both share 
alterations in these gene pathways, muscle in later stage CKD (stages 4&5), exhibits a unique 
upregulation in the cytokine/cytokine-receptor signaling gene networks indicative of active 
inflammatory processes that may present its own set of negative consequences on muscle health. 
 Consistent with our findings of significantly elevated circulating inflammatory cytokines (IL-
6 and TNF-a) in late-stage CKD, we found significant upregulation of genes involved in 
inflammatory cytokine signaling in skeletal muscle in late-stage CKD. Specifically, activators of 
NF-KB, the primary inflammatory-responsive muscle regulatory network were increased in their 
expression – IL1R, EDA2R, TNF-a receptor TNFRSF10D, CX3CL1 all act as pro-inflammatory 
receptors that activate canonical NF-KB signaling in skeletal muscle (Figure.10, Table 2) (119, 120, 
121, 122, 123). Moreover, we also observe increased expression of LBP, a lipopolysaccharide 
binding protein that acts a key mediator of IL-6 and IL-1 signaling (124). However, as mentioned 
previously, inflammatory signaling in skeletal muscle is carried out through a coordinated network 
of different cell types and paracrine and autocrine signaling. Keeping this in mind, our results 
suggest that many aspects of this signaling cascade are upregulated in late-stage CKD as genes 
governing the inflammatory response and leukocyte recruitment were also significantly increased in 
expression.  
Of interest was the upregulation of CX3CR1, a chemokine gene involved in leukocyte 




expression, and also serves as cell-surface protein found on inflammatory macrophages that invade 
injured muscle after phagocytosis of injured debris (Table 2) (125). Similarly, we observe increased 
expression of ADAMTS12, a matrix metalloproteinase induced by inflammatory cytokines (ie. TNF-
a and IL-1B) in the ECM to mediate inflammatory response and guide collagen-producing-cell fate 
(126). We also report elevated expression of other inflammatory genes known to be responsive to 
cell stress (PRKAB1), induction of the sarcoplasmic and cytoplasmic inflammasome (NLRC4), and 
chemokine signaling (Figure.10, Table 2) (127, 128, 129). Of particular interest however, was the 
novel finding of drastic upregulation of the major histocompatibility complex 2 (MHC II complex) 
in those with stage 4&5 CKD. MHC class 2 expression in muscle is induced when the muscle 
becomes immunologically activated, often in response to inflammatory cell types. We specifically 
find very large increases in expression of MHC class 2 component genes – HLA-DRB1 (+2.83x), 
HLA-DRB5 (+5x), HLA-DRA (+2.4x), HLA-DPB1 (+3.8x), and HLA-B (+8x) (Figure 10, Table 2). 
While a rare finding, this has been uniquely demonstrated previously as a feature of inflammatory 
myositis, and has been postulated to potentially precede leukocyte muscle infiltration (130). Yet, 
despite the striking transcriptomic evidence of active inflammatory signaling in late-stage CKD 
muscle, CCR1 gene expression was attenuated by more than 2-fold. CCR1 is a myoblast receptor, 
that upon interaction with inflammation-stimulated MIp1a secretion by macrophages, engages in 
proliferation and asymmetric division (131) (Figure.10). Thus, this receptor is a critical component 
to SC activation in response to injury-induced inflammatory signaling, and its reduction in CKD 
skeletal muscle may impede proper SC kinetics in the face of inflammatory stimulation. While 
inflammatory transcriptome changes were much more evident in late-stage CKD, we find altered 
expression of genes involved in inflammatory cytokine signaling in middle-stage as well. 




inhibits TNF-a production and NF-KB signaling, suggesting a potential avenue of disinhibition of 
inflammatory signaling (132) (Figure.10, Table 3). Similar to late-stage CKD, we also observe 
upregulation of CXCL12, a chemoattractant that attracts monocytes and lymphocytes with muscle 
damage (133). Thus, the transcriptome in stage 3 CKD supports the theory of muscle damage, 
altered structural integrity, and inflammatory signaling is also present, though to a lesser extent, in 
middle stage CKD. Intruigingly however, one of the most significantly upregulated gene networks in 
stage 3 CKD involved key structural protein subunits of the 26S proteasome – the degradative 
complex of the ubiquitin proteasome pathway (Figure.11). This suggests that even in middle-stage 
CKD, the degradative process may be stimulated above that in early-stage disease.  
Conclusion 
T2DM-induced CKD progression, and its associated uremic environment, independent of 
diabetic severity or duration, negatively impacts physical function, potentially via impairment of 
muscle force generation, and power. We demonstrate, for the first time, that these muscle 
performance decrements strongly relate to intrinsic changes in skeletal muscle maintenance and 
health that is dictated by changes in the muscle transcriptome, SC and inflammatory abundance, SC 
functional capacity (proliferative and myogenic capacity), and myogenic gene program with CKD 
progression. Of particular importance – our findings suggests CKD-associated changes across all 
levels of skeletal muscle health and performance, begin as early as stage 3 disease. Future studies are 
needed to investigate the direct mechanisms driving such changes (ie. uremic environment-










Demographics. Participant demographics were compared using 1-way ANOVA, and chi-square was 
used for sex distribution, and peripheral neuropathy status between groups. Values listed are mean 
and standard deviation in (). The following symbols represent post-hoc pairwise comparisons in the 
event of significant F-test - *(between Stage 1&2 and Stage 3), ^(between stage 1&2 and Stage 







Stage 4&5 vs. Stage 1&2 Significant GO and KEGG terms: selected genes 
 
Cytokine/Cytokine-receptor interaction 
IL1R (+1.47x) upstream activator of NFKB through IL1 pro-inflammatory signaling 
EDA2R (+1.61x) positive activator of NF-KB signaling  
TNFRSF10D (+1.7x) TNF-family receptor, induces NFK-B pathway, part of TNF-alpha 
signaling pathway 
CX3CL1 (+1.63x) Positive regulatory of canonical NF-KB signaling (upregulates 
NFKB signaling, and induces authophagy) 
LBP (+2.1x) 
lipopolysaccharide-binding protein, binds lipopolysaccharides to 
modulate inflammatory pathways. Levels of LBP are greater in 
presence of cytokines like IL-6 and IL-1  
PRKAB1 (+1.6x) upregulated in response to cellular stress, connected to AMPK stress 
signaling  
CXC3R1 (+1.63x) 
Monocyte receptor subtype. chemokine involved in adhesion, 
signaling, and migration of leukocytes. After monocytes phagocytose 
the injured muscle, macrophages that are CXC3R1-positive take over 
to promote muscle regeneration, and positively attracts macrophages 
(acts as a chemokine receptor for tissue-resident macrophages), and 






HLA-B (+8)  
MHC complex 2 constituent proteins. Its expression is induced in 
skeletal muscle when the muscle becomes immunologically activated 
– often in response to inflammatory cell signaling. This is a feature of 
inflammatory myositis, and may precede leukocyte infiltrations into 
muscle. 
ACKR1 (+1.5x) chemokine receptor 
ECM Organization 
COL19A1 (+2.1x) encodes collagen type 19 alpha 1, a fibril-associated collagen that 




Serves as scaffold for ECM construction 
COL27A1 (+1.53x) ECM collagen member 
TNC (+1.5x) 
ECM protein expressed only in actively remodeling muscle tissue 
from micro-damage. Exerts strong proliferative effect on interstitial 
cells, and shown to make SCs de-adhesive to their niche so they can 
engage in myogenic program 
Molecular Transducer Activity 
IGF1 (-1.5x) 
Growth hormone/signaling protein involved in SC proliferation, 
differentiation, and myogenesis-mediated regeneration. Its attenuated 
signaling shown to a potential key factor in murine models of skeletal 
muscle SC dysfunction in CKD  
RPTOR (+1.4x) Links mTORC1 signaling in SCs. Responsible for Galert phase 
transition in SCs  
CDKN1A (+2x) 
Pro-atrophy, cyclin-dependent kinase inhibitor that mediates p53 
inhibition of SC proliferation while simultaneous stimulating protein 
degradation and inhibiting protein synthesis 
MYOC (-1.9x) 
Encodes the protein link between the dystrophin-associated protein 
complex (DAPC) and intracellular signaling machinery. Myocillin 
not only acts as the bridge to translate extracellular mechanical 
signals into metabolic change (ie. Akt activation), but also serves to 
stabilize the DAPC link to the ECM 
PIK3R (-1.6x) 
Receptor link between IGF-1 signaling and muscle protein synthesis. 
PIK3R is recruited to activated IRS sites to signaling activation of 
Akt, which then inhibits protein breakdown through repression of 
FoXO family degradative transcription factors, while also stimulating 
protein-synthesis mTOR pathway  
 
Table 2  
Table of significantly differentially expressed genes from Figure 10A (genes down or upregulated in 











When deficient, results in impaired actin fiber recruitment to myoblast 
contact sites, essential for SC fusion and myogenesis -- (FROM "The 
small G-proteins Rac1 and Cdc42 are essential for myoblast fusion in 
the mouse") 
CORTACTIN (-1.6x) Actin binding filament, important in the cytoskeletal structure of 
muscle 
PTPRS (-1.45x) cell surface receptor, normally down regulates NFK-B and TNFa 
production 
CX3CL12 (+1.5x) 
Acts to induce rapid chemotaxis, and positive attractor of monocytes 
and T-lymphocytes. Has been shown to be upregulated following 
exercise-induced damage 
Myf5 (-1.4x) Myogenic SC lineage director. Downregulation could be indicative of 
fewer of SCs. 
FZD4 (-1.8x)  
 
receptor for wnt5a 
CMKLR1 (-2.3x) g-protein-coupled receptor activated by leukocyte attractants and 
adipokines. When reduced in expression, it impairs SC differentiation 
Signaling Receptor Activity 
ACTB (-1.5x) Beta actin, links dystrophin complex to the cytoskeleton 
WNT5a (-1.42x) 
With early muscle damage, WNT5A should be upregulated, promotes 
slow myofiber type, modulates chromatin structure of MyoD and 
Myf5 promoters to induce their expression, and promotes SC 
proliferation and self-renewal (through upregulation of B-catenin) 
TCF7 (-1.74x) encodes crucial B-catenin co-factor, and downstream effector of Wnt 




FGF1 (-1.81x) growth factor, expressed in SCs, promotes SC differentiation 
CRKL (-1.6x) 
SC adaptor protein that facilitates Fibroblast Growth Factor signaling 
to SCs, which then activates MAPK signaling that fuels SC 
proliferation. If its down, this may inhibit SC proliferation 
FN1 (-1.92x) Fibronectin, contributes to myogenesis and differentiation, when 
downregulated leads to disorganization of myofibers 
CCND2 (-2.25x) cyclin D2, it directly interacts with cyclin-dependent kinase Cdk4 to 
block myogenic switch during fusion 
Focal Adhesion Pathway 
DOCK1 (-1.5x) plays a major role in governing SC fusion 
PTEN (-1.9x) 
present in quiescent SCs, when downregulated, leads to premature SC 
differentiation, lack of proliferation and SC pool reduction and 
regenerative failure, and once activated, these SCs cannot return to 
quiescence 
CAV3 (-1.8x) 
Major muscle membrane protein of caveolae. If downregulated, leads 
to reduced sarcolemmal integrity in response to mechanical strain. 
Also interacts with dysferlin in sarcolemmal membrane repair, and 
plays an important role in myoblast fusion 
SKIL (-2.3x) 
Ski-like protooncogene -- encodes a repressor of TGF-b signaling, and 
enhances muscle differentiation through modulation of the myogenin 
promoter via activation of the MEF2 complex and inhibition of the 
histone deacetylase activity, AND activates the enhancer and promoter 
of myosin proteins and muscle creatine kinase 
EFNA5 (-2.65x) 
Ephrin A5, target of NFK-B signaling. Ephrin A5 stimulates myoblast 
motility and proliferation (via NG2+ interstitial cells). When 
downregulated, causes significant reduction in myoblast mottility and 
increases number of interstitial cells  
 
Table 3  
Table of significantly differentially expressed genes from Figure 10B (genes down or upregulated in 





Figures for Chapter 3: 
Figure 1 
 
FIGURE 1 – Physical function capacity was assessed across CKD-stage groups with 1-way 
ANOVAs, and Bivariate pearson correlations. Bar heights represent group mean and error bars 
represent + SD. The following symbols represent significant post-hoc tests of pairwise comparisons:  
*(between Stage 1&2 and Stage 3), ^(between stage 1&2 and Stage 4&5), #(Between stage 3 and 
Stage 4&5). A. Pearson Bivariate Correlation with eGFR (glomerular filtration rate) plotted on the x-
axis, and PPT score (0-36) plotted on the y-axis (higher scores indicate better functional 
performance) (not pictured – p<.001). B. Calculated stair power (watts), higher values indicate more 
lower extremity power produced to ascend stairs (F=14.7, p<.001). C. Chair rise score (from the 
physical performance test) (F=13.9, p<.001). As shown in B, and C, there are significant step-wise 







FIGURE 2- Bivariate pearson correlation matrix depicting interrelationships between renal filtration 
rate (eGFR), serum markers (BUN, inflammatory cytokines – IL-6, TNF-a), functional performance 
(stair power), muscle performance (knee extensor torque and power), muscle quality (non-contractile 
% = % of muscle sample that is non-contractile tissue), SC count and function, and muscle-resident 
leukocyte population (CD45+). Color key is shown bottom left. Stronger correlations are reflected 
by higher r-value range, and darker shade (red = negative correlation, green = positive correlation). 
This range is also displayed at right in bar format. Correlation r-values are inset within each 
correlation pair circle, with an * denoting significant correlation (p<.05). Gray circles mark variables 
correlating with itself. (Note – knee extensor torque was assessed at 300/sec isokinetic speed, Knee 
extensor power assessed at 300/sec and expressed in watts. Hip extensor muscle performance not 







FIGURE 3-  
Lower extremity muscle strength (hip extensor, knee extensor torque), and power (hip extensor 
power and knee extensor power) were assessed across CKD-stage groups with 1-way ANOVAs. Bar 
heights indicate group means, with errors bars indicating + SD. The following symbols represent 
significant post-hoc tests of pairwise comparisons:  *(between Stage 1&2 and Stage 3), ^(between 
stage 1&2 and Stage 4&5), #(Between stage 3 and Stage 4&5).  A. Group differences in knee 
extensor torque (assessed at isokinetic speed of 300/sec, knee extensor torque measured in ft-lbs) 
(F=16.9, p<.001). B. Hip extensor torque (1200/sec, ft-lbs) (F=8.8, p=.01). C. Knee extensor power 












FIGURE 4-  
Plasma inflammatory cytokine concentration (pg/mL) was assessed across CKD-stage groups with 
1-way ANOVAs, specifically comparing TNF-α, and IL-6. Bar heights indicate group means, with 
errors bars indicating + SEM. TOP. IL-6 concentration by CKD Stage (F=6.8, p=.005), ^ denotes 
post-hoc significant difference between stage 1&2 and stage 4&5 (p<.005). BOTTOM. TNF-α 
concentration by CKD Stage (F=3.9, p=.035), as above, ^ denotes post-hoc significant difference 









FIGURE 5-  
Fluorescence Activated Cell Sorting (FACS) Results for SC and CD45+ (leukocytes) cells in all 
samples. SC count was assessed across CKD-stage groups with 1-way ANOVA. The following 
symbols denote significant post-hoc tests: *(between Stage 1&2 and Stage 3), ^(between stage 1&2 
and Stage 4&5), #(Between stage 3 and Stage 4&5). A. FACS results counting SC population, 
expressed as the % of mononuclear cells (y-axis) in the sample. Red horizontal lines indicate the 
average count for that stage, with SD bars. Small circles represent each individual’s SC count 
(F=9.6, p=.001). Inset above Stage 1&2 are the ^ and * symbols denoting significant differences 
between stage 1&2 and 4&5, and stage 1&2 and stage 3 respectively. B. Pearson bivariate 
correlation chart plotting SC count (% of mononuclear cells – y-axis) against renal filtration rate 
(eGFR – x-axis) (not shown, p<.001). C. Pearson bivariate correlation chart plotting CD45+ 
(leukocyte) population expressed once again as % of mononuclear cell population (y-axis) against 









FIGURE 6-  
SC in-vitro proliferative capacity, assessed with EdU click-it-reaction.  A. Experiment setup – SCs 
were plated at 3,125 cells per cm2 on matrigel-coated dishes, and incubated for 12 hours at 370C 
with growth media containing 1 mM EdU solution. Cells were then fixed, stained and imaged to 
track the % of EdU+ cells out of all cells in 5 random locations over 2 dishes per sample. % of EdU+ 
cells assessed across CKD-stage groups with 1-way ANOVA. The following symbols denote 
significant post-hoc tests: *(between Stage 1&2 and Stage 3), ^(between stage 1&2 and Stage 4&5), 
#(Between stage 3 and Stage 4&5). B. Bar graph depicting stage-specific group differences in % of 
EdU+ cells (EdU+/Total cells – Y-axis) (marker of proliferative capacity) (F=27, p<.001). C. 
Representative EdU images (10x). TOP – SCs in early (stage 2) CKD demonstrate high proportion 
of EdU+ cells (red). MIDDLE- SCs in middle (stage 3) CKD. BOTTOM – SCs in late-stage CKD. 








FIGURE 7-  
Muscle histology (H&E) to assess gross muscle quality on a subset of 13 participants where enough 
muscle sample was extracted.  A. Bivariate pearson correlation depicting the negative relationship 
between renal filtration rate (eGFR-axis), and % of non-contractile tissue infiltration in muscle 
[((whole area – healthy area)/whole area) = %non-contractile, y-axis] (not pictured p=.004). B. 
Representative cross-sectional images of the H&E-stained muscle samples. BOTTOM LEFT – cross-
section from early (stage 1) CKD. UPPER RIGHT – cross-section of middle (stage 3) CKD muscle. 
Arrows highlighting presence of intermuscular adipose tissue and likely connective/fibrotic tissue. 
BOTTOM RIGHT- cross-section from late (stage 5) CKD, with arrows highlighting presence of 








FIGURE 8-  
SC in-vitro myogenic capacity. A. Experiment setup – SCs were plated at 10,400 cells per cm2 on 
matrigel-coated dishes, and grown to confluence. At day 0, growth media was changed to 
differentiation media, with day 1 denoting 24 hours post-differentiation induction and so on through 
day 5. Cells were fixed and imaged at 20x magnification at days 1,2, 3 and 5 post-differentiation 
after staining for MyHC, and DAPI ([fusion index = # of cells that had fused into multinucleated 
MyHC+ myotubes / total nuclei in the field of view], averaged over all 10 images per day, per 
participant. Cells were also collected in trizol at days 1, 3, and 5, for RNA extraction and MRF gene 
expression patterns. B. Plot of SC fusion kinetics over the 5-day experimental protocol for early 
(stage 1&2 -- green), middle (stage 3 -- blue), and late (stage 4&5 -- red) CKD SCs. Each dot 
represents the average fusion % for that day for that group (with SD bars). For each time point, 1-
way ANOVAs were used to assess for differences in degree of fusion between the 3 groups. The 




stage 1&2 and Stage 4&5), #(Between stage 3 and Stage 4&5), these symbols are placed over the 
respective day, above stage 1&2 cells. C. Representative immunostained images of SCs from early 
(stage 1 CKD), middle (stage 3 CKD), and late (stage 5 CKD), at day 1 (top panel segment), day 2 
(middle panel segment), and day 3 (bottom panel segment). Images from left to right depict DAPI 
(blue – cell nuclear stain), MyHC (stained with Cy5/Alexa-Fluor 647), and the merged image 




























FIGURE 9-  
SC myogenic gene expression (RT-PCr) across the differentiation experiment (days 1, 3, and 5) for 
stage 1&2 CKD (reference – green bars), stage 3 (blue bars), and stage 5 (red bars). Groups were 
assessed for gene expression differences with 1-way ANOVAs. Bar heights indicate gene expression 
relative to reference (stage 1&2), with errors bars indicating + SD. The * symbol with accompanying 
line, denotes significant post-hoc differences between the denoted groups. A. Group differences in 
MyoD gene expression at day 1 (24-hours post-differentiation induction), day 3, and day 5. 
Significant differences were observed on day 1 (between all groups), day 3 (between stage 1&2 and 
middle and late-stage groups), and day 5 (between stage 1&2 and middle and late-stage groups) (all 
p<.05).  B. Group differences in Myogenin gene expression. Significant differences were observed 
on day 1 (between stage 1&2 and middle and late-stage groups), day 3 (between stage 1&2 and 
middle and late-stage groups), and day 5 (between stage 1&2 and middle and late-stage groups). C. 
Group differences in MyHC gene expression. Significant differences were observed on day 1 
(between stage 1&2 and middle and late-stage groups), on day 3 (between stage 1&2 and late-stage 








Selected GO terms and KEGG pathways from a larger list of top 25 down and upregulated gene 
networks across stage-wise transcript analysis. Bar charts depict top downregulated (blue bars) or 
upregulated (red bars) gene networks, with their accompanying network label listed next to its 
corresponding bar (all GO terms list have FDR <.05, and all KEGG terms have p-value <.05). 
Pathway up or downregulation is expressed in mean log-fold-change units, and was determined to be 
significant when compared to background log 2 fold change for genes not contained within the 
network/pathway. Below/bottom are selected genes from the significant GO or KEGG pathways that 
are differentially expressed, and the fold change listed in parentheses next to the gene term. A. 
Comparing late-stage CKD muscle transcriptome to early stage 1&2 (early CKD is the reference). 
Extracellular matrix organization, molecular transducer activity, MAPK signaling, growth factor 
activity, and g-protein coupled receptor activity components were significantly downregulated in 
late-stage CKD compared to early. Conversely, late-stage CKD demonstrates significant 
upregulation in cytokine/cytokine-receptor interaction, DNA repair, complement cascade, and 




significantly differentially expressed genes from some of these pathways are listed at the bottom. B. 
Comparing middle-stage CKD to early stage 1&2 (early is the reference). Genes governing signaling 
receptor activity, molecular transducer activity, cell morphogenesis, MAPK signaling, focal 
adhesion and hippo pathway were significantly downregulated in middle-stage CKD compared to 
early. However, pathways governing the degradative proteasome, transcription factor binding, and 
epigenetic chromatin binding are significantly upregulated. Below, are listed specific genes that 




























KEGG pathway image of the 26S ubiquitin proteasome responsible for contractile muscle protein 
degradation. Each labeled circle represents a protein subunit of the proteasome. The chart depicts the 
upregulation of many key proteasome structural subunit protein genes (as shown in figure 10, listed 
at right, with the fold differences between stage 3 CKD and stage 1&2, with stage 1&2 being the 
reference), the proteasome subunit they encode (listed next to the gene), and highlited in red in the 
proteasome construction (left). Note – significant upregulation in core subunit proteins responsible 











1. Center for Disease Control and Prevention (CDC). National Chronic Kidney Disease Fact Sheet: 
General Information and National Estimates on Chronic Kidney Disease in the United States, 2014. 
Atlanta, GA: US Dept. of Health and Human Services, CDC; 2014.  
2. Zapponi, G., Targher, G., Chonchol, M., Ortalda, V., et al. (2012) Predictors of estimated GFR 
decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol, 7(3); 
401-8. 
3. Otobe, Y., Hiraki, K., Hott, C. et al. (2017) The comparison of the muscle strength in pre-dialysis 
chronic kidney disease patients and the average levels in healthy individuals. Physical Therapy 
Japan, 6(44): 401-407. 
4. McManus, D., Slipak, M., Ix, J.H., Ali, S. et al. (2007) Association of cystatin c with poor 
exercise capacity and heart rate recovery: data from the heart and soul study. Am J Kidney Dis, 
49(3); 365-72. 
5. Anand, S., Johansen, K.L., & Tamura, M.K. (2014) Aging and chronic kidney disease: the impact 
on physical function and cognition. J Gerontol A Biol Sci Med Sci, 69A(3); 315-322. 
6. Diesel, W., Noakes, T.D., Swanepoel, C., & Lambert, M. (1990) Isokinetic muscle strength 
predicts maximum exercise tolerance in renal patients on chronic hemodialysis. Am J Kidney Dis, 
16(2): 109-14. 
7. Roshanravan, B., Gamboa, J., & Wilund, K. (2017) Exercise and CKD: skeletal muscle 
dysfunction and practical application of exercise to prevent and treat physical impairments in CKD. 
Am J Kidney Dis, 69(6); 837-52. 
8. Neirynck,	  N.	  Glorieux,	  G.,	  Schepers,	  E.,	  Dhondt,	  A.,	  Verbeke,	  F.,	  &	  Vanholder,	  R.	  (2015)	  Pro-­‐
inflammatory	  cytokines	  and	  leukocyte	  oxidative	  burst	  in	  chronic	  kidney	  disease:	  culprits	  or	  
innocent	  bystanders.	  Nephrol	  Dial	  Transplant,	  30(6);	  943-­‐51.	  
	  
9. Wang, X.H., & Mitch, W.E. (2014) Mechanisms of muscle wasting in chronic kidney disease. 
Nat Rev Nephrol, 10(9): 504-16 
 
10. Neirynck,	  N.	  Glorieux,	  G.,	  Schepers,	  E.,	  Dhondt,	  A.,	  Verbeke,	  F.,	  &	  Vanholder,	  R.	  (2015)	  Pro-­‐
inflammatory	  cytokines	  and	  leukocyte	  oxidative	  burst	  in	  chronic	  kidney	  disease:	  culprits	  or	  
innocent	  bystanders.	  Nephrol	  Dial	  Transplant,	  30(6);	  943-­‐51.	  
	  





12. Marcus, R.L., LaStayo, P.C., Ikizler, T.A., Wei, G. et al. (2015) Low physical function in 
maintenance hemodialysis patients is independent of muscle mass and comorbidity. Journal of Renal 
Nutrition, 25(4); 371-375. 
13. Dayanidhi, S., & Lieber, R.L. (2014) Sketal muscle satellite cells: mediators of muscle growth 
during development and implications for developmental disorders. Muscle Nerve, 50(5): 723-32. 
14. Liu, J.X., Hoglund, A.S., Karlsson, P., Lindblad, J. et al (2009) Myonuclear domain size and 
myosin isoform expression in muscle fibers from mammals representing a 100,000-fold difference in 
body size. Exp Physiol, 94(1) 
15. Schultz, E. (1989) Satellite cel behavior during skeletal muscle growth and regeneration. Med Sci 
Sports Ecerc, 21, S181-S186 
16. Goh, Q., & Millay, D.P. (2017) Requirement of myomaker-mediated stem cell fusion for skeletal 
muscle hypertrophy. Elife, 10(6) 
17. Jackson JR, Kirby TJ, Fry CS, Cooper RL, et al. (2015). Reduced voluntary running performance 
is associated with impaired coordination as a result of muscle satellite cell depletion in adult mice. 
Skeletal Muscle. 41 doi: 10.1186/s13395-015-0065-3 
18. Yin, H., Price, F., & Rudnicki, M.A. (2013) Satellite cells and the muscle stem cell niche. 
Physiol Rev, 93(1): 23-67. 
19. Murphy, M.M., Lawson, J.A., Mathew, S.J., Hutcheson, D.A., & Kardon, G. (2011) Satellite 
cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. 
Development, 138(17): 3625-37 
20. Bentzinger, C.F., Wang, Y.X., Dumont, N.A., & Rudnicki, M.A. (2013) Cellular dynamics in the 
muscle satellite cell niche. EMBO Rep, 14(12): 1062-72. 
21. Serrano AL, Muñoz-Cánoves P (2010) Regulation and dysregulation of fibrosis in skeletal 
muscle. Exp Cell Res 316: 3050–3058 
22. Gilbert, P.M. et al. (2010) Substrate elasticity regulates skeletal muscle stem cell self-renewal in 
culture. Science 329: 1078–1081 
23. Fry, C.S., Kirby, T.J., Kosmac, K., McCarthy, J.J., & Peterson, C.A. (2017) Myogenic 
progenitor cells control extracellular matrix production by fibroblasts during skeletal muscle 
hypertrophy. Cell Stem Cell, 20(1): 56-69. 
24. Kovanen V. (2002) Intramuscular extracellular matrix: complex environment of muscle cells. 




25. Boonen KJ, Rosaria-Chak KY, Baaijens FP, van der Schaft DW, Post MJ (2009) Essential 
environmental cues from the satellite cell niche: optimizing proliferation and differentiation. Am J 
Physiol Cell Physiol 296: C1338–C1345 
26. Cornelison D. D. (2008). Context matters: in vivo and in vitro influences on muscle satellite cell 
activity. J. Cell. Biochem. 105, 663-669 
27. Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, Rando TA (2007) Increased Wnt 
signaling during aging alters muscle stem cell fate and increases fibrosis. Science 317: 807–810 
28. Bentzinger CF, Wang YX, Rudnicki MA (2013) Treating muscular dystrophy by stimulating 
intrinsic repair. Regen Med 8: 237–240 
29. Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal 
integration in development. Science 284: 770–776 
30. Brack AS, Conboy IM, Conboy MJ, Shen J, Rando TA. (2008) A Temporal Switch from Notch 
to Wnt Signaling in Muscle Stem Cells Is Necessary for Normal Adult Myogenesis. Cell stem cell. 
2(1):50–59. 
31. Snijders, T., Nederveen, J.P., McKay, B.R., Joanisse, S. et al. (2015) Satellite cells in human 
skeletal muscle plasticity. Front Physiol, 2105; 6:283 
32. Relaix F., Montarras D., Zaffran S., Gayraud-Morel B., Rocancourt D., Tajbakhsh S., et al. . 
(2006). Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. J. 
Cell Biol. 172, 91–102.  
33. Zhang, L., Wang, X. H., Wang, H., Du, J., & Mitch, W. E. (2010). Satellite Cell Dysfunction and 
Impaired IGF-1 Signaling Cause CKD-Induced Muscle Atrophy. Journal of the American Society of 
Nephrology  : JASN, 21(3), 419–427 
34. Lanza D, Perna AF, Oliva A et al (2015) . Impact of the uremic milieu on the osteogenic 
potential of mesenchymal stem cells. PLoS One  10: e0116468 
35. Jourde-Chiche N, Dou L, Sabatier F et al (2009) Levels of circulating endothelial progenitor 
cells are related to uremic toxins and vascular injury in hemodialysis patients. J Thromb Haemost 7: 
1576–1584 
34. Noh H, Yu MR, Kim HJ et al (2012) Uremia induces functional incompetence of bone marrow-
derived stromal cells. Nephrol Dial Transplant; 27: 218–225 
35. Levin, A., & Stevens, P.E. (2013) KDIGO 2012 Clinical Practice Guidelines for the evaluation 




36. Bittel, D.C., Bittel, A.J., Tuttle, L.J., Hastings, M.K., et al. (2015) Adipose tissue content, muscle 
performance and physical function in obese adults with type 2 diabetes mellitus and peripheral 
neuropathy. J Diabetes Complications, 29(2); 250-257. 
37.	  Brown	  M,	  Sinacore	  DR,	  Binder	  EF,	  Kohrt	  WM.	  Physical	  and	  performance	  measures	  for	  the	  
identification	  of	  mild	  to	  moderate	  frailty.	  J	  Gerontol	  A	  Biol	  Sci	  Med	  Sci	  2000;	  55:M350–M355	  	  
38.	  Reuben	  DB,	  Siu	  AL.	  An	  objective	  measure	  of	  physical	  function	  of	  elderly	  outpatients:	  the	  
Physical	  Performance	  Test.	  J	  Am	  Geriatr	  Soc.1990;38:1105–12.	  	  
39.	  Reuben	  DB,	  Siu	  AL,	  Kimpau	  S.	  (1992)	  The	  predictive	  validity	  of	  self-­‐report	  and	  
performance-­‐based	  measures	  of	  function	  and	  health.	  J	  Gerontol.	  47:M106–10.	  	  
 
40. Tuttle, L.J., Sinacore, D.R., & Mueller, M.J. (2012) Intermuscular adipose tissue is muscle 
specific and associated with poor functional performance. J Aging Res, 2012; 172957 
41. Hilton, T.N., Tuttle, L.J., Bohnert, K.L., Mueller, M.J., & Snacore, D.R. (2008) Excessive 
adipose tissue infiltration in skeletal muscle in individuals with obesity, diabetes mellitus, and 
peripheral neuropathy: association with performance and function. Phys Ther, 88(11); 1336-44. 
42. Tuttle, L.J., Hastings, M.K., & Mueller, M.J. (2012) A moderate-intensity weight-bearing 
exercise program for a person with type 2 diabetes and peripheral neuropathy. Phys Ther, 92(1); 
133-41. 
43. Meyer, C., Corten, K., Wesseling, M. et al. (2013) Test-retest reliability of innovated strength 
tests for hip muscles. Plos One. 
44. Kirn, D.R., Reid, K.F., Hau, C. et al. (2016) What is a clinically meaningful improvement in leg-
extensor power for mobility-limited older adults. J Gerontol A Biol Sci Med Sci, 71(5), 632-6. 
45. Worrell, T.W., Karst, G., Adamczyk, D. et al. (2001) Influence of joint position on 
electromyographic and torque generation during maximal voluntary isometric contractions of the 
hamstrings and gluteus maximus muscles. J Orthop Sports Phys Ther, 31(12); 730-40. 
46. Frey-Law, L.A., Laake, A., Avin, K.G. et al. (2012) Knee and elbow 3D strength surfaces: peak 
torque-angle-velocity relationships. J Appl Biomech, 28(6): 726-37. 
47. Harbo, T., Brincks, J., & Andersen, H. (2012) Maximal isokinetic and isometric muscle strength 
of major muscle groups related to age, body mass, height, and sex in 178 healthy subjects. Eur J 
Appl Physiol, 112(1): 267-75 
48. Pincivero, D.M., Lephart, S.M., & Karunakara, R.A. (1997) Reliability and prevision of 





49. Roshanravan	  B,	  Patel	  KV,	  Fried	  LF,	  et	  al.	  (2017)	  Association	  of	  muscle	  endurance,	  
fatigability,	  and	  strength	  with	  functional	  limi-­‐	  tation	  and	  mortality	  in	  the	  Health	  Aging	  and	  
Body	  Composition	  Study.	  J	  Gerontol	  A	  Biol	  Sci	  Med	  Sci.	  72(2):284-­‐291.	  	  
	  
50. Entrekin, K., Work, B., & Owen, J. (1998) Does a high carbohydrate preparatory diet affect the 
3-hour oral glucose test in pregnancy. J Matern Fetal Med, 7(2): 68-71. 
51. Smith, G.I., Yoshino, J., Kelly, S.C., et al. (2016) High-protein intake during weight loss therapy 
eliminates the weight-loss induced improvement in insulin action in obese postmenopausal women. 
Cell Rep, 17(3): 849-861. 
52. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. (1985) 
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma 
glucose and insulin concentrations in man. Diabetologia. 28:412–419 
53. Steensberg, A., van Hall, G., Osada, T., et al. (2000) Production of interleukin-6 in contracting 
human skeletal muscles account for the exercise-induced increase in plasma interleukin-6. J Physiol, 
529 (Pt1): 237-242. 
54. Rauchhaus, M., Doehner, W., Francis, D.P., et al. (2000) Plasma cytokine parameters and 
mortality in patients with chronic heart failure. Circulation, 102(25): 3060-7. 
55. Merriwether, E.N., Host, H.H., & Sinacore, D.R. (2012) Sarcopenic indices in community-
dwelling older adults. J Geriatr Phys Ther, 35(3): 118-25. 
56. Shanely, R.A., Zwetsloot, K.A., Triplett, N.T., et al. (2014) Human skeletal muscle biopsy 
procedures using the modified bergstrom technique. J Vis Exp, (91): 51812 
57. Selected Histochemical and Histopathological Methods. Thompson, S.W. (1966). CC Thomas 
Publishers, Chicago, IL. 
58. Van Putten, M., de Winter, C., van Roon-Mom, W., van Ommen, G.J., et al. (2010) A 3 month 
mild functional test regime does not affect disease parameters in young mdx mice. Neuromuscul 
Disord, 20(4): 273-80. 
59. Conboy, M.J., Cerletti, M., Wager, A.J., & Conboy, I.M. (2010) Immuno-analysis and FACS 
sorting of adult muscle fiber-associated stem/precursor cells. Methods Mol Biol, 621: 165-73. 
60. Smith, L. R., Chamber, H. G., & Lieber, R. L. (2013). Reduced satellite cell population may lead 
to contractures in children with cerebral palsy. Developmental Medicine and Child Neurology, 55(3), 
264–270. 
61. Cheng, C. S., El-Abd, Y., Bui, K., Hyun, Y.-E., Hughes, R. H., Kraus, W. E., & Truskey, G. A. 




in vitro. American Journal of Physiology - Cell Physiology, 306(4), C385–C395. 
62. Guardiola, O., Lafuste, P., Brunelli, S., Iaconis, S. et al. (2012) Cripto regulates skeletal muscle 
regeneration and modulates satellite cell determination by antagonizing myostatin. PNAS, 109(47): 
E3231-E3240. 
63. Andley, U.P., Tycksen, E., McGlasson-Naumann, B.N., & Hamilton, P.D. (2018) Probing the 
changes in gene expression due to α-crystallin mutations in mouse models of hereditary human 
cataract. Plos One, Jan 16 
67. Robinson-Cohen C, Katz R, Mozaffarian D, Dalrymple LS, de Boer I, Sarnak M, Shlipak M, 
Siscovick D, Kestenbaum B. (2009) Physical activity and rapid decline in kidney function among 
older adults. Arch Intern Med. 169:2116–2123 
68. Robinson-Cohen, C., Littman, A.J., Duncan, G.E., et al. (2014) Physical activity and change in 
estimated GFR among persons with CKD. J Am Soc Nephrol, 25(2); 399-406.  
69. Robinson-Cohen, C., Katz, R., Mozaffarian, D., et al. (2009) Physical activity and rapid decline 
in kidney function among older adults. Arch Intern Med, 169(22): 2116-2123. 
70. Ortiz-Costa, S., Sorenson, M.M., & Sola-Penna, M. (2002) Counteracting effects of urea and 
methylamines in function and structure of skeletal muscle myosin. Arch Biochem Biophys, 408(2): 
272-8 
71. Kaizu, Y., Kimura, M., Yoneyama, T., & Miyaji, K. (1998) Interleukin-6 may mediate 
malnutrition in chronic hemodialysis patients. Am J Kidney Dis, 31(1): 93-100 
72. Stenvinkel, P., Ketteler, M., Johnson, R.J., Lindholm, B. et al (2005) IL-10, IL-6, and TNF-
alpha: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. 
Kidney Int, 67(4): 1216-33 
73. Serrano, A.L., Baeza-Raja, B., Perdiguero, E., Jardi, M., & Munoz-Canoves, P. (2008) 
Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell 
Metab, 7(1): 33-44. 
73. Adams, G.R., Vaziri, N.D (2006) Skeletal muscle dysfunction in chronic renal failure: effects of 
exercise. Am J Physiol Renal Physiol, 290(4): F753-61 
74. Cesari M, Penninx BWJH, Pahor M, et al. (2004) Inflammatory markers and physical 
performance in older persons: the InCHIANTI study. J Gerontol Med Sci. 59A:242-248. 
75. Ferrucci L, Penninx BWJH, Volpato S, et al. (2002) Change in muscle strength explains 
accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am 




76. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-
alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J 
Gerontol Med Sci. 2002;57A:M326-M332. 
77. Dumont, N. A., & Rudnicki, M. A. (2016). Targeting muscle stem cell intrinsic defects to treat 
Duchenne muscular dystrophy. NPJ Regenerative Medicine, 1, 16006 
78. Schaaf, G. J., van Gestel, T. J., Brusse, E., Verdijk, R. M., de Coo, I. F., van Doorn, P. A., … 
Pijnappel, W. P. (2015). Lack of robust satellite cell activation and muscle regeneration during the 
progression of Pompe disease. Acta Neuropathologica Communications, 3, 65. 
79. Yue, F., Bi, P., Wang, C., Li, J., Liu, X., & Kuang, S. (2016). Conditional Loss of Pten in 
Myogenic Progenitors Leads to Postnatal Skeletal Muscle Hypertrophy But Age-dependent 
Exhaustion of Satellite Cells. Cell Reports, 17(9), 2340–2353 
80. Heslop L, Morgan JE, Partridge TA. Evidence for a myogenic stem cell that is exhausted in 
dystrophic muscle. J Cell Sci. 2000;Pt 1:2299–2308 
81. Sousa-Victor P., Gutarra S., Garcia-Prat L., Rodriguez-Ubreva J., Ortet L., Ruiz-Bonilla V., et al. 
(2014). Geriatric muscle stem cells switch reversible quiescence into senescence. Nature 506, 316 
82. Barberi L., Scicchitano B. M., De Rossi M., Bigot A., Duguez S., Wielgosik A., et al. (2013). 
Age-dependent alteration in muscle regeneration: the critical role of tissue niche. Biogerontology 14, 
273 
83. Renault V, Thornell LE, Eriksson PO et al.  . Regenerative potential of human skeletal muscle 
during aging. Aging Cell  2002; 1: 132–139 
84. Collins CA, Zammit PS, Ruiz AP, Morgan JE, Partridge TA (2007) A population of myogenic 
stem cells that survives skeletal muscle aging. Stem Cells. 25(4):885–994. 
85. Goligorsky, M.S., Yasuda, K., & Ratliff, B. (2010) Dysfunctional endothelial progenitor cells in 
chronic kidney disease. JASN, 21(6): 911-919 
86. Liu L, Cheung TH, Charville GW, Hurgo BMC, Leavitt T, Shih J, et al. (2013) Chromatin 
modifications as determinants of muscle stem cellquiescence and chronological aging. Cell Re. 
4(1):189–204 
86. Chakkalakal JV, Jones KM, Basson MA, Brack AS (2012) The aged nichedisrupts muscle stem 
cell quiescence. Nature. 490(7420):355–360 
87. Bernet JD, Doles JD, Hall JK, Kelly Tanaka K, Carter Ta, Olwin BB (2014) p38 MAPK 





88. Claflin DR, Jackson MJ, Brooks SV (2015) Age affects the contraction-induced mitochondrial 
redox response in skeletalmuscle. Front Physiol. p. 6.  
89. Liu D, Sartor M, Nader G, Pistilli EE, Tanton L, Lilly C, et al. (2013) Microarray analysis 
reveals novel features of the muscle agingprocess in men and women. J Gerontol A Biol Sci Med 
Sci;68(9):1035–1044.  
90. Signer RAJ, Morrison SJ (2013) Mechanisms that regulate stem cell agingand life span. Cell 
Stem Cell;12(2):152–165 
91. Zampieri M, Ciccarone F, Calabrese R, Franceschi C, Bürkle A, Caiafa P (2015) 
Reconfiguration of DNA methylation in aging. Mech Ageing Dev. pii:S0047-6374(15)00007-X.  
92. Zammit, P.S., Relaix, F., Nagata, Y., Ruiz, A.P. et al. (2006) Pax7 and myogenic progression in 
skeletal muscle satellite cells. Journal of Cell Science, 19: 1824-1832 
93. Relaix F, Zammit PS. (2012) Satellite cells are essential for skeletal muscle regeneration: the cell 
on the edge returns centre stage. Development.139:2845–2856. doi: 10.1242/dev.069088. 
94. Charrin, S., Latil, M., Soave, S., Polesskaya, et al. (2013) Normal muscle regeneration requires 
tight control of muscle cell fusion by tetraspanins CD9 and CD81. Nature Communications, 
1674(2013) 
95. Meadows, E., Cho, J.H., Flynn, J.M., & Klein, W.H. (2008) Myogenin regulate a distinct genetic 
program in adult muscle stem cells. Dev Biol, 322(2): 406-414 
96. Sharples, A.P., Polydorou, I, Hughes, D.C., Owens, D.J., et al. (2016) Skeletal muscle cells 
possess a memory of acute early life TNF-a exposure: role of epigenetic adaptation. Biogerontology, 
17(3): 603-17 
97. Chevrel G, Hohlfeld R, Sendtner M (2006) The role of neurotrophins in muscle under 
physiological and pathological conditions. Muscle Nerve 33: 462–476 
98. Vasyutina, E., Martarelli, B., Brakebusch, C., Wende, H., & Birchmeier, C. (2009). The small G-
proteins Rac1 and Cdc42 are essential for myoblast fusion in the mouse. Proceedings of the National 
Academy of Sciences of the United States of America, 106(22), 8935–8940. 
99. Pawlikowski, B., Vogler, T.O., Gadek, K., & Olwin, B.B. (2017) Regulation of skeletal muscle 
stem cells by fibroblast growth factors. Dev Dyn, 246 (5): 359-367. 
100. Laurin, M., Fradet, N., Blangy, A., Hall, A., Vuori, K., & Côté, J.-F. (2008). The atypical Rac 
activator Dock180 (Dock1) regulates myoblast fusion in vivo. Proceedings of the National Academy 
of Sciences of the United States of America, 105(40), 15446–15451 




necessary for the quiescence and maintenance of adult muscle stem cells. Nature Communications, 
8, 14328 
102. Francetic, T., & Li, Qiao. (2011) Skeletal myogenesis and Myf5 activation. Transcription, 2(3): 
109-114 
103. Zhang, H., & Stavnezer, E. (2009). Ski Regulates Muscle Terminal Differentiation by 
Transcriptional Activation of Myog in a Complex with Six1 and Eya3. The Journal of Biological 
Chemistry, 284(5), 2867–2879. 
104. Gu, J.-M., Wang, D. J., Peterson, J. M., Shintaku, J., Liyanarachchi, S., Coppola, V., … 
Guttridge, D. C. (2016). An NF-κB – EphrinA5 – Dependent Communication between NG2+ 
Interstitial Cells and Myoblasts Promotes Muscle Growth in Neonates. Developmental Cell, 36(2), 
215–224. 
105. von Maltzahn, J., Chang, N.C, Bentzinger, C.F., & Rudnicki, M.A. (2012) Wnt signaling in 
myogenesis. Trends Cell Biol, 22(11): 602-609 
106. Karczewska-Kupczewska, M, Stefanowicz, M, Matulewicz, N, Nikołajuk, A, Strączkowski, M 
(2016) Wnt signaling genes in adipose tissue and skeletal muscle of humans with different degrees 
of insulin sensitivity. J Clin Endocrinol Metab, 101(8): 3079-87 
107. Majmundar, A. J., Lee, D. S. M., Skuli, N., Mesquita, R. C., Kim, M. N., Yodh, A. G., … 
Simon, M. C. (2015). HIF modulation of Wnt signaling regulates skeletal myogenesis in vivo. 
Development (Cambridge, England), 142(14), 2405–2412. 
108. Malam, Z. & Cohn, R.D. (2014) Stem cells on alert: priming quiescent stem cells after remote 
injury. Cell Stem Cell, 15(1): 7-8 
109. Calura, E., Cagnin, S., Raffaello, A., Laveder, P., Lanfranchi, G., & Romualdi, C. (2008). 
Meta-analysis of expression signatures of muscle atrophy: gene interaction networks in early and 
late stages. BMC Genomics, 9, 630. 
110. Dominov, J.A., Houlihan-Kawamoto, C.A., Swap, C.J., & Miller, J.B. (2001) Pro- and anti-
apoptotic members of the Bcl-2 family in skeletal muscle: a distinct role for Bcl-2 in later stages of 
myogenesis. Dev Dyn, 220(1): 18-26. 
111. Nazari, H., Khaleghian, A., Takahashi, A., Harada, N., Webster, N. J. G., Nakano, M., … 
Nakaya, Y. (2011). Cortactin, an Actin Binding Protein, Regulates GLUT4 Translocation via Actin 
Filament Remodeling. Biochemistry. Biokhimiia, 76(11), 1262–1269.  
112. The Three Musketeers of Skeletal Membrane Repair♦: Membrane Repair Defects in Muscular 
Dystrophy Are Linked to Altered Interaction between MG53, Caveolin-3, and Dysferlin. (2009). The 




113. Volonte, D., Peoples, A. J., & Galbiati, F. (2003). Modulation of Myoblast Fusion by Caveolin-
3 in Dystrophic Skeletal Muscle Cells: Implications for Duchenne Muscular Dystrophy and Limb-
Girdle Muscular Dystrophy-1C. Molecular Biology of the Cell, 14(10), 4075–4088 
114. Bentzinger, C. F., Wang, Y. X., von Maltzahn, J., Soleimani, V. D., Yin, H., & Rudnicki, M. A. 
(2013). Fibronectin regulates Wnt7a signaling and satellite cell expansion. Cell Stem Cell, 12(1), 75–
87. 
115. Lukjanenko, L., Jung, M. J., Hegde, N., Perruisseau-Carrier, C., Migliavacca, E., Rozo, M., … 
Bentzinger, C. F. (2016). Loss of fibronectin from the aged stem cell niche affects the regenerative 
capacity of skeletal muscle in mice. Nature Medicine, 22(8), 897–905 
116. Mouw, J. K., Ou, G., & Weaver, V. M. (2014). Extracellular matrix assembly: a multiscale 
deconstruction. Nature Reviews. Molecular Cell Biology, 15(12), 771–785 
117. Flück, M., Mund, S. I., Schittny, J. C., Klossner, S., Durieux, A.-C., & Giraud, M.-N. (2008). 
Mechano-regulated Tenascin-C orchestrates muscle repair. Proceedings of the National Academy of 
Sciences of the United States of America, 105(36), 13662–13667 
118. Joe,	  M.	  K.,	  Kee,	  C.,	  &	  Tomarev,	  S.	  I.	  (2012).	  Myocilin	  Interacts	  with	  Syntrophins	  and	  Is	  
Member	  of	  Dystrophin-­‐associated	  Protein	  Complex.	  The	  Journal	  of	  Biological	  Chemistry,	  
287(16),	  13216–13227	  
119. Li,	  H.,	  Malhotra,	  S.,	  &	  Kumar,	  A.	  (2008).	  Nuclear	  Factor-­‐kappa	  B	  Signaling	  in	  Skeletal	  
Muscle	  Atrophy.	  Journal	  of	  Molecular	  Medicine	  (Berlin,	  Germany),	  86(10),	  1113–1126. 
120. Hindi,	  S.	  M.,	  Sato,	  S.,	  Xiong,	  G.,	  Bohnert,	  K.	  R.,	  Gibb,	  A.	  A.,	  Gallot,	  Y.	  S.,	  …	  Kumar,	  A.	  (2018).	  
TAK1	  regulates	  skeletal	  muscle	  mass	  and	  mitochondrial	  function.	  JCI	  Insight,	  3(3),	  e98441	  
121. Llano-Diez, M., Gustafson, A., Olsson, C., Goransson, H., & Larsson, L. (2011) Muscle 
wasting and the temporal gene expression pattern in a novel rat intensive care unit model. BMC 
Genomics, 12:602 
122. Hussain,	  K.	  M.,	  Lee,	  R.	  C.	  H.,	  Ng,	  M.	  M.-­‐L.,	  &	  Chu,	  J.	  J.	  H.	  (2016).	  Establishment	  of	  a	  Novel	  
Primary	  Human	  Skeletal	  Myoblast	  Cellular	  Model	  for	  Chikungunya	  Virus	  Infection	  and	  
Pathogenesis.	  Scientific	  Reports,	  6,	  21406.	  
123. Stromberg, A., Olsson, K., Dijksterhuis, J.P., Rullman, E., et al. (2016) CX3CL1 – a 
macrophage chemoattractant induced by a single bout of exercise in human skeletal muscle. Am J 
Physiol Regul Integr Comp Physiol, 310(3): R297-304 
124. Amino	  acid	  sequence	  and	  distribution	  of	  mRNA	  encoding	  a	  major	  skeletal	  muscle	  laminin	  
binding	  protein:	  an	  extracellular	  matrix-­‐associated	  protein	  with	  an	  unusual	  COOH-­‐terminal	  




125. Arnold,	  L.,	  Perrin,	  H.,	  de	  Chanville,	  C.	  B.,	  Saclier,	  M.,	  Hermand,	  P.,	  Poupel,	  L.,	  …	  Combadiere,	  
C.	  (2015).	  CX3CR1	  deficiency	  promotes	  muscle	  repair	  and	  regeneration	  by	  enhancing	  
macrophage	  ApoE	  production.	  Nature	  Communications,	  6,	  8972. 
126. Lin,	  E.	  A.,	  &	  Liu,	  C.	  (2009).	  The	  emerging	  roles	  of	  ADAMTS-­‐7	  and	  ADAMTS-­‐12	  matrix	  
metalloproteinases.	  Open	  Access	  Rheumatology :	  Research	  and	  Reviews,	  1,	  121–131.	  
127. Nitert,	  M.	  D.,	  Dayeh,	  T.,	  Volkov,	  P.,	  Elgzyri,	  T.,	  Hall,	  E.,	  Nilsson,	  E.,	  …	  Ling,	  C.	  (2012).	  Impact	  
of	  an	  Exercise	  Intervention	  on	  DNA	  Methylation	  in	  Skeletal	  Muscle	  From	  First-­‐Degree	  Relatives	  
of	  Patients	  With	  Type	  2	  Diabetes.	  Diabetes,	  61(12),	  3322–3332	  
128. Pillon, N.J., & Krook, A. (2017) Innate immune receptors in skeletal muscle metabolism. Exp 
Cell Res, 360(1): 47-54 
129. Rayavarapu,	  S.,	  Coley,	  W.,	  Kinder,	  T.	  B.,	  &	  Nagaraju,	  K.	  (2013).	  Idiopathic	  inflammatory	  
myopathies:	  pathogenic	  mechanisms	  of	  muscle	  weakness.	  Skeletal	  Muscle,	  3,	  13.	  
130. Englund,	  P.,	  Lindroos,	  E.,	  Nennesmo,	  I.,	  Klareskog,	  L.,	  &	  Lundberg,	  I.	  E.	  (2001).	  Skeletal	  
Muscle	  Fibers	  Express	  Major	  Histocompatibility	  Complex	  Class	  II	  Antigens	  Independently	  of	  
Inflammatory	  Infiltrates	  in	  Inflammatory	  Myopathies.	  The	  American	  Journal	  of	  Pathology,	  
159(4),	  1263–1273	  
131. Yahiaoui,	  L.,	  Gvozdic,	  D.,	  Danialou,	  G.,	  Mack,	  M.,	  &	  Petrof,	  B.	  J.	  (2008).	  CC	  family	  
chemokines	  directly	  regulate	  myoblast	  responses	  to	  skeletal	  muscle	  injury.	  The	  Journal	  of	  
Physiology,	  586(Pt	  16),	  3991–4004.	  
132. Sajnani-Perez, G., Chilton, J.K., Aricescu, A.R., Haj, F., & Stoker, A.W. (2003) Isoform-
specific binding of the tyrosine phosphatase PTP-sigma to a ligand in developing muscle. Mol Cell 
Neurosci, 22(1): 37-48. 
133. Brzoska, E., Kowalewska, M., Markowska-Zagrajek, A., Archacka, K. et al. (2012) sdf-1 
(CXCL12) improves skeletal muscle regeneration via the mobilization of Cxcr4 and CD34 
































Summary of Overall Findings 
The objectives of this research were to 1. Determine the relationship between diabetes-induced renal 
dysfunction or CKD progression and its systemic environment, on skeletal muscle performance and 
overall physical function and when this becomes apparent, and 2. Determine the physiological 
mechanisms that promote muscle and functional impairment in CKD progression, and when this 
occurs in the course of disease.  
Chapter 1 aimed to accomplish objective 1. Our results suggest that muscle performance of 
the lower extremity, particularly the quadriceps, and physical function decline in-parallel with 
progression of CKD in T2DM, with these declines becoming significant and clinically evident in 
stage 3. Moreover, we find that CKD-stage, and renal filtration/function (eGFR) are both significant 
predictors of overall physical function, with increasing CKD stage/worsening kidney filtration 
predicting worse functional mobility, and this is true even after for controlling for potentially 
confounding age and diabetes-related variables (HbA1c, BMI). Additionally, CKD-associated 
metabolic bi-products, like BUN are significant negative predictors of functional mobility, and those 
in stage 3+ CKD demonstrate functional deficits that reflect a pre-mature geriatric state.  
These data shed new light on the deleterious effects of poor kidney function on overall 
health. We demonstrate, for the first time, that CKD imparts significant reductions in performance of 
key lower extremity muscle groups like the quadriceps, as early as stage 3, which carries strong 
relationships to functional mobility deficits that may independently contribute to CKD exacerbation. 
Chapter 2 aimed to provide mechanistic insights into the physiological ways in which poor 
kidney function with CKD progression negatively affects muscle health, performance, and overall 




skeletal muscle mitochondrial ATP production, and electron transport chain kinetics, as these are 
critical cellular processes to fuel muscle cross-bridge cycling, contraction and movement. We find 
that skeletal muscle mitochondrial electron transport chain function is reduced with progression of 
CKD, once again, with significant reductions in ATP-production capacity emerging as early as stage 
3 CKD. Moreover, we report mitochondrial abundance is maintained with CKD progression, 
suggesting these ATP-production deficits are secondary to intrinsic mitochondrial deficits. These 
suggestions are further bolstered with our ETC complex-specific enzyme tests demonstrating 
significaint complex 4 functional deficits in stage 3 and 4&5 CKD. Lastly, using RNA-sequencing, 
we find gene pathway alterations may drive these intrinsic mitochondrial deficits in middle and late-
stage CKD, primarily through attenuated transcription of key ETC complex subunit proteins and 
assembly factors, reduced expression of mitochondrial turnover and transport channels, and altered 
expression of genes that govern reactive oxygen species handling and generation.  Most importantly, 
we demonstrate that intrinsic mitochondrial function is strongly related to lower extremity muscle 
performance and physical function. 
These data mark the first time anyone has investigated intrinsic mitochondrial function with 
CKD progression, and highlights new time-frames and potential targets of conservative treatment, to 
improve muscle health, function, and attenuate the functional declines seen in this disease. 
Chapter 3 aimed to answer, in-tandem with chapter 2, the second objective of this research – 
to determine the physiological ways in which poor kidney function with CKD progression 
negatively affects muscle health, performance, and overall physical function. However, while 
chapter 2 focused on skeletal muscle energetics as a contributing mechanism, chapter 3 studies 
muscle regenerative and maintenance capacity. Specifically, chapter 3 examines the CKD-stage 




maintaining muscle integrity and repairing muscle fibers after injury. We find the muscle-resident 
SC pool to decline significantly at stage 3 CKD, and remain reduced in late-stage disease. Moreover, 
we demonstrate that such SC loss may be secondary to their poor capacity to renew themselves 
through duplication and division. Additionally, we report impaired myogenic capacity of these SCs 
secondary to altered gene activation patterns, that relate strongly to findings of poor muscle quality 
with progressive CKD stage (increased fibrotic and adipose tissue accrual). Similar to chapter 2, 
using transcriptomics, we report significant dowregulation in gene networks that influence muscle 
SC behavior and myogenesis, with concomitant upregulation in epigenetic mechanisms, and 
inflammatory cytokine signaling pathways with progression of CKD stage. This inflammatory 
signaling is supported by our findings of increased circulating pro-inflammatory cytokines (IL-6 and 
TNF-a), and increased muscle-resident leukocytes with worsening kidney function.  
As in chapter 2, the investigation in chapter 3 marks the first time anyone has studied 
myogenesis in human skeletal muscle with CKD progression in those most at risk – type 2 diabetics. 
This data lends new insights into the mechanisms that may relate the CKD-associated environment 
with muscle gene pathway changes, reparative capacity, and cell-cell interactions that are all crucial 
in ensuring proper muscle health and function. 
In summary, our data suggests that the progression of diabetes-induced chronic kidney 
disease, is paralleled by impairments in skeletal muscle ATP-producing capacity, and these energetic 
deficits are accompanied by CKD-associated reductions in muscle SC abundance, and reparative 
function. Both changes perhaps stem from alterations in gene pathway expression that is imparted by 
the altered uremic environment. These impairments may promote the development of poor muscle 





 Based on these results, it is clear that skeletal muscle impairments, even on a cellular level, 
become significant in middle-stage CKD (stage 3). Stage 3 also marks the point of entry for many of 
these patients, into nephrology care. In light of this, these results suggest that conservative exercise 
prescription, specifically targeted to the underlying energetic and cellular factors earlier in CKD 
progression (ie. stage 2 or 3) may prove highly beneficial in attenuating the progression of muscle 
impairment with CKD. Healthcare workers should aim to educate patients regarding the importance 
of maintained mobility and exercise, specifically activities that target large lower extremity muscle 
groups such as the quadriceps studied in this work. Of particular emphasis should be stimuli that 
promote improved mitochondrial respiration and SC abundance and myogenic function – cellular 
adaptations often reported in exercise physiology literature for both aerobic and resistance training 
regimens. 
Future Studies 
 As mentioned in chapter 2 and 3, this work provides many avenues of potential future 
investigation. The use of transcriptome analysis via RNA-sequencing revealed epigenetic 
mechanisms to be significantly upregulated in both middle and late-stage CKD. Chromatin binding 
pathways, histone modifications, and miRNA signaling were all among the most significantly 
upregulated gene networks seen in CKD skeletal muscle. Such factors have been shown in other 
conditions, to be induced by environmental changes (i.e hyperglycemia of diabetes), to promote 
changes in DNA packing and to prevent or allow RNA polymerase or transcription factor binding 
and subsequently, repress or upregulate gene expression. An exciting avenue of future research 




environment, and how this translates into skeletal muscle health and function. Such work may even 
highlight epigenetic marks in those in various stages of CKD that may predispose them to deficient 
muscle energetics or SC-mediated repair processes. This could potentially serve as a biomarker from 
which to proactively introduce treatment before the onset of symptoms or functional loss. Similarly, 
we highlight several potential mechanisms by which CKD and its associated signaling factors may 
negatively affect mitochondrial function. Further investigations aimed at determining the precise 
influences of the uremic environment on specific mitochondrial-governing genes and how this 
relates to function, is needed.  
From a clinical perspective however, based on our results, construction and implementation of a 
targeted exercise program would be immensely useful and informative. Specifically, an exercise 
regimen (ie. resistance training) may be implemented in early/middle stage CKD to track the 
outlined cellular adaptations (intrinsic mitochondrial function, SC abundance, SC function, 
transcriptome changes) and subsequently follow these patients longitudinally to monitor their muscle 
performance and functional mobility in-tandem with their CKD status. Such an investigation that 
addresses the point of intersection between disease and functional outcome before the end-stage of 
the disease, is needed in this population. 
 
 
 
